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David Allison          Advisor:  
Brock University, 2016        Dr. D.S. Ditor 
                    
         
 This thesis investigated the influence of chronic inflammation on several 
neural/behavioural disorders following spinal cord injury (SCI) including depression, 
cognitive impairment, neuropathic pain, and somatic nerve deficits.   
 Ample evidence exists to suggest that the immune system communicates with, 
and influences the nervous system both centrally and peripherally. Pro-inflammatory 
cytokines have been shown to influence the nervous system directly by altering ion 
channel kinetics, as well as indirectly by altering enzyme function thereby resulting in 
changes in critical neuroactive compounds. Proinflammatory mediators have been shown 
to up-regulate the enzyme indoleamine 2,3 dioxygenase (IDO) resulting in the 
accelerated degredation of serotonin precursor tryptophan (TRP) and increased 
production of TRP metabolites such as kynurenine (KYN). They have also been shown to 
upregulate the enzyme cyclooxygenase (COX) resulting in the increased production of 
pain inducing eicosanoids such as prostaglandin E2 (PGE2).  Immune dysfunction in the 
form of chronic inflammation may therefore contribute to the severity of behavioural 
disorders such as depression and cognitive impairment, as well as neural disorders such 
neuropathic pain and somatic nerve deficits. SCI is typically associated with not only a 
state of chronic inflammation but also a drastically higher prevalence of each of the 
aforementioned neural and behavioural disorders. This makes SCI an ideal population to 
study the interaction between the immune and nervous systems, and assess the potential 
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efficacy of novel treatment strategies which target the immune system for the 
management of such disorders.  
 A 3-month anti-inflammatory diet was utilized as a treatment intervention for the 
purpose of reducing chronically elevated levels of pro-inflammatory mediators. This 
intervention allowed for the assessment of each of the outcome variables of interest at 
baseline (under an elevated inflammatory status) as well as at 1-month and 3-months 
during the intervention (under a reduced inflammatory state). Changes in inflammation 
were assessed by the quantification of serum pro (IL-1β, IL-2, IL-6, IFN-У, TNF-α, 
CRP) and anti-inflammatory (IL-4, IL-10, IL-1RA) cytokines. Cytokine-induced 
alterations in enzyme function and corresponding changes in neuroactive compounds 
were assessed by tryptophan (TRP), the competing amino acids phenylalanine (PHE), 
tyrosine (TYR), leucine (Leu), isoleucine (Ile), and valine (Val), the tryptophan 
metabolite kynurenine (KYN), and the pain-inducing eicosanoids prostaglandin E2 
(PGE2) and leukotriene B4 (LTB4). In addition to such molecular indices, actual changes 
in each of the outcome variables of interest were assessed. Levels of depression were 
assessed by questionnaire via the Center for Epidemiological Studies Depression Scale 
(CES-D). Cognitive function (in the form of verbal learning) and memory was assessed 
via the California Verbal Learning Test (CVLT). Neuropathic pain was assessed via the 
Neuropathic Pain Questionnaire (NPQ). Somatic nerve function was assessed by EMG, 
including the assessment of nerve conduction velocity and signal amplitude in both motor 
and sensory nerves.     
The intervention significantly reduced serum concentrations of pro-inflammatory 
mediators in the treatment group (n=12) by 28%, while no significant change was found 
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in the control group (n=8). Among other changes in amino acids, the most notable was 
that the change in the KYN/TRP ratio (an indicator of IDO activity) and the TRP/LNAA 
ratio (an indicator of TRP availability for serotonin synthesis) was significantly different 
between groups. The treatment group showed a significant reduction in scores of 
depression, as well as a significant reduction in sensory neuropathic pain scores. No 
significant changes were observed in regards to somatic nerve conduction and most 
indices of cognitive function (with the exception of the ability to avoid incorrect 
responses on the CVLT).   
 These results may suggest a substantial role for chronic inflammation in 
depression and neuropathic pain following SCI and provide a potential alternative 
treatment strategy for the management of such intractable disorders.       
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Traditionally, the human body has been studied as a number of individual, 
isolated systems which carry out unique and independent functions. However, there is 
now well-established and growing evidence that the body functions as one entity whereby 
each ‘system’ acts synergistically with the ability to communicate and influence one-
another. This has important implications regarding the way in which diseases are 
characterized and treated. Although a disorder or disease may be characterized as 
belonging to one system, in reality, this is rarely (if ever) the case. Complex, bidirectional 
communicatory pathways exist between systems of the body making it possible for 
various systems to contribute to a disorder. An understanding of this phenomenon is of 
critical importance as it may allow for a more holistic understanding of various diseases 
and result in more effective treatment strategies. 
Chronic inflammation plays an increasingly appreciated role in the pathogenesis 
of a number of neurological and behavioral disorders.1–3 Communicatory pathways 
between systems allows for immune dysfunction to contribute to both neural and 
endocrine impairment via a number of inflammatory mechanisms. Proinflammatory 
mediators possess the ability to directly influence the nervous system by acting on vagal 
afferents4, or by crossing the blood brain barrier (BBB) either through leaky sites at the 
circumventricular organs5 (brain regions which lack BBB), or via specialized active 
transporters.6 Proinflammatory cytokines have also been shown to influence hormone 
secretion by acting directly on receptors within the hypothalamic-pituitary-adrenal (HPA) 
axis.7 Alternatively, a number of cytokines have been shown to indirectly influence 
neural and endocrine disorders by altering the regulation of enzymes. This may result in a 
shift in key metabolic pathways resulting in an imbalance in critical neuroactive 
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compounds. In addition to impacting neural and behavioural disorders, chronic 
inflammation contributes to the pathogenesis of a number of metabolic disorders, and 
these disorders in turn, have been shown to contribute to the elevated inflammatory state, 
creating a viscous cycle.8–12 The high prevalence of metabolic disorders is among the 
many factors which contribute to the chronic inflammatory status commonly observed 
following spinal cord injury (SCI).      
Immune impairment and chronic inflammation have been commonly 
demonstrated following SCI by elevated concentrations of proinflammatory cytokines 
and autoantibodies which are apparent in individuals who are symptomatic or 
asymptomatic for secondary health complications.13–17 As such, this population is often 
found to be in a perpetual low-grade inflammatory state which is elevated to an even 
further extent when other health complications and associated disorders are present. Due 
to the complex bidirectional communication between the immune and neuroendocrine 
systems, damage to the spinal cord often results in the widespread dysfunction in other 
systems.18 Both the endocrine and immune systems may be affected due to respective 
dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and a loss of direct 
sympathetic innervation of lymphoid organs. Despite the elevated inflammatory state, 
SCI is typically associated with a state of immunosuppression and a heightened 
susceptibility to infection.18–21 Suppressed function of natural killer (NK) cells, 
neutrophils, macrophages, and lymphocytes have each been documented following 
SCI.18,22,23 The loss of motor and sensory function also contribute to this populations’ 
greater susceptibility to a number of acute infections including urinary tract infection 
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(UTI) and pressure ulcers as well as metabolic disorders associated with a more sedentary 
lifestyle such as obesity, atherosclerosis, and type 2 diabetes.24–26   
    There is evidence to suggest disorders such as depression, cognitive impairment 
and neuropathic pain share a common inflammatory etiology stemming from a cytokine-
induced imbalance of neuroactive compounds. Individuals diagnosed with major 
depression have been consistently reported to demonstrate elevated levels of 
proinflammatory cytokines,27,28 while those with neuropathic pain have been shown to 
have altered levels of inflammatory mediators with elevations in the proinflammatory 
cytokines TNF, IL-6, and IL-2 along with reductions in anti-inflammatory cytokines such 
as IL-10 and IL-4.13,29 Chronic inflammation has also been suggested to play a role in 
cognitive deficits via several mechanisms.3 As each of these disorders have been shown 
to be far more prevalent following SCI30–33 (a condition typically associated with an 
elevated inflammatory status), inflammatory mediators may contribute to the severity of 
such disorders in this population. It has also been suggested that cytokines may have a 
direct influence on nerves causing alterations in ion channel kinetics when at elevated 
concentrations.34 As such, cytokines and other inflammatory mediators may have the 
potential to cause somatic or autonomic nerve deficits. 
An understanding of how the immune and neuroendocrine systems interact may 
provide a unique opportunity to treat neural and behavioral disorders by targeting aspects 
of immune impairment. The reestablishment of immune homeostasis may not only help 
to improve the body’s ability to fight infection and avoid unnecessary consumption of 
resources, but may also induce beneficial alterations in enzyme regulation, protein 
balance, hormone levels, and neural function. Currently, the majority of treatment 
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strategies for conditions such as major depression and pain utilize drugs which target 
“downstream” enzymes and receptors. As such, these treatments provide temporary relief 
from symptoms but do not treat the core inflammatory basis of these disorders. Natural 
anti-inflammatory interventions including a diet consisting of foods and supplements 
with anti-inflammatory properties may be an effective option for treating inflammation in 
this population. As this treatment strategy will target the inflammatory basis of many 
disorders it would be expected to result in a reduction in pro-inflammatory mediators 
thereby leading to more sustainable long-term immune improvements. Despite this, little 
research has focused on the use of anti-inflammatory foods and supplements for the 
treatment of chronic inflammatory conditions and effects specific to those with SCI. 
Therefore, the use of anti-inflammatory foods and supplements as an intervention 
strategy and its potential influence on inflammation, depression, cognitive impairment, 
neuropathic pain, and somatic nerve function in individuals with SCI is the focus of this 
thesis.  
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Background and Epidemiology of Spinal Cord Injury 
Epidemiology and Demographics   
The incidence rate of SCI in North America has been on the rise over the past 
thirty years and currently stands at 35 and 40 per million population per year in Canada 
and the United states respectively.35 Of these individuals, an estimated 55% have 
incomplete SCI, meaning some degree of motor and/or sensory capabilities are 
maintained below the lesion. In regards to the level of the SCI, those to the cervical 
region are the most common, accounting for approximately 51% of all cases. Lower level 
SCI such as those affecting the thoracic and lumbar region are less common accounting 
for 21% and 28% respectively.36  
The mean age of individuals living with SCI has traditionally been quite young at 
approximately 32 years of age. However, over the past thirty years an increase in the 
number of older adults living with SCI has become evident, due in part to advancements 
in treatment and care. In 2001, Sekhon and Fehlings reported an increase in SCI 
occurring in older adults from 4.7% in the 1970’s to 10% in 2001.37 The mean age in 
North America is now approximated at 42.2 years of age.38 Despite the shift in the mean 
age of individuals living with SCI, when concerning the age of onset, young males are 
still deemed to be at the highest risk and outnumber females by a ratio of 3:1.39   
Etiology   
Etiological data suggests that the primary cause of SCI in North America is motor 
vehicle accidents, accounting for approximately 50% of all cases.40 This includes injuries 
sustained to the driver or passenger of a vehicle as well as to those hit by vehicles. Falls 
are regarded as the second most common cause accounting for approximately 24% of all 
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cases. Although SCI caused by falls are only half as common as motor vehicle accidents, 
they are the only cause which has steadily increased over the past 30 years. Sports related 
injuries have shown a decline over the past 3 decades and are now responsible for only 
9% of injuries. Lastly, injuries caused by violence showed a steady increase, until 
peaking in the mid 1990’s, however, they have since declined to an estimated 11.2%.       
 Based on an estimated prevalence of 755 per million population, approximately 
250 000 people are currently living with a SCI in North America.40 This creates a need 
for further research and new treatment methods to help alleviate the physiological, 
psychological, and socioeconomic impact placed on individuals with SCI. As the location 
and severity of a SCI are highly variable from one individual to the next, no two injuries 
are ever exactly the same. Therefore, the development of treatment methods which can be 
individualized for each patient’s unique pathology is of extreme importance.      
Anatomy of the Spinal Cord  
The spinal cord provides a pivotal conduit between the brain and body in which 
all motor and sensory information travels. Ascending tracts carry sensory information 
such as touch, temperature, pain, and joint position to the brain whereas descending tracts 
carry motor signals to muscle groups throughout the body to initiate movement. The 
spinal cord is composed of outer spinal tracts known as white matter, and an inner 
segment comprised of neuronal cell bodies and interneurons known as grey matter. 
Contained within the protective sheath of the vertebral column, and surrounded by a 
cushion of cerebral spinal fluid, the delicate tissue of the spinal cord relays critical signals 
to the limbs, trunk, and organs. These signals exit and enter the spinal cord via small 
spinal roots which branch out through spaces known as foramina within the vertebral 
9 
 
 
column. These roots then travel to their target tissue and innervate them by means of 
neurotransmitter release.   
Innervation of the Spinal Cord  
The spinal cord is categorized into five regions, each of which is further divided 
into a number of segments. Each spinal segment is responsible for innervating a unique 
muscle group or organ as well as receiving sensory information from a particular region 
of the body. Groups of muscles receiving innervation from a specific spinal segment are 
known as myotomes. A single spinal segment typically innervates more than one 
myotome, just as most muscle groups are innervated by more than one spinal segment. 
This overlap may have important functional implications concerning damage to the spinal 
cord. If a particular region of the spinal cord is to become damaged, resulting in loss of 
innervation to the myotome, partial innervations may still be possible from a more rostral 
segment. This allows for the partial preservation of motor abilities to that muscle group. 
Specific areas of the skin responsible for relaying sensory information to particular areas 
of the spinal cord are termed dermatomes. Unlike myotomes however, dermatomes 
generally provide information to only one spinal segment. Due to the complex overlaying 
innervations in addition to varying levels, severities, and the specific location of damage 
to the motor neuron, spinal cord injuries (SCI) are highly variable and often differ greatly 
from one individual to the next. 
Injury Level  
 The level of spinal tissue damage will vary depending on the nature of the 
accident or disease and may affect one spinal segment or span over several segments. As 
each segment of the spinal cord is responsible for innervating a particular myotome and 
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receiving information from a particular dermatome, the level of the injury will dictate the 
diagnosis of either tetraplegia or paraplegia. Tetraplegia refers to the loss or impairment 
of motor and/or sensory function due to a lesion in the cervical region of the spinal cord. 
As an injury to the cervical region is a high level injury, innervations to the upper 
extremities, in addition to the lower extremities, trunk, and pelvic organs will all be 
affected.  Paraplegia refers to the loss or impairment of motor and/sensory function due 
to a lesion in the thoracic, lumbar, or sacral region. Due to the relatively lower level of 
the injury, the upper extremities remain unaffected while the degree to which the lower 
extremities, trunk and pelvic organs are affected vary depending on the specific spinal 
segment affected.   
Severity   
A SCI may widely vary in severity or the completeness of the injury. A complete 
injury is one in which there is no sensory or motor function at some point below the level 
of the lesion. However, with less severe injuries there is a greater sparing of neural tissue 
and improved functional outcome. Such injuries are termed incomplete and the potential 
for the exchange of some sensory and/or motor information remains. The completeness 
of an injury is determined by the presence or absence of motor and sensory capabilities in 
the fourth and fifth sacral regions of the spinal cord. If any amount of sensory or motor 
ability exists, the injury is deemed incomplete. This classification can be further specified 
by considering the amount of motor and sensory capabilities preserved following SCI. By 
means of the American Spinal Injury Association (ASIA) impairment scale (AIS) an 
individual’s motor and sensory function can be evaluated based on a 5 tier scale. The 
scale ranges from AIS A, denoting a complete injury, to AIS E, signifying the individual 
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has normal motor and sensory capabilities. A grade of B, C, or D, indicates an incomplete 
injury and specifies the degree to which motor and sensory capabilities are maintained 
(see appendix for precise definition of each classification).         
Dyscomplete SCI 
 In certain cases, a SCI may be clinically classified as complete (i.e. no sensory or 
motor function corresponding to the s4-s5 spinal segment) despite the preservation of the 
structural integrity of a number of spinal tracts (as revealed by MRI). In situations such as 
these, the spinal cord will have a structural appearance much like that of an incomplete 
injury and the preservation of partial motor and sensory function below the level of the 
lesion would be expected. The fact that there is an absence of function below the lesion, 
(specifically in the 4th and 5th sacral regions) despite a lack of structural damage to all 
tracts, suggests that a non-structurally based mechanism must be responsible for the 
apparent conduction deficits. It has been hypothesized that molecules seen at high levels 
during periods of physiological or psychological stress may be responsible. As SCI is a 
condition typically characterized by a state of chronic inflammation and immune 
dysfunction, such immune mediators may contribute to neural deficits in this population.    
The Nervous System  
Signal Transmission  
An individual axon can reach lengths of up to one meter, and as such, the ability 
to transmit signals rapidly while maintaining signal strength is of extreme importance. 
Supporting cells of the peripheral nervous system known as Schwann cells ensure the 
structural integrity of the neuron is maintained, and thereby act to sustain signal strength. 
By growing around the axon and producing several layers of lipid based protective 
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covering known as myelin, Schwann cells act to insulate the axon. As lipids are poor 
conductors of electrical current, this covering provides a strong insulator to help contain 
travelling signals.   
The axon is segmented into regions of both myelinated and non-myelinated areas. 
Although myelinated areas are extremely important concerning efficient signal 
transmission, non-myelinated areas are necessary for the re-initiation of action potentials. 
Signals are typically generated at a region where the axon joins the cell body known as 
the axon hillock. As the signal travels along the axon it is re-initiated at non-myelinated 
regions known as Nodes of Ranvier. These regions are densely populated with voltage 
regulated gates which allow the signal to be boosted back to its original strength. This 
process occurs at an extremely rapid rate and is termed saltatory conduction due to the 
way the signal seemingly jumps from one node to the next.41       
 At the site of the axon hillock and each Node of Ranvier, the exchange of sodium 
and potassium ions causes an alteration in the resting membrane potential. As the action 
potential generated from the previous node travels to the next, the membrane becomes 
depolarized, stimulating the opening of a number of sodium channels. This allows an 
influx of sodium (Na+) to diffuse into the cell, leading to further depolarization and 
stimulating the opening of additional Na+ channels. If this depolarization meets the 
threshold of approximately -55mv, the triggering of a new action potential will result. 
Upon reaching threshold, Na+ channels close, preventing further depolarization, and 
potassium (K+) channels open, allowing an efflux of K+ ions to diffuse out of the cell, 
causing repolarization and the return of resting membrane potential.42 These action 
potentials are non-graded, meaning that regardless of the strength of the stimulus applied, 
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as long as the threshold is met, a standardized amplitude action potential will always be 
produced. These action potentials are also non-decremental meaning they maintain their 
strength as they travel along the axon. This is due to the constant re-initiating of the 
action potential at each Node of Ranvier. As the action potential arrives at the next node 
in the sequence the signal will be just strong enough to cause opening of the voltage 
gated channels and initiate a new action potential of equal strength to that of the previous 
node. Electrical signaling such as this is an effective communicatory pathway but can be 
performed only along a single continuous axon. Therefore, when an impulse must 
transition between two neurons, or from a neuron to a muscle fiber, such as that seen at 
the site of the neuromuscular junction, a different means of signaling must be utilized. 
This is accomplished through chemical signaling by means of neurotransmitter release.43  
Upon reaching the targeted skeletal muscle, the electrical impulse traveling along 
the pre-synaptic neuron must be converted to a chemical signal, cross the synaptic cleft, 
and initiate a new electrical impulse on the post-synaptic muscle fibre. This is 
accomplished through the release of the neurotransmitter acetylcholine (ACh) from 
vesicles within the pre-synaptic neuron. Upon being released, ACh crosses the synaptic 
cleft whereby it binds to receptors which open chemically gated channels.43 This allows 
Na+ ions to flow into the muscle fibre causing depolarization of the resting membrane 
potential and the production of a new action potential.  
The newly generated impulse then travels along specialized tubes known as 
transverse tubules (T-tubules) which carry the signal deep into the muscle fiber. These T-
tubules transport the impulse to an internal membrane system responsible for housing 
calcium (Ca++) ions known as the sarcoplasmic reticulum (SR). Upon stimulation of the 
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SR, Ca++ ions are released into the cell.44 This release is a crucial component in the 
contraction of skeletal muscle, and is required for the functioning of specialized 
contractile proteins. Contractile proteins including a thick filament composed of myosin 
and a thin filament composed of actin cause the contraction of skeletal muscle through 
the formation of crossbridges. Molecules of actin have binding sites for myosin which, 
through an energy dependent process, allow for contraction by means of a process known 
as the sliding filament theory. However, until stimulated by the release of Ca++ ions, these 
binding sites remain blocked by a protein known as tropomyosin. The binding of Ca++ 
ions to an associated protein known as troponin causes a conformational change in 
tropomyosin, revealing the actin binding sites and allowing for crossbridge formation.44 
The myosin heads may then perform a power stroke causing a shortening in sarcomere 
length, and ultimately a skeletal muscle contraction.  
Somatic Nerves   
 Peripheral nerves consist of bundles of axons which exit and enter the central 
nervous system from various sites along the spinal cord and brain stem. They are 
categorized by the direction in which they carry signals and the function which is carried 
out by those signals. Peripheral nerves of the somatic nervous system are responsible for 
relaying sensory, afferent signals throughout the body to the CNS as well as motor, 
efferent signals from the CNS to skeletal muscles for the voluntary contraction of 
muscles. 
Assessment of Somatic Nerves 
 Both motor and sensory nerves can be assessed via electrical stimulation. Through 
stimulation of the median nerve and recording of the resulting motor response of the 
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flexor pollicis brevis, motor nerve conduction velocity as well as the strength of the 
corresponding motor response may be assessed. Supramaximal stimulation of the nerve 
results in the recording of a waveform known as a compound muscle action potential 
(CMAP). This waveform represents the summation of individual motor unit action 
potentials and can be used to assess the health of motor nerves. Sensory nerves may also 
be assessed via the recording of sensory nerve action potentials (SNAP). These signals 
may be recorded in either an orthodromic or antidromic fashion. The median nerve may 
be assessed orthodromically by stimulating the 4th finger by means of ring electrodes and 
recording the response over the median nerve at the wrist. Reversing the stimulation and 
recording sites allow for the recording of an antidromic signal. The SNAP waveform 
represents the summation of individual impulses traveling through all stimulated sensory 
nerves and is recorded directly from the sensory nerve. This results in a much smaller 
amplitude than that of a CMAP. However, through the application of a supramaximal 
stimulation, SNAPs may also be used to assess nerve conduction velocity and SNAP 
amplitude.     
Autonomic Nerves  
Nerves of the autonomic nervous system are responsible for relaying signals for 
the control of a variety of involuntary processes. Afferent, signals are sent from a number 
of structures throughout the body such as the blood vessels, heart, or sweat glands and 
travel to the medulla, pons, and hypothalamus where they do not reach conscious 
thought. Efferent signals are then relayed to various structures where they elicit 
involuntary excitatory or inhibitory effects. The autonomic nervous system is further 
divided into sympathetic and parasympathetic divisions based on these effects. The 
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sympathetic division is responsible for inducing the “fight or flight” response, causing 
such responses as increases in heart rate, vasoconstriction of blood vessels, or activation 
of sweat glands. The parasympathetic division is responsible for inducing the “rest and 
digest” response, causing such responses as decreases in heart rate, and the promotion of 
responses necessary for digestion such as salivary gland stimulation and accelerated 
peristalsis.      
Assessment of the Autonomic Nervous System   
Heart rate variability (HRV) examines the variation in time between normal 
heartbeats and can be used to assess the state of cardiac autonomic regulation. More 
specifically, HRV is used as an indicator of autonomic modulation of the heart. HRV 
may be assessed in various domains including the time domain, frequency domain, or by 
means of non-linear methods. Both time and frequency domain indices of HRV are 
closely related however, frequency domain analysis allows for the differentiation 
between sympathetic and parasympathetic components. The performance of a spectral 
analysis via a fast-Fourier transformation allows for signals to be separated into low and 
high frequency components. Low frequency signals are those found between 0.04-0.15Hz 
and represent both sympathetic and parasympathetic modulation of the heart. High 
frequency signals are those found between 0.15-0.4Hz and represent parasympathetic 
modulation of the heart. From this, the LF:HF ratio may also be used as an estimate of 
sympathovagal balance. A parasympathetically dominated nervous system at rest results 
in increased HF power and is considered healthy, whereas sympathetic domination results 
in a an increased LF:HF ratio and is associated with an increased risk of heart disease.               
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Susceptibility of the Nervous System to Neuropathy    
The above describes neuronal functioning and signal transmission under normal 
healthy conditions. With the support from glial cells, neurons of the somatic and 
autonomic nervous system function to send and receive signals throughout all regions of 
the body. This system is however, extremely sensitive to any disturbances and, in 
addition to physical trauma, may be influenced by alterations in other systems of the 
body including the endocrine and immune systems. 
Immunoregulatory Function  
Cytokine Production  
Cytokines are small signaling proteins involved in an array of immunoregulatory 
responses including hematopoiesis, and inflammation.45 Historically, they have been 
viewed solely as molecules produced and released by a variety of immune cells in 
response to an immune stimulus. They may be produced by cells within the brain and 
spinal cord such as neurons, astrocytes, and oligodendrocytes, or by a variety of 
circulating immune cells.34 More recently, cytokines have been shown to be associated 
with exercising skeletal muscle. These cytokines termed "myokines" are produced by 
skeletal muscle and may act to help regulate glucose levels during periods of intensive 
exercise.46  
The Immune System  
 The immune system is responsible for protecting the body against foreign, 
potentially pathogenic, molecules which would otherwise cause harm through infection 
or disease. Human immunoregulation is a complex process characterized by two branches 
of immunity; the innate and adaptive systems.47 Each system works synergistically on 
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both systemic and local levels to recognize, attack, and destroy foreign materials. Upon 
initial attack from a foreign molecule the innate system is activated. The innate system 
uses non-specific defenses including physical barriers such as the skin and mucous 
membranes, cells such as phagocytes and natural killer cells, and soluble factors such as 
complement to prevent infection.48 If the defenses of the innate system fail, the adaptive 
system is activated and pathogen specific defenses are used to fight off infection. A 
variety of lymphocytes are able to recognize antigens by means of surface receptors and 
produce specific defensive proteins and antibodies to respond.49   
Innate Immunity  
 Within the innate immune system, cells known as phagocytes including 
macrophages, dendritic cells, and neutrophils, act on foreign molecules, engulfing and 
destroying them through a process known as phagocytosis.48 Virally infected cells and 
cancer cells are dealt with in a different manner through a process known as apoptosis in 
which the cell is stimulated to undergo self-destruction. In this process, specialized cells 
of the innate immune system known as natural killer cells prevent viral spreading by 
releasing pore-forming proteins into the infected cell leading to eventual lysis.50 Natural 
killer cells, in addition to macrophages, are among the most prolific cytokine producers 
of the innate immune system and through this production, assist in the recruitment of 
additional immune cells during an immune response.50 These cytokines may function in 
autocrine or paracrine fashions and can cause a variety of responses including the up-
regulation or down-regulation of the production of other cytokines, an increase in the 
number of a particular surface receptor, or the suppression of their own effects through 
feedback inhibition.51     
19 
 
 
Adaptive Immunity  
 Immune cells known as lymphocytes, belonging to the adaptive immune system, 
produce specific responses to invading antigens. The adaptive immune system may be 
categorized into either humoral or cell mediated immunity. Humoral immunity deals with 
extracellular pathogens by means of circulating antibodies. When an antigen is present in 
circulation, phagocytes such as macrophages, monocytes, and dendritic cells, which 
function as antigen presenting cells (APC’s), are able to initiate an immune response.49 
Receptors on the surface of APC’s are activated by molecular patterns associated with a 
pathogen, leading to the increased expression of a protein found on the cell surface 
known as major histocompatibility complex 2 (MHC-2).52 This protein is able to accept 
some of the foreign digested proteins of the antigen after it has been destroyed by the 
phagocyte. It can then present this matter to either a naïve T-lymphocytes or a memory T-
lymphocyte. Naïve T-cells are a subset of T-cells which have never before encountered 
an antigen. Upon being presented with a new antigen a primary immune response is 
initiated in which the T-cell undergoes extensive proliferation within the lymph nodes 
producing further copies of T-cells capable of recognizing the specific antigen.49 Memory 
T-cells are those which have previously encountered the antigen, and as such, can 
produce a faster, stronger secondary immune response following re-exposure.53 Upon 
being presented with the antigen, T-helper cells, particularly effector cells, are stimulated 
to release cytokines. These cytokines cause the proliferation and differentiation of B-cells 
into memory cells as well as immunoglobulin secreting plasma cells. The antibodies 
produced by these new plasma cells do not directly destroy antigens but instead bind to 
specific antigens and assist in their destruction. Upon binding to the antigen, the antibody 
may act to block the toxic actions of the antigen, or cause the clumping of several 
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antigens making them more easily phagocytized.54 In addition, antibodies activate 
circulating complement which coat antigens increasing the likelihood of 
phagocytization.54 Antibodies are an effective, specialized means of destroying 
circulating pathogens. However, they are unable to enter the cell and act intracellularly.54 
As such, if the pathogen has already entered a cell, different means of immunity are 
necessary.  
Cell Mediated Immunity  
Cell mediated immunity utilizes activated T-cells in order to attack and destroy 
infected host and foreign cells. T-helper cells bind to the surface of macrophages 
whereby MHC proteins display antigenic determinants.52 This binding causes the 
macrophage to release the cytokine interleukin-1 (IL-1) which stimulates the proliferation 
of additional T-cells. The activated T-cells also release additional cytokines known as 
interleukin-2 (IL-2) which cause further proliferation of T-cells including T-helper cells 
and T-cytotoxic (Tc) cells.49 These Tc cells recognize and attach to cells expressing the 
same antigen determinants as the original MHC protein. In a process similar to that of 
natural killer cells, the Tc cell releases perforin into the infected cell causing lysis.49 The 
remnants of the destroyed cell are then engulfed and cleared by phagocytes.     
The Inflammatory Response  
The role cytokines play in cellular communication during both innate and 
adaptive immune responses is an essential component of the body’s defenses. Without 
the increased recruitment and proliferation of necessary immune cells, the body would be 
unable to cope with invading pathogens and tissue damage brought on by infection would 
result. Although healthy individuals are generally able to fight off infection, especially 
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when confronted by a pathogen dealt with in the past, at times the body does succumb to 
tissue damage. 
 Whether due to infection or physical trauma, the inflammatory response is 
triggered in order to prevent the spreading of any pathogens, and heal damaged tissue. 
After the onset of trauma, vasodilators such as histamine and bradykinin are released by 
specific leukocytes known as mast cells and basophils. As a result, vessels are triggered 
to vasodilate allowing for an increase in blood flow to the site of the injury.55 This 
hyperemia causes an increase in the rate of delivery of different immune cells, as well as 
the removal of wastes and toxins. In the initial stages of the response, clotting proteins 
such as fibrinogens travel to the injury site and help prevent the spreading of pathogens 
by forming a sticky mesh in the areas adjacent to the tissue damage.56 Once the pathogens 
are contained, phagocytic cells such as macrophages and neutrophils begin to engulf and 
destroy any foreign molecules. Additional phagocytes are recruited from the circulation 
by means of a chemical attraction to the cytokines released by local neutrophils through a 
process known as chemotaxis.55 As these newly recruited phagocytes travel towards the 
site of inflammation they are seized by the sticky membranes of local endothelial cells 
due to the local production of cell adhesion molecules.57 In addition to increased 
recruitment, enhanced leukocyte proliferation from red bone marrow is stimulated by the 
release of cytokines from activated T-cells through a process known as leukopoiesis. 
Together, this increase in leukocyte proliferation and recruitment aid in the inflammatory 
response and help return the damaged tissue to a healthy state.    
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Cytokine Homeostasis    
 The classification of cytokines is made extremely difficult due to their redundant 
and pleiotropic properties.58 This causes a large degree of overlap, making the 
categorization of cytokines a daunting task. One such method which can be used to 
distinguish the properties of one cytokine from another is by their overall effect on the 
inflammatory process. In this sense cytokines may be deemed as either pro-inflammatory 
or anti-inflammatory. Pro-inflammatory cytokines act to enhance the inflammatory 
process by promoting leukocyte recruitment and proliferation.59 In healthy individuals an 
elevation in pro-inflammatory cytokines will be seen during periods of trauma or 
infection. These cytokines possess the ability to pass freely through the blood brain 
barrier and up-regulate their own expression.60 As the damaged tissue is repaired and 
bacteria and foreign matter are engulfed and destroyed, a rise in anti-inflammatory 
cytokines occurs. These anti-inflammatory cytokines act as antagonists and deactivate 
many of the cytokine-producing immune cells to help return cytokine concentrations to 
basil levels.61 This cytokine balance is maintained in healthy individuals but a disruption 
in cytokine homeostasis has been shown to be related to several conditions including SCI.    
Immune Dysfunction and Chronic Inflammation Following SCI  
 Bidirectional communicatory pathways between the nervous, endocrine, and 
immune systems create a complex multifaceted etiological basis to immune dysfunction 
following SCI. Direct insult to the nervous system may induce immune dysfunction via 
the loss of autonomic innervation of lymphoid organs and corresponding endocrinal 
dysfunction stemming from HPA axis dysregulation. Damage to the somatic nervous 
system and the corresponding loss of motor and sensory function may also increase the 
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risk of developing a number of secondary health complications as well as metabolic 
disorders associated with a state of inflammation. In addition, a number of related 
disorders associated with a state of chronic inflammation have been found to be at a 
substantially higher prevalence following SCI. Together, such factors help explain the 
chronic inflammatory state and immune impairment typically observed following SCI.     
Autonomic Nerve Damage   
The immune system is under neuromodulatory control via the direct innervation 
of primary and secondary lymphoid tissues by autonomic nerve fibers of the sympathetic 
nervous system (SNS).22 Preganglionic sympathetic neurons originating from the spinal 
column synapse in ganglia with peripheral sympathetic neurons. These nerve fibers are 
responsible for innervating several lymphoid organs and their blood vessels including the 
spleen, thymus, and lymph nodes, whereby they act to regulate blood flow as well as 
communicate directly with immune cells.22 Within these organs, postganglionic 
noradrenergic fibers release catecholamines, such as norepinephrine (NE), for direct 
communication with lymphocytes which bear receptors for various neurally active 
hormones, neurotransmitters, and neuropeptides.62 The initial release of catecholamines 
has been shown to induce a rapid, transient increase in blood lymphocytes, however, 
prolonged exposure induces a number of anti-inflammatory effects including reduced 
circulating lymphocyte numbers and suppressed NK cell activity.20 Prolonged exposure 
to catecholamines also seem to inhibit proinflammatory cytokine production by Th1 cells, 
while having no effect or even acting to enhance the production of anti-inflammatory 
cytokines by Th2 cells.20  
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As lymphoid organs such as the spleen and adrenal gland are innervated by 
sympathetic neurons which originate from regions throughout the thoracolumbar spinal 
cord, an injury at or above this region may be expected to induce immune suppression.21 
Damage to the cervical spine would interfere with supraspinal control over preganglionic 
neurons below the injury, whereas damage at the mid-thoracic region would damage 
preganglionic sympathetic neurons directly.19 Level dependent impairment in B-cell 
function has been demonstrated in mice subjected to high (T3) vs mid-thoracic (T9) SCI. 
It was shown that only after high thoracic SCI (causing disruption of autonomic control 
of the spleen) was splenic NE elevated and immune function suppressed,21 whereas mid-
thoracic SCI (leaving autonomic control of the spleen intact) has been shown to induce 
B-cell activation, increase the synthesis of autoantibodies63 and activate autoreactive T 
cells.64 Catecholamines such as noradrenaline have also been shown to be significantly 
reduced in humans with cervical or high thoracic injuries and have been attributed to a 
loss of adrenal gland innervation and dysfunction in sympathetic pathways.65,66 
Alternatively, certain aspects of post SCI immune alterations appear to be independent of 
injury level. Similar alterations in NK cell and T cell cytotoxic activity have been 
demonstrated in humans with both high and low level injuries,23,67 as have elevations in 
viral load following infection in mouse models of high and low thoracic SCI.19 It may be 
possible that the level of injury has a greater impact on certain aspects of immunity than 
others. Additional factors such as autonomic completeness of injury, and time since 
injury may also explain some of the variability in findings.       
Damage to the SNS may also contribute to reduced immune function due to a loss 
of afferent signaling from the adrenal gland to the hypothalamus. A loss of such afferent 
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pathways would reduce facilitation of hypothalamic nuclei and may ultimately induce 
dysfunction in the HPA axis.18 Lesions on the anterior hypothalamus have been shown to 
lead to diminished numbers of nucleated spleen cells and thymocytes as well as 
diminished antibody production, while lesions on the medial hypothalamus have been 
shown to lead to diminished T and B cell numbers.18 It may be possible to speculate that 
damage to sympathetic afferents and corresponding reductions in the facilitation of 
hypothalamic nuclei could produce similar effects to that observed under conditions of 
hypothalamic lesions and contribute to the HPA axis dysfunction commonly reported 
following SCI.     
Endocrine Dysfunction  
The hypothalamic-pituitary-adrenal (HPA) axis provides an additional 
immunoregulatory pathway whereby the immune response may be influenced 
hormonally. Within this pathway the release of corticotropin releasing hormone (CRH) 
from the hypothalamus induces the release of adrenocorticotropic hormone (ACTH) from 
the pituitary, which ultimately stimulates the release of glucocorticoids such as cortisol 
from the adrenal gland. Glucocorticoids induce immunosuppressive effects by acting on 
leukocytes equipped with receptors for various stress hormones. Once bound, 
glucocorticoids induce the up-regulation of anti-inflammatory cytokines as well as the 
suppression of proinflammatory cytokines and other proinflammatory mediators.68 
Glucocorticoids also suppress the maturation, differentiation, and proliferation of a 
number of immune cells. Due to this critical hormonal influence, an imbalance in the 
HPA axis in either direction may result in immune dysfunction. Excessive glucocorticoid 
production may result in immunosuppression and an increased risk of infection, whereas 
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a non-responsive HPA axis may result in a lack of suppression resulting in an elevated 
inflammatory state. 
Proinflammatory cytokines possess the ability to up-regulate the HPA axis and as 
such, may contribute to HPA axis over-activation under conditions of chronic 
inflammation as typically observed following SCI.  Such an influence may lead to the 
excessive production of glucocorticoids from the adrenal gland causing elevated 
circulating levels and a greater immunosuppressive influence. Increased levels of urine-
free cortisol, stimulated by elevated plasma ACTH, have been demonstrated in humans 
following SCI and have been shown to remain elevated for 3-months post injury.18,69 This 
process may induce the hormonally driven suppression of both the innate and adaptive 
immune systems and explain in part, the increased susceptibility to infection and 
reduction in wound healing capabilities observed following SCI.70 Such an influence has 
been demonstrated within the innate immune system by reductions in NK cell function as 
well as in the adaptive immune system by reductions in T-cell function which were 
shown to be inversely related to cortisol levels.18 The majority of studies demonstrating 
this up-regulation of the HPA axis and elevated levels of cortisol have however, typically 
been performed under acute SCI conditions. It may be possible that under chronic 
conditions, the ongoing stress placed upon the HPA axis could result in adrenal 
insufficiencies. Several studies performed on individuals with chronic SCI have eluded to 
such an effect.  
 Individuals with chronic SCI have been shown to have reduced basal cortisol 
levels and a reduced cortisol response to exogenous CRH administration.71 A similar 
blunted cortisol response has also been demonstrated following intramuscular injection of 
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ACTH.72 Interestingly, in a similar study performed under acute SCI conditions, ACTH 
injection was shown to produce a normal elevation in plasma hydroxycorticosteroid 
levels.73 These results may further support the theory that SCI results in adrenal 
insufficiencies which take time to develop and are not apparent until the chronic stages. 
Such effects have been suggested to be the result of mild adrenocortical atrophy and/or a 
reduction in the sensitivity of corresponding adrenal receptors.71 Of note, an increased 
adrenal volume within chronic SCI has been demonstrated in individuals with impaired 
adrenal reserves, suggesting a reduction in adrenal receptor sensitivity may be the more 
likely cause.74 However, due to a limited sample size, further studies are required to make 
any definitive conclusions regarding the true cause of adrenal insufficiency following 
SCI. Regardless of the cause, if the adrenal gland does not sufficiently respond to ACTH 
released by the pituitary, adrenal insufficiencies may result, causing reduced levels of 
circulating glucocorticoids and a lack of immunosuppression, resulting in an elevated 
inflammatory state.68 
Therefore, whether due to an elevation in glucocorticoid production caused by 
overstimulation of the HPA axis, or an eventual reduction in glucocorticoid production 
caused by desensitization of the ACTH receptors on the adrenal gland, immune 
dysfunction may result. This may explain in part, an endocrine role in chronic 
inflammation following SCI. 
Somatic Nerve Damage  
 A loss of motor and/or sensory function following SCI places individuals at a 
heightened risk for the development of a variety of acute infections. Secondary health 
complications such as urinary tract infections (UTI) and pressure ulcers are common 
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occurrences in this population, resulting in frequent spikes in inflammatory mediators. A 
recent study by Street et al. (2013), followed a group of 171 patients receiving acute care 
for traumatic spinal cord injury and found 77% experienced an adverse event during their 
stay including UTI’s, pneumonia, neuropathic pain, pressure ulcers, and delirium. Of 
these complications, UTI’s were found to be the most common occurrence.75 
A loss of voluntary motor control of the bladder and/or the ability to sense when 
the bladder is full, may result in insufficient bladder voidance. This results in the 
accumulation of stagnant urine within the bladder, allowing for an increase in bacterial 
growth and a resulting risk of infection.14 UTI’s have been consistently shown to be the 
most frequent cause of re-hospitalization in the SCI population, accounting for 
approximately 24-54% of cases.76 This indicates that UTI’s are a common occurrence, 
not only during the acute stages of SCI, but also long term as well.      
Both paralysis and atrophy of skeletal muscle, in combination with a loss of 
functioning dermatomes, also increases the risk of tissue damage and infection via 
pressure ulcer development. An inability to shift one’s body weight and/or sense the pain 
and pressure associated with remaining in the same seated or supine position for an 
extended period of time, may lead to the occlusion of blood flow to an area of tissue. As 
such, various areas of the body, particularly the gluteal and sacral regions, may be at risk 
for oxygen deprivation and necrosis.14 Individuals with SCI are at a particularly high risk 
for pressure ulcer development with approximately 40% of individuals developing a 
pressure sore within any three year period.76 
Acute secondary health complications such as these result in an acute inflammatory 
response characterized by a spike in proinflammatory mediators.77,78 The frequent 
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occurrence of such complications paired with slower healing times makes this population 
prone to frequent and prolonged elevations in inflammatory mediators, further 
compounding the already elevated basal inflammatory state. 
Metabolic Disorders   
Following SCI, the loss of motor function typically leads to inactivity and 
increases the likelihood of living a sedentary lifestyle. Further, the additional physical, 
psychological and biochemical demands placed on the body makes proper diet even more 
crucial to meet the body’s elevated nutrient requirements. Unfortunately, a lack of 
awareness in this area combined with the cost and effort involved in maintaining a 
healthy diet places this population at high risk for nutrient deficiencies. Together, this 
places the SCI population at a higher risk for the development of metabolic disorders 
such as obesity, type 2 diabetes and atherosclerosis;24–26 each of which are independently 
associated with a chronic inflammatory status.8,24  
Obesity is now classified as an inflammatory disorder due to the discovery that 
adipose tissue acts as an endocrine organ, possessing the ability to secrete 
proinflammatory mediators, termed adipokines, such as TNF-α, IL-1, and IL-6.79 As 
such, an abundance of adipose tissue, as seen in obesity, may result in the overproduction 
of proinflammatory mediators and contribute to a low-grade inflammatory state. Adipose 
tissue is also known to secrete adiponectin, a protein with a critical role in fatty acid 
oxidation and glucose regulation.80 Elevated concentrations of proinflammatory 
cytokines have however, been shown to blunt the release of adiponectin thereby limiting 
its ability to induce fatty acid oxidation and aid in glucose regulation by means of 
enhanced insulin sensitivity. This decrease in fatty acid oxidation further contributes to 
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the over-abundance of adipose tissue, which in turn leads to a greater secretion of 
proinflammatory cytokines, creating a vicious inflammatory cycle. A reduction in plasma 
concentrations of adiponectin has been reported in individuals with obesity, as well as in 
those with type 2 diabetes, and cardiovascular disease.81  
 Closely related to this obesity-induced inflammatory state, is a state of insulin 
resistance associated with the development of type 2 diabetes. Several cross-sectional 
studies using non-diabetic subjects have demonstrated that those with impaired glucose 
tolerance displayed elevated concentrations of proinflammatory cytokines such as C-
reactive protein (CRP), sialic acid, TNF- α, and IL-6. Additionally, each were shown to 
be positively correlated with insulin resistance.10,11,82 In addition to adiponectin related 
mechanisms, a number of proinflammatory cytokines including TNF-α, IL-1, and IL-6 
have each been suggested to play a role in insulin resistance via the down-regulation of 
GLUT 4 gene transcription and translocation, as well as the inhibition of insulin receptors 
by mechanisms related to the up-regulation of the suppressors of cytokine signaling 
(SOCS) proteins.83,84 Insulin resistance may in turn, result in elevated blood glucose 
concentrations placing excess strain on the kidneys and ultimately resulting in tissue 
damage and further inflammation.     
Atherosclerotic plaques associated with cardiovascular disease are also influenced 
by, and further induce, elevations in proinflammatory mediators. A variety of 
proinflammatory mediators have the ability to induce vasoconstriction, thereby increasing 
shear force on vessels and the likelihood of endothelial damage. Additionally, 
proinflammatory mediators act to increase chemotaxis and the production of adhesion 
molecules thereby increasing leukocyte infiltration and platelet aggregation at the site of 
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endothelial damage.12 Together, these mechanism act to increase the risk of plaque 
formation in the form of an atherosclerotic plaque. Such plaques are treated similarly to 
that of any other form of tissue damage with the elicitation of an inflammatory response. 
However, in the case of an atherosclerotic plaque, the inflammatory response is unable to 
repair the damaged tissue. Instead, migrating immune cells become trapped within the 
plaque and release inflammatory mediators contributing to an even greater inflammatory 
response and state of low-grade inflammation.12    
For these reasons, among others, the highly sedentary lifestyle often adopted 
following SCI, in combination with a lack of necessary dietary alterations may contribute 
to the chronic low-grade inflammatory response. 
Mononuclear Cells  
Following SCI, changes in immune-regulation have been shown to coincide with 
chronically elevated levels of circulating proinflammatory cytokines. This elevation is 
apparent in both the acute and chronic stages of SCI and has been shown whether or not 
the individual is symptomatic for secondary health complications.13 There is evidence to 
suggest that this occurs due to a bias in the immune system towards a particular subset of 
T-cells. T-cells can be categorized into either effector T-cells or regulatory T-cells. 
Although overall levels stay relatively similar, after SCI there is a shift in the 
predominant T-cell type whereby a greater proportion of effector T-cells is evident.13 
Regulatory T-cells are crucial in the maintenance of immunological tolerance and 
produce immunosuppressive effects through the production of anti-inflammatory 
cytokines.13 Effector T-cells differentiate into one of two helper T-cell subsets including 
T-1 helper (Th1) cells or T-2 helper (Th2) cells. Th1 cells are responsible for the 
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promotion of cell mediated immune responses and predominantly produce pro-
inflammatory cytokines such as, interleukin-2 (IL-2), interferon-gamma (IFN-y), and 
tumour necrosis factor beta (TNF-β). Th2 cells promote humoral immune responses and 
predominantly produce anti-inflammatory cytokines such as, interluekin-4 (IL-4) and 
interluekin-10 (IL-10).45 A shift towards a Th1 cell dominated immune system following 
SCI would lead to a greater proportion of pro-inflammatory cytokines. This dominance 
may be due to several factors including antigen quantity, and the initial APC interaction 
with T-cells.85 For example, APC’s known as dendritic cells will induce the development 
of Th1 cells when in the presence of high antigen levels. As individuals with SCI are 
prone to secondary health complications, the resulting pathogen-derived products may 
influence the T-helper cell response. This shift to a greater proportion of pro-
inflammatory cytokines would lead to an up-regulated immune response and potentially a 
state of chronic inflammation.    
Related Disorders   
A number of disorders including depression and neuropathic pain are associated 
with a state of chronic inflammation. Individuals diagnosed with major depression have 
been consistently reported to demonstrate elevated levels of proinflammatory 
cytokines,27,28 and those with neuropathic pain have been shown to have altered levels of 
inflammatory mediators with elevations in the proinflammatory cytokines TNF, IL-6, and 
IL-2 along with reductions in anti-inflammatory cytokines such as IL-10 and IL-4.13,29 As 
these disorders have a highly elevated prevalence following SCI, they too may contribute 
to the elevated inflammatory status observed in this population. The prevalence of 
depression following SCI is estimated to be 5 times greater in comparison to the general 
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population with rates of approximately 20-40%.30,31 Neuropathic pain is also far more 
prevalent, affecting an estimated 29-75% of the SCI population.32 Although the 
inflammatory mechanisms behind these disorders are not fully understood, the ability of 
proinflammatory cytokines to act as neuromodulators allows them to contribute to these 
disorders via both direct and indirect influences.5           
Cytokines have the ability to directly influence the central nervous system and 
play a role in a variety of responses including behaviour modification by accessing the 
brain through leaky sites of the blood brain barrier (BBB) via the circumventricular 
organs5, or utilizing specific active transporters to cross the BBB.6 Alternatively, 
cytokines can communicate by acting on the vagal afferents thereby avoiding the need to 
cross the BBB.4 Proinflammatory mediators have also been suggested to directly 
influence nociceptors, by reducing ion channel activation thresholds leading to peripheral 
sensitization.86 
Proinflammatory cytokines also possess the ability to indirectly influence 
neuronal function via their ability to alter the regulation of key enzymes. The chronically 
elevated levels of proinflammatory cytokines often reported following SCI, may 
therefore result in chronically up-regulated enzyme activity leading to potential protein 
imbalances related to both depression and neuropathic pain. For example, a number of 
proinflammatory cytokines have been shown to up-regulate the enzyme indoleamine 2,3-
dioxygenase of the kynurenine pathway. As this enzyme is responsible for the 
degradation of tryptophan, a critical precursor in the synthesis of serotonin, its chronic 
up-regulation may result in serotonin deficiencies and related depressive symptoms.87 
Proinflammatory cytokines have also been shown to up-regulate the enzyme 
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cyclooxygenase (COX). This enzyme is responsible for the production of potent, 
proinflammatory eicosanoids with established pain inducing properties such as 
prostaglandin 2 (PGE2).88 An up-regulation of COX may therefore result in greater and 
far more frequent neuropathic pain.          
It is debated whether an elevated inflammatory status is the product of, or rather 
the cause of such disorders. However, as both psychological stress and neurological 
damage would be expected to result in an elevation in proinflammatory mediators, it is 
likely a combination of effects.  
The Inflammatory Etiology of Neural Disorders 
The Inflammatory Etiology of Depression and Cognitive Impairment  
 
Both depression and cognitive impairment may share a closely linked 
inflammatory etiology stemming from a cytokine-induced imbalance in the kynurenine 
pathway. As this pathway provides the primary route for tryptophan (TRP) degradation, it 
plays a major role, not only in the maintenance of serotonin (5-HT) synthesis, but also in 
the critical balance between neurotoxic and neuroprotective metabolites. As such, a state 
of chronic inflammation, as is commonly reported in cases of depression and severe 
cognitive deficits, may contribute to the pathogenesis of each of these disorders.27,28,89,90 
The Kynurenine Pathway  
 
 The kynurenine (KYN) pathway involves a cascade of enzymatic steps 
responsible for the degradation of tryptophan (TRP) into a number of metabolites, known 
as kynurenines. This pathway is responsible for approximately 95% of whole body TRP 
metabolism, and is of critical importance concerning the maintenance of several key 
amino acids with neuromodulatory roles.91,92 As TRP is the precursor for serotonin (5-
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HT) synthesis within the brain, the maintenance of sufficient levels has important 
implications concerning depression. Additionally, several TRP metabolites such 
quinolinic acid (QUIN) and kynurenic acid (KYNA) have roles in symptoms of both 
depression and cognitive impairment, further stressing the importance of a strictly 
controlled rate of TRP metabolism.   
 The degradation of TRP is controlled by two rate limiting enzymes known as 
indoleamine 2,3-dioxygenase (IDO), and tryptophan 2,3-dioxygenase (TDO).87,93 
Together, under the regulation of cytokines, steroids, and growth factors, these enzymes 
control the conversion of TRP into the first metabolite of the kynurenine pathway; 
kynurenine (KYN). This metabolite is then further metabolized along one of two distinct 
branches of this enzymatic cascade including the kynurenine-kynurenic acid (KYN-
KYNA) branch and the kynurenine-nicotinamide adenine dinucleotide (KYN-NAD) 
branch.87 Within the former branch, KYN is further converted to the metabolite 
kynurenic acid (KYNA) via the enzyme kynurenine aminotransferase (KAT). The latter 
branch utilizes the enzyme kynurenine 3-monooxygenase (KMO) to convert KYN to the 
metabolite 3-hydroxykynurenine (3-HK) and further in the cascade, quinolinic acid 
(QUIN). 
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Figure 1: Simplified depiction of tryptophan breakdown in the kynurenine pathway  
Tryptophan (TRP) that is not transported across the blood brain barrier (BBB) for the synthesis of 
serotonin (5-HT) is degraded into kynurenine (KYN) by the enzymes indoleamine 2,3-
dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO). After this point, KYN is further 
degraded along one of two distinct branches; either the kynurenine-nicotinamide adenine 
dinucleotide (KYN-NAD) branch, or the kyneine-kynurenic acid (KYN-KYNA) branch. Within 
the KYN-NAD branch, KYN is acted on by the enzyme kynurenine 3-monooxygenase (KMO) 
whereby it is converted to 3-hydroxykynurenine (3-HK) and later quinolinic acid (QUIN) via a 
spontaneous reaction (and ultimately NAD+). Within the KYN-KYNA branch, KYN is acted on 
by the enzyme kynurenine aminotransferase (KAT) whereby it is converted to kynurenic acid 
(KYNA). 
 
The kynurenine pathway has both a peripheral and central component, and as they 
are not completely autonomous, the central component is heavily influenced by that of 
the periphery. The rate limiting enzyme TDO has been shown to be highly expressed 
within various regions of the brain including the hippocampus and cerebellum.93 Both 
IDO and TDO have however been shown to be expressed at substantially lower levels 
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within the brain than in the periphery making the concentration of kynurenines within the 
brain largely influenced by those transported across the BBB from the periphery.94 
Tryptophan, as well as the peripheral kynurenines, KYN and 3-HK are readily 
transported across the BBB via specialized transporters. Once in the brain, these TRP 
metabolites may become further degraded to produce the kynurenines KYNA and QUIN, 
which do not easily cross the BBB from the periphery (making within brain levels largely 
dependent on the synthesis from these kynurenine precursors).95 KYNA and QUIN are 
synthesized along distinct pathways within the brain due to their reliance on their 
respective KAT and KMO enzymes. Astrocytes possess KAT while lacking KMO 
thereby allowing them to participate only in the conversion of KYN to KYNA. 
Alternatively, microglia possess the enzyme KMO, allowing them to convert KYN to 3-
HK which is later converted to QUIN via a spontaneous reaction further downstream.96 
An appropriate balance between these 2 branches of the kynurenine pathway is therefore 
critical in the maintenance of appropriate QUIN and KYNA levels within the brain.    
 Under healthy conditions the peripheral component of the kynurenine pathway is 
well regulated, resulting in a healthy balance between peripheral concentrations of TRP 
and its kynurenine metabolites. As such, appropriate levels of TRP and its BBB 
transportable metabolites, KYN, and 3-HK are available for transportation into the brain. 
This allows for the synthesis of adequate levels of the neurotransmitter 5-HT, and the 
neuroactive kynurenines KYNA, 3-HK, and QUIN, within the brain.     
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Figure 2: Peripheral and central kynurenine pathway interaction 
As indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) are found at only 
very low concentrations within the brain, concentrations of within-brain tryptophan (TRP) and 
kynurenines are largely dependent on those from the periphery. TRP from the periphery competes 
with other large neutral amino acids (LNAA) for passage across the blood brain barrier (BBB) to 
be used in the synthesis of serotonin (5-HT). Kynurenine (KYN) and 3 hydroxykynurenine (3-
HK) are also capable of crossing the BBB whereby they participate in the production of 
kynurenic acid (KYNA) and quinolinic acid (QUIN) which do not easily cross it. 
 
 
The Kynurenine Pathway and Chronic Inflammation  
 
 During a typical immune challenge, the body responds with an acute elevation in 
peripheral proinflammatory cytokines. Certain cytokines, such as interferon gamma 
(IFN-y), up-regulate IDO activity, thereby causing an elevation in TRP degradation and 
an increased production of kynurenines.97,98 As various parasites, viruses, and bacteria 
rely on TRP to grow and spread throughout the body, this acute response is a crucial 
adaptive mechanism meant to reduce TRP availability and thereby limit the spread of the 
pathogen.97 During a healthy immune response, the elevation of proinflammatory 
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cytokines is followed by an elevation in anti-inflammatory cytokines, acting to restore a 
balance in inflammatory mediators.  
 However, under a state of chronic inflammation, proinflammatory cytokines are 
maintained at a perpetually elevated state. This results in the chronic up-regulation of 
IDO leading to a potential lasting shift in the kynurenine pathway. This shift may lead to 
dramatic reductions in peripheral TRP availability as well as a surplus of peripheral 
kynurenines.2 Elevated concentrations of kynurenines such as KYN, 3-HK, and QUIN 
have been shown to suppress T-cell proliferation and inhibit the production of TH1 
cytokines.99,100 Such an effect may partly explain the impact that TRP metabolism has on 
immunity under pathological conditions.  A reduction in peripheral TRP concentrations 
may also result in a TRP deficit within the brain, thereby leading to reduced levels of 5-
HT synthesis. In addition, TRP metabolites within the brain may become elevated via 
several mechanisms. First, the surplus of peripheral kynurenines may result in elevated 
levels of KYN and 3-HK within the brain due to their ability to cross the BBB. Second, 
during an inflammatory response, macrophages, which house key enzymes, have the 
ability to infiltrate the brain and thereby participate in the production of kynurenines. 
Lastly, as cytokines are able to cross the BBB they are able to up-regulate corresponding 
enzymes within astrocytes, microglia and invading macrophages resulting in an even 
further up-regulated production of kynurenines.101 Together, these inflammatory based 
mechanisms may result in a 5-HT deficit and surplus of kynurenines within brain which 
have important implications in symptoms of both depression and cognitive impairment.  
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Figure 3: Influence of chronic inflammation on the kynurenine pathway  
Certain proinflammatory cytokines possess the ability to up-regulate enzymes of the kynurenine 
pathway, thereby increasing the rate of tryptophan (TRP) degradation and production of 
kynurenines in the periphery. This may result in reduced concentrations of peripheral TRP and 
elevated peripheral levels of kynurenines. The reduced levels of peripheral TRP may then result 
in insufficient levels within the brain and a corresponding serotonin (5-HT) deficit. 
Proinflammatory cytokines also up-regulate enzymes in the brain, housed within astrocytes, 
microglia, and infiltrating macrophages, which utilize the elevated kynurenine concentrations for 
the production of further metabolites such as quinolinic acid (QUIN) and kynurenic acid 
(KYNA). 
 
 
Depression  
 
An elevated inflammatory status may influence depressive symptoms via several 
potential mechanisms related to neuroactive compounds of the kynurenine pathway. First, 
proinflammatory cytokines such as IFN-y, interferon alpha (IFN-α), interleukin-1 beta 
(IL-1β) and tumour necrosis factor alpha (TNF- α) have each been shown to directly up-
regulate serotonin transporter (SERT) proteins within the brain leading an increased 
reuptake of 5-HT and a corresponding reduction in extracellular concentrations.102,103 
Second, proinflammatory mediators may influence depressive symptoms by means of 
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several indirect mechanisms associated with alterations in the activity of enzymes of the 
kynurenine pathway.  
The up-regulation of IDO and TDO and the resulting increased rate of TRP 
degradation may result in a TRP deficit within the periphery. This may lead to an 
insufficient level of TRP transportation across the BBB and ultimately contribute to a 5-
HT deficit within the brain. The importance of maintaining appropriate peripheral levels 
of TRP have been evidenced by a number of studies in which reductions of 5-HT 
synthesis and relapses in depressive symptoms have been demonstrated following the 
transient reduction of TRP levels by means of dietary restriction.104–108 In order to be 
utilized in the synthesis of 5-HT, peripheral tryptophan must compete with other large 
neutral amino acids (LNAA) to cross the blood brain barrier via a common transport 
mechanism. As an over-activation of IDO and TDO induces a selective decline in 
peripheral tryptophan levels, a reduction in the peripheral TRP/LNAA ratio results, 
thereby reducing TRP availability for the synthesis of 5-HT.87  Therefore under 
conditions of chronically elevated levels of proinflammatory cytokines the resulting 
alterations in enzyme activity and peripheral tryptophan levels may contribute to a 5-HT 
deficit within the brain. 
 The up-regulation of IDO and TDO also results in an elevated peripheral 
concentration of 3-HK and QUIN. Peripheral 3-HK is able to cross the BBB and induce 
oxidative damage via the production of reactive oxygen species (ROS) following an 
interaction with the enzyme xanthine oxidase.109 Additionally, 3-HK may be further 
metabolized within microglia along the KYN-NAD branch of the kynurenine pathway to 
produce QUIN within the brain. QUIN is a potent agonist of a glutamatergic receptor 
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known as the N-methyl-D-aspartate (NMDA) receptor. These receptors are heavily 
concentrated on the hippocampus and play an important role in synaptic plasticity. When 
at elevated concentrations, QUIN is capable of inducing excitotoxicity by causing an 
over-activation of NMDA receptors leading to an increased influx of calcium (Ca+) and 
corresponding neuronal damage.110 This can also lead to the production of additional free 
radicals and further contribute to the oxidative stress brought on by 3-HK. In this way, 
both 3-HK and QUIN may contribute to neurodegeneration associated with depression.  
 The ability of elevated QUIN concentrations to cause an over-activation of 
NMDA receptors may also contribute to the hippocampal atrophy and hypothalamic-
pituitary-adrenal (HPA) axis over-activity commonly reported in individuals with major 
depression.111–115 The hippocampus plays an integral role in the attenuation of the HPA 
axis via a glucocorticoid induced negative feedback loop. When glucocorticoids, such as 
cortisol, are released by the adrenal glands they act on corresponding receptors of the 
hippocampus, resulting in an inhibitory cascade within the HPA axis. Specifically, the 
activation of glucocorticoid receptors on the hippocampus results in a blunted release of 
corticotropin releasing hormone (CRH) from the hypothalamus, which inhibits the 
release of adrenocorticotropic hormone (ACTH) from the pituitary, ultimately reducing 
glucocorticoid release from the adrenal gland. However, overstimulation of NMDA 
receptors may result in hippocampal atrophy and a corresponding loss of glucocorticoid 
receptors. This may result in the loss of negative feedback and HPA axis over-activity. 
An elevation in QUIN levels within the brain as well as elevations in systemic cortisol 
levels may therefore contribute to these aspects of depression. Elevated levels of both 
QUIN and cortisol have been demonstrated in individuals with depression.116,117     
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 In addition to these proposed mechanisms, several pre-clinical and clinical lines 
of evidence support the relationship between proinflammatory cytokines and depression. 
Individuals diagnosed with major depression have been consistently reported to 
demonstrate elevated levels of proinflammatory cytokines.27,28,89 Evidence that such 
elevations contribute to depression via an IDO related mechanism has also been 
demonstrated following cytokine therapy, utilized during human cancer trials. The acute 
administration of the pro-inflammatory cytokines, interleukin-2 (IL-2) and interferon- α 
(IFN- α), was shown to induce an increase in IDO activity and a corresponding reduction 
in both the peripheral TRP/LNAA ratio and absolute TRP concentrations.118 Such 
changes in enzyme regulation and protein balances have been shown to result in the 
development of major depressive disorders in 15-40% of patients undergoing cytokine 
therapy with IFN-α.119 As such, a state of chronic inflammation associated with an 
elevation in inflammatory mediators may contribute to symptoms of depression by means 
of various mechanisms associated with imbalances in the kynurenine pathway.  
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Figure 4: Inflammatory mechanisms of depression  
Proinflammatory cytokines may contribute to depressive symptoms by means of various 
mechanisms. (1) Proinflammatory cytokines act on serotonin transporter (SERT) proteins within 
the brain causing a re-uptake of serotonin (5-HT) and corresponding reduced extracellular 
concentrations. (2) Proinflammatory cytokines up-regulate enzymes such as indoleamine 2,3-
dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) resulting in reduced tryptophan 
(TRP) availability, ultimately contributing to reduced 5-HT synthesis. (3) Both 3-
hydroxykynurenine (3-HK) and quinolinic acid (QUIN) may contribute to elevated levels of 
reactive oxygen species (ROS) and oxidative stress within the brain. (4) QUIN may induce N-
methyl-D-aspartate (NMDA) over-activity thereby contributing to hippocampal atrophy and a 
loss of glucocorticoid receptors, ultimately leading to a loss of negative feedback and 
hypothalamic-pituitary-adrenal (HPA) axis over-activity. 
 
 
Cognitive Impairment  
 
Cognitive impairment has been commonly demonstrated in depressed individuals 
and the severity of deficits have been shown to correlate with the number of depressive 
episodes experienced.120 The relationship between depression and cognitive impairment 
is not fully understood, however, they may share a closely linked inflammatory etiology. 
The influence of chronic inflammation on hippocampal volume and HPA axis 
dysregulation may play an important role in the severity of each of these disorders. 
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Hippocampal volume loss in the form of reduced grey matter density has been 
demonstrated in depressed individuals and has been shown to correlate with reduced 
scores in verbal recognition memory.121 As previously discussed, there is evidence to 
support a role for chronic inflammation in the reduction in hippocampal volume 
involving heightened levels of metabolites and steroid hormones such QUIN and 
glucocorticoids. The potential apoptosis and/or inhibition of neurogenesis caused by 
over-activation of the hippocampus would be expected to result in cognitive deficits, due 
to the integral role the hippocampus plays in learning and memory. It may also lead to a 
vicious cycle whereby the loss of hippocampal-mediated inhibition of the HPA axis 
results in excess glucocorticoid production, ultimately further contributing to the extent 
of hippocampal atrophy.    
 In addition to the potential structural damage, the shift in the kynurenine pathway, 
brought on by chronic inflammation, may also contribute to cognitive deficits, via 
reductions in neurotransmitter release. Elevated concentrations of KYN within the brain 
result in its metabolism along one of the two distinct branches of the kynurenine 
pathway. The KYN-NAD branch results in the production of 3-HK and QUIN which 
have implications in the production ROS and excitotoxicity (as previously discussed). 
However, the primary enzyme of the KYN-NAD branch, KMO, has been shown to be far 
less active in the brain in comparison to the periphery, and as such, becomes rapidly 
saturated by elevated levels of KYN.122 This may result in a shift in the kynurenine 
pathway towards the KYN-KYNA branch and an increased production of KYNA by the 
more active KAT enzyme.      
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 KYNA acts as an antagonist of the alpha-7-nicotinic acetylcholine receptor 
(α7nAChR) and to a lesser extent, the glycine co-agonist site of the N-metheyl-D-
asparate receptor (NMDAR).123 Each of these receptors can be found on the hippocampus 
and are known to play important roles in synaptic plasticity, associate with learning and 
memory.124 The inhibition of α7nACh receptors by KYNA has been shown to result in 
the reduced release of neurotransmitters such as glutamate, acetylcholine, and dopamine; 
each of which play critical roles in cognitive processes.125–127 Additionally, the reduction 
of KYNA has been demonstrated to enhance extracellular glutamate and corresponding 
cognitive behavior124 
 This relationship has been demonstrated using animal models whereby elevations 
of KYNA within the brain have been shown to induce cognitive deficits in contextual 
learning and memory. Whether induced indirectly, via intraperitoneal administration of 
kynurenine, or via direct intracerebroventricular KYNA infusion, corresponding 
elevations in KYNA levels within the brain have been shown to induce spatial working 
memory deficits and reduced orienting behavior in mice.128,129 Similar results have been 
demonstrated in healthy humans whereby administration of the non-competitive NMDA 
glutamate receptor antagonist, ketamine, has been shown to result in reductions in verbal 
declarative memory.130  Alternatively, animal models displaying low levels of KYNA 
have demonstrated superior cognitive performance. This has been shown using 
kynurenine aminotransferase II (KAT II) knock-out mice, who lack the major enzyme for 
brain KYNA formation. These mice exhibited a 66% reduction in extracellular KYNA 
accompanied by a significantly increased performance in object exploration and 
recognition, passive avoidance, and spatial discrimination.124 
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 A shift in the kynurenine pathway as well as corresponding elevated levels of 
inflammatory mediators have also been demonstrated in humans afflicted with conditions 
associated with severe cognitive deficits. Individuals with Alzheimer’s disease have been 
shown to exhibit reduced peripheral tryptophan concentrations, along with heightened 
levels of the tryptophan metabolite, QUIN.131 Additionally, severe elevations, of up to 
25-fold, of the proinflammatory cytokine TNF-α have been demonstrated.132 As TNF-α is 
a proinflammatory cytokine and potent IDO activator, it may suggest an inflammatory 
contribution to the molecular imbalances observed in this population. Further to these 
observations, the administration of the TNF-α antagonist, etanercept, has been shown to 
result in improved cognitive scores over a 6-month administration period as well as 
acutely following a single dose.132,133 Such improvements provide further evidence of a 
role for inflammatory mediators in cognitive processes via alterations in enzyme 
regulation and corresponding imbalances of critical neuroactive compounds.  
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Figure 5: Inflammatory mechanisms of cognitive impairment  
Hippocampal atrophy caused by the over-activation of respective receptors for glucocorticoids 
and quinolinic acid (QUIN) may contribute to cognitive impairment. Additionally, elevated 
concentrations of kynurenine (KYN) that is preferentially metabolized along the kynurenine-
kynurenic acid (KYN-KYNA) branch of the kynurenine pathway results in elevations of 
kynurenic acid (KYNA). As KYNA acts as an antagonist for both the alpha-7-nicotinic 
acetylcholine (α7nACh) and N-methyl-D-aspartate (NMDA) receptors it may contribute to 
cognitive deficits by reducing neurotransmitters such as glutamate, acetylcholine, and dopamine. 
 
The Inflammatory Etiology of Neuropathic Pain  
Nociceptive pain reflects our capacity to detect potentially harmful stimuli. This 
sensation is mediated in the periphery by sensory neurons known as nociceptors which 
transmit information through nociceptive pathways in the spinal cord to the brain. 
Peripheral tissue injury/inflammation causes reversible changes to this sensory system 
causing pain hypersensitivity whereby reduced thresholds at the peripheral nerve 
terminals of nociceptors allow mechanical, thermal, and chemical stimuli to be converted 
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into voltage potentials. This process is beneficial as ensures any contact or overuse of the 
damaged area is avoided until healing has occurred. However, when the nervous system 
itself is injured, neuropathic pain may result whereby threshold changes are persistent or 
permanent and allodynia and/or hyperalgesia may result.134 In this case, nerve lesions 
result in the heightened peripheral sensitization of nociceptors leading to ectopic firing of 
injured sensory axons. Traditionally, this phenomenon has been considered a purely 
neuronal response, however, it is now well established that supporting glial cells and the 
environment with which the nociceptor interacts are also important factors in neuronal 
function.135 Evidence of this has been demonstrated as alterations in ion channel 
trafficking and expression at the nociceptor nerve terminal have been shown to occur in 
both injured and uninjured sensory fibers.136   
Chemicals which surround peripheral nerve terminals of nociceptors determine 
baseline sensitivity and activation thresholds.135 In this way, inflammatory mediators 
such as cytokines can sensitize nociceptors such that they respond to normally innocuous 
thermal and mechanical stimuli.135 Proinflammatory cytokines such as IL-1B, IL-6, and 
TNF-α have been proposed to induce algesic effects by means of both indirect and direct 
influences on nociceptors.137 Indirectly, cytokines can reduce nociceptive thresholds in a 
prostaglandin-dependent manner. Proinflammatory cytokines cause the up-regulation of 
the enzyme COX which leads to increased gene transcription of further mediators such as 
NO and PGE2. These mediators are believed to induce algesic effects through their 
ability to sensitize nociceptors by acting directly on receptors on the neuronal cell 
membrane.88 A potential direct neural influence of cytokines has also been suggested due 
to the rapid onset of pain following their administration in animal models. For example, 
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injection of IL-1B excites nociceptive fibers within 1 minute of administration, indicating 
a more direct action then the aforementioned prostaglandin dependent mechanism.137 IL-
1B has also been implicated in neuropathic pain mechanisms based upon the significant 
reduction in mechanical hypersensitivity in mice with a genetic impairment of IL-
1B.138,139   
The overall outcome of human chronic pain states may correlate strongly with the 
balance between pro and anti-inflammatory cytokines. Studies have shown that 
individuals with complex regional pain syndrome, painful neuropathy, and SCI have 
systemic increases in pro-inflammatory cytokines TNF, IL-6, and IL-2, while anti-
inflammatory cytokines IL-10 and IL-4 are reduced.13,29 Alternatively, studies examining 
subjects with painless neuropathies have shown elevated levels of anti-inflammatory 
cytokines.140 There is also evidence in animal models that blockade of proinflammatory 
cytokines or administration of anti-inflammatory cytokines reduces neuropathic 
hyperalgesia,141–143 whereas administration of the proinflammatory cytokines IL-1B and 
TNF reduce nociceptive thresholds and induce further pain.144 Furthermore, 
proinflammatory cytokines induce the production of one another which may lead to a 
positive feedback loop of increasing chronic inflammation and pain if not adequately 
suppressed.   
Therefore, anti-inflammatory treatments to help shift the TH1:TH2 balance 
whereby proinflammatory cytokines are reduced and anti-inflammatory cytokines are 
increased may be an effective strategy for treatment chronic neuropathic pain.  
The Inflammatory Etiology of Neural Deficits  
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At highly elevated concentrations certain cytokines (eg. TNF-α) have been shown 
to directly influence nerve conduction in a reversible dose dependent manner.34 This has 
been demonstrated using spinal cord tissue in ex-vivo animal models. Although no direct 
evidence of such an effect occurring in humans has been sufficiently demonstrated, 
indirect evidence exists to suggest this potential role. In a case study performed by 
Mcdonald et al. (2002), a complete tetraplegic was examined 5 years post injury upon 
beginning an intensive diet and exercise program.145 After undergoing no observable 
changes for the initial 5 years post injury, the initiation of the diet and exercise program 
resulted in a dramatic reduction in secondary health complications over the following 
several years. Interestingly, the reduction in infections was matched by significant 
improvement in both motor and sensory scores. The improvement in sensation is of 
particular interest as this cannot be considered a direct result of the training itself. It is 
important to note that that this study did not assess inflammatory mediators. However, it 
is possible to speculate that the reduction in secondary health complications would have 
in all likelihood led to a reduction in inflammatory mediators. Such reductions may be 
partly responsible for the improvements in somatic nerve conduction via mitigation of 
similar channelopathic effects as suggested in the study by Davies et al. (2006).        
 Therefore, depending on the severity of the effect cytokines and other 
inflammatory mediators may have on somatic nerve function, anti-inflammatory 
interventions may have the potential to improve somatic nerve function which could even 
translate into improved motor and sensory function.  
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Treatment  
Current Treatment Strategies  
The majority of current treatment strategies aimed at improving symptoms of 
depression utilize drug treatments which target downstream enzymes, transporters, or 
receptors. Of these, selective serotonin reuptake inhibitors (SSRI) have become the most 
commonly used; due to their ability to induce a relatively strong and immediate 
alleviation of symptoms. Drug treatments of the SSRI class target serotonin transporters 
(SERT), and inhibit them from carrying out their role concerning 5-HT reuptake, thereby 
increasing extracellular levels. Use of SSRIs is however, associated with a number of 
side-effects and only provides transient relief of symptoms. They have also been shown 
to be ineffective in approximately 30% of patients 146, in whom a particularly elevated 
inflammatory state is typically reported 147,148. Additionally, of individuals who do 
respond to treatment, an estimated 20-80% will relapse and experience a depressive 
episode within 1-5 years following initial treatment 149. It may be possible that under 
extreme or reoccurring inflammatory episodes, the shift in the kynurenine pathway and 
resulting imbalance in neuroactive kynurenines, hippocampal damage and HPA axis 
dysfunction, may cause alterations too severe for SSRI treatment to remedy. This could 
partially explain the ineffectiveness of drug treatments such as SSRIs in individuals with 
a highly elevated inflammatory state and may suggest a need for the addition of anti-
inflammatory interventions in the treatment of depression.   
 More recent attempts to treat cognitive impairment have focused on counteracting 
and/or limiting the antagonizing effects of KYNA. Agonists of the α7nACh and NMDA 
receptors such as galantamine have been utilized in an attempt to counteract the 
antagonizing role of KYNA. Such attempts have however, produced inconclusive and 
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only partially positive results 150–154. It may be possible that elevated concentrations of 
KYNA lead to receptor saturation thereby making it difficult to achieve any benefit from 
such receptor agonists. In an alternative approach, early studies examining the use of 
selective inhibitors for the primary enzyme involved in KYNA production, KAT II, have 
shown positive results in animal models. The administration of KAT II inhibitors resulted 
in reductions in extracellular KYNA along with elevations in glutamate, dopamine, and 
acetylcholine 127. Further studies are required to examine the effectiveness of such 
treatments in humans as well as an appropriate dosage. As α7nACh and NMDA receptor 
activity has important implications in both depression and cognitive impairment, 
maintaining the delicate balance between receptor agonists and antagonists is critically 
important. As such, if either receptor agonists or KAT II inhibitors were to be used in the 
long-term treatment of cognitive impairment, the dose would need to be strictly 
controlled in order to avoid NMDA over-activity and the possibility of hippocampal 
atrophy and HPA axis dysregulation over time. A safer alternative may be to naturally 
induce molecular alterations over time via anti-inflammatory intervention strategies.   
 There is currently no effective treatment to alleviate neuropathic pain. Patients 
with neuropathic pain do not respond to non-steroidal anti-inflammatory drugs 
(NSAIDs), commonly become resistant to opiates, and show little improvement paired 
with undesirable side-effects following treatment with anti-depressants.155 The majority 
of current treatments therefore focus on psychological coping strategies rather than the 
elimination of pain.       
 Although the value of current drug treatments should not be discounted, 
alternative therapies which target the inflammatory basis of such disorders should also be 
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considered. Utilizing intervention strategies which target upstream proinflammatory 
mediators may help to restore proper enzyme regulation and induce corresponding 
beneficial alterations in neuroactive compounds, thereby positively influencing a variety 
of disorders. Simple lifestyle alterations including the adoption of diet consisting of foods 
and supplements with proven anti-inflammatory properties and participation in regular 
exercise may provide a safer, sustainable, and more universally applicable treatment 
option to that of traditional drug treatments. Although such intervention strategies do not 
provide the immediate effects of drug therapies, they may contribute to a more permanent 
solution while helping to reduce the many side-effects associated with a heavy reliance 
on drug interventions.    
Exercise as an Anti-inflammatory Intervention  
Regular moderate exercise has been consistently shown to reduce chronic low-
grade inflammation and protect against a number of associated diseases 156,157. Numerous 
cross-sectional studies have demonstrated reductions in inflammatory mediators within 
trained vs. untrained individuals158–161. Although the anti-inflammatory nature of regular 
exercise has been well established, the mechanisms by which this is accomplished are not 
fully understood and are likely the result of numerous exercise-related factors.  
 One such theory involves a unique exercise-induced inflammatory response 
which differs from that of the typical response evoked by infection. Whereas infection 
results in the initial elevation in proinflammatory cytokines, such as TNF-α and IL-1β, it 
has been suggested that during an exercise-induced inflammatory response, the elevation 
in proinflammatory cytokines is bypassed. Instead the initial response is a large elevation 
in interleukin-6 (IL-6); a cytokine with both pro and anti-inflammatory properties. This 
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spike in IL-6 is followed by an elevation in anti-inflammatory cytokines, such as 
interleukin-10 (IL-10) and interleukin-1 receptor antagonist (IL-1RA) 156,157. It has been 
suggested that IL-6 promotes an anti-inflammatory environment during exercise by 
promoting IL-10 and IL-1RA while inhibiting TNF-α production. This IL-6-induced 
inhibition of TNF-α has been demonstrated in-vitro,162 as well as in-vivo in animal 
models 163, and in humans 164. Exercise may also inhibit proinflammatory mediators 
through IL-6-independent pathways via exercise-induced elevations in hormones such as 
epinephrine. This has been suggested due to the demonstration of TNF-alpha inhibition 
during exercise in IL-6 knockout mice 165, as well as the suppression of TNF-alpha 
following epinephrine infusion in-vivo 166. Whether hormonally driven, or due to a 
unique influence from IL-6, if acute bouts of exercise promote an anti-inflammatory 
environment, it may explain how exercise, when performed on a regular basis, may act to 
protect against a chronic low-grade inflammatory state.       
Of note, many studies have demonstrated that acute bouts of exercise do in fact 
result in a proinflammatory response characterized by leukocytosis and elevations in 
proinflammatory mediators 167–169. An acutely elevated rate of TRP metabolism and 
resulting increase in serum kynurenine concentrations have also been demonstrated and 
have been suggested to relate to a cytokine-induced up-regulation of IDO 170,171. Further, 
exercise is known to result in an acute elevation in glucocorticoids 172 which have been 
suggested to induce the up-regulation of TDO2, further contributing to the elevated rate 
of TRP metabolism during exercise 173. Despite the proposed short-term proinflammatory 
response, long-term metabolic and cardiovascular training adaptations are associated with 
a chronic reduction in inflammatory mediators which likely override the acute 
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proinflammatory effects of exercise, resulting in a chronic shift towards an anti-
inflammatory state. For example, adipose tissue is known to act as an endocrine organ, 
responsible for the release of a variety of proinflammatory mediators termed adipokines. 
As such, a reduction in adipose tissue, as would be expected over the span of a chronic 
training program, may result in a reduction in such proinflammatory mediators 174. 
Corresponding improvements in vascular health may also protect against plaque 
formation seen in atherosclerosis leading to reductions in vascular inflammation 157. In 
addition to these factors, individuals who participate in regular exercise are also likely to 
be non-smokers, less prone to hypertension, and have lower cholesterol levels, which 
have each been shown to be inversely correlated with C-reactive protein (CRP) 
concentrations158.  
 Inconsistencies in the literature regarding the inflammatory response to an acute 
bout of exercise may be due to a lack of consistent exercise protocols. Differences in the 
mode, duration, and intensity of exercise bouts may lead to inconsistent levels of 
exercise-induced muscle damage, and metabolic demands resulting in variable levels of 
inflammatory mediators. It will be important to determine the most ideal exercise 
parameters to achieve the greatest inflammatory benefit if there are hopes of utilizing 
exercise as an effective treatment for inflammatory based disorders. This gap in the 
literature may also help explain inconsistencies regarding the degree to which exercise 
reduces symptoms of depression and cognitive impairment. Although there is a general 
consensus that exercise positively impacts mood and cognition, some studies show 
improvements equivalent to that of traditional medications 175,176, while others show that 
exercise is only mildly more effective than control conditions 177. Additionally, the 
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mechanisms by which such benefits may be accomplished are widely debated, ranging 
from increased cerebral blood flow, to changes in neurotransmitter release, to actual 
structural changes in the central nervous system (CNS), such as the hippocampus 178. 
Interestingly, each of these proposed adaptations can be influenced by the inflammatory 
response through mechanisms previously discussed. There is a need for more 
methodologically robust, prospective trials with consistent exercise protocols in order to 
examine the true potential of exercise as a treatment strategy following SCI. 
Nevertheless, the anti-inflammatory properties of regular exercise have been well-
established, and in theory, it should help to improve or prevent symptoms related to 
depression and cognitive impairment by targeting upstream inflammatory processes. As 
such, despite the insufficient evidence to definitively state the degree to which exercise 
interventions may impact these disorders, it would seem there is certainly merit to 
implement them along with traditional drug treatments.     
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Figure 6: Targets of treatment interventions  
Common treatment strategies for disorders associated with depression and cognitive impairment 
typically target downstream enzymes or receptors. Alternatively, intervention strategies such as 
regular exercise possess anti-inflammatory properties which helps restore a balance in 
inflammatory mediators, thereby restoring proper enzyme regulation and protein balances 
upstream. 
 
Diet as an Anti-inflammatory Intervention  
 Diet may be used as a powerful tool for treating immune dysfunction and chronic 
inflammation. The consumption of foods and supplements with anti-inflammatory 
properties can induce beneficial effects by means of a variety of mechanisms including 
alterations in cell membrane composition, enzyme activity, and gene transcription. The 
intake of antioxidants has also been demonstrated to aid in the treatment of chronic 
inflammation via the reduction of free radicals necessary in oxidative burst and anti-
microbial activities of phagocytes. The corresponding reduction in the redox ratio has 
also been shown to induce a reduced activation in NFkB thereby reducing gene 
transcription of inflammatory enzymes. Lastly, proper diet may aid in the reduction of 
inflammation via loss of adipose tissue resulting in a reduced production of 
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proinflammatory adipokines. Altering one’s diet to include sufficient quantities of such 
nutrients and appropriate caloric intakes may aid in immune health by modifying the 
production of proinflammatory mediators and thereby helping to reestablish a more 
balanced immune state. Unfortunately, a lack of awareness, as well as the perceived cost 
and effort involved in maintaining a healthy diet commonly leads to nutrient 
insufficiencies in the general population as well as in those with SCI.  
One such example of this pertains to the intake of polyunsaturated fatty acids 
(PUFAs). In a typical Western diet, omega-6 (n6) intake is on average much higher than 
that of n3. As such, these fatty acids are preferentially utilized in the composition of cell 
membranes and typically greatly predominate n3 concentrations. Specialized enzymes 
known as cyclooxygenase (COX) and lipooxygenase (LOX) act on these membranes and 
utilize their fatty acids to produce inflammatory mediators. When n6 is utilized as a 
substrate, potent proinflammatory molecules such as prostaglandin-2 (PGE2) and 
leukotriene4 (LTB4) are produced. These molecules (known as eicosanoids) produce 
proinflammatory effects such as increased chemotaxis, increased production of adhesion 
molecules, vasoconstriction, and pain.179 However, when the COX and LOX enzymes 
utilize n3 as a substrate much less potent proinflammatory eicosanoids are produced such 
as prostaglandin-3 (PGE3) and leukotriene-5 (LTB5). These eicosanoids produce a far 
weaker proinflammatory response. The utilization of n3 may also result in the production 
of anti-inflammatory and inflammation resolving proteins known as resolvins.179 These 
resolvins act to inhibit chemotaxis, suppress proinflammatory cytokines, and aid in the 
clearance of cellular debris. Therefore, increased n3 intake in the diet may help to reduce 
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inflammation by means of alterations in cell membrane composition resulting in the 
production of less potent proinflammatory eicosanoids and anti-inflammatory resolvins. 
 Omega-3 fatty acids are also capable of reducing inflammation by limiting gene 
transcription of inflammatory molecules and enzymes. By inhibiting the translocation of 
the transcription factor NFkB to the nucleus of cells, n3 can prevent the transcription of 
genes for proinflammatory cytokines as well as the COX and LOX enzymes. Through 
these effects n3 may help to aid in the reduction of the chronic low grade inflammatory 
response associated with many pathologies.179 
  
  
Figure 7: Intracellular inflammatory mechanisms of polyunsaturated fatty acids  
Omega-6 acts intracellularly to increase phosphorylation of IkappaB proteins thereby enhancing 
translocation of NFkB to the nucleus of the cell where it can participate in the transcription of 
inflammatory mediators and enzymes. Omega-3 acts intracellularly to reduce phosphorylation of 
IkappaB proteins thereby limiting NFkB translocation to the nucleus of the cell and therefore 
reducing the production of inflammatory mediators and enzymes.    
 
 Various types of antioxidants induce anti-inflammatory effects via a number of 
mechanisms. Vitamin E consists of 4 different tocopherol homologues including α-
tocopherol, β-tocopherol, У-tocopherol, and δ-tocopherol. Each homologue acts as an 
antioxidant whereby it may provide an electron to free radicals thereby converting them 
from their reduced state to their oxidized state. This helps to protect host tissue from 
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damage induced by free radicals but has also been suggested to play an inflammatory role 
via alterations in the redox ratio. When free radicals are converted from their reduced to 
oxidized state it causes a reduction in the redox ratio. This reduction has been shown to 
be associated with reduced activation of the transcription factor NFkB resulting in the 
reduced gene transcription for proinflammatory mediators and enzymes.180 Therefore, 
tocopherols may help limit the inflammatory response not only by reducing levels of 
reactive oxygen species, but also by limiting NFkB activation.  
 Much like tocopherols, flavonoids also possess antioxidant and radical scavenging 
capabilities. In addition, flavonoids have been shown to possess their own mechanisms of 
anti-inflammatory activity in various animal models of inflammation.181 Certain 
flavonoids have been shown to modulate enzyme activities such as the arachidonic acid 
(AA) metabolizing enzyme phospholipase A2 (PLA2) resulting in lower production of 
this omega-6 fatty acid. Flavonoids have also been shown to inhibit the enzymes COX 
and LOX resulting in reduced production of the potent proinflammatory eicosanoids 
PGE2 and LTB4.182 Arachidonic acid, PGE2 and LTB4 are each crucial mediators of 
inflammation and the inhibition of their production would provide important anti-
inflammatory effects.  
 Despite the known anti-inflammatory benefits of many naturally occurring 
nutrients and supplements, little attention has been paid to the utilization of an anti-
inflammatory diet in the treatment of inflammation following SCI. The vast majority of 
studies which have examined the anti-inflammatory effect of supplements such as n3 
have been performed on animal models or healthy human subjects. Of the few studies 
that have been performed on humans with chronic inflammatory conditions the focus has 
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typically been placed on subjects with rheumatoid arthritis. These studies have 
successfully demonstrated reduced pain and swelling, as well a reduction in 
proinflammatory mediators following n3 supplementation.183,184 In spite of these positive 
findings, the use of anti-inflammatory diets as a potential treatment in the SCI population 
have been largely neglected. As an inflammatory basis is being established for an 
increasing number of disorders associated with SCI, such an intervention is worthy of 
examination.  
Conclusion  
 
  As an inflammatory basis is becoming evident for a growing number of disorders, 
therapies which target the immune system and act to restore a balance in inflammatory 
mediators should be considered as potential methods of treatment and prevention. 
Although the effectiveness of current drug treatments should not be undervalued, pairing 
them with intervention strategies which target upstream inflammatory influence, may 
enhance the outcome of drug treatments for disorders impacted by chronic inflammation. 
Being that SCI is typically characterized by chronic inflammation as well as a higher 
prevalence of secondary neural and behavioural disorders, SCI is one such population 
which may particularly benefit from such strategies. It is difficult to make definitive 
conclusions regarding the degree to which diet and exercise, as an anti-inflammatory 
strategy, could influence neural and behavioural disorders as previous inferences are 
largely based on observational studies with highly variable protocols. However, the 
inflammatory etiology behind such disorders, and anti-inflammatory mechanisms of diet 
and exercise have been well established and therefore, should in theory, provide some 
benefit. Additionally, given the minimal side effects associated with such lifestyle 
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alterations, as well as the potential for a variety of other health benefits, there is 
seemingly little reason not to promote diet and exercise as treatment options. Whether 
these options have the potential to be effective as a stand-alone treatment, or would need 
to be utilized in conjunction with common drug treatments, is currently unclear and will 
likely vary between patients depending upon a number of factors. Further research will 
also be needed to determine the most appropriate exercise parameters in order to achieve 
the greatest anti-inflammatory benefit. A greater emphasis on lifestyle intervention 
strategies which target inflammation may provide stronger and more sustainable 
improvements by targeting the inflammatory mediators initially responsible for the 
alterations in enzyme regulation which ultimately contribute to a number of disorders. 
Such strategies may help to reduce disorders associated with SCI such as depression, 
cognitive impairment and neuropathic pain while avoiding the many side-effects 
associated with a heavy reliance on current drug treatments. If inflammatory mediators 
are proven to negatively influence somatic and/or autonomic nerve function, such anti-
inflammatory strategies may even prove to benefit motor, sensory, and autonomic 
function in this population.  
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Overall Purpose & Hypotheses   
  The purpose of this study was to evaluate how reductions in chronic inflammation 
by means of an anti-inflammatory diet, in those with a SCI, may influence disorders with 
an established inflammatory basis including: depression, cognitive dysfunction, 
neuropathic pain, and somatic nerve deficits.  
 It was hypothesized that a diet focusing on foods and supplements with anti-
inflammatory properties would be sufficient to significantly reduce levels of 
proinflammatory mediators such as cytokines and eicosanoids. Certain proinflammatory 
cytokines are capable of up-regulating key enzymes known to play a role in 
neuroimmune communication by means of altering pathways of protein catabolism. 
Therefore, the reduction of chronically elevated levels of proinflammatory cytokines was 
expected to result in beneficial alterations in both enzyme regulation, and levels of 
neuroactive compounds. If sufficient alterations were achieved, it was expected to 
translate into improvements in each of the disorders of interest.   
 
Manuscript 1: Targeting inflammation to influence mood following spinal cord 
injury: A randomized clinical trial 
 
The purpose of this study was to assess the relationship between mood and 
inflammation in individuals with SCI. It was hypothesized that by targeting the immune 
system and reducing levels of chronic inflammation it would be possible to induce 
corresponding changes in neuroactive compounds and improvements in mood and 
symptoms of depression.  
 
Manuscript 2: Targeting inflammation to influence cognitive function following 
spinal cord injury: A Randomized Clinical Trial 
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The purpose of this study was to assess the relationship between cognitive 
function and inflammation in individuals with SCI. It was hypothesized that by targeting 
the immune system and reducing levels of chronic inflammation it would be possible to 
induce corresponding changes in neuroactive compounds and improvments in verbal 
learning and memory. 
 
Manuscript 3: Targeting Inflammation as a Treatment Modality for Neuropathic 
Pain in Spinal Cord Injury: A Randomized Clinical Trial 
 
The purpose of this study was to assess the relationship between neuropathic pain 
and inflammation in individuals with SCI. It was hypothesized that by targeting the 
immune system and reducing levels of chronic inflammation and eicosanoids, it would be 
possible to induce corresponding reductions nociceptor sensitization and scores of 
neuropathic pain.  
 
Manuscript 4: Targeting inflammation to influence peripheral somatic nerve 
function following spinal cord injury: A Randomized Clinical Trial 
 
The purpose of this study was to assess the relationship between somatic nerve 
function and inflammation in individuals with SCI. It was hypothesized that by targeting 
the immune system and reducing levels of chronic inflammation, it would be possible to 
improve nerve conduction velocity and signal amplitude in both motor and sensory 
nerves.  
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Study Design and Participants  
 The study was a randomized, parallel-group clinical trial. Participant recruitment 
occurred between September and November 2014. The study intervention was 12 weeks 
and included testing at baseline, 1 month, and 3 months. Participants with various levels 
and severities of SCI were recruited for participation in the study. Inclusion criteria 
included (1) over the age of 18, (2) SCI of any level or severity (American Spinal Injury 
Association A-D), (3) at least 2 years post injury. Exclusion criteria included (1) any 
contraindications to supplements provided in the study, (2) unstable dosage of any anti-
depressive medications, (3) unstable medical condition within 2 weeks prior to 
intervention (4) pregnancy, (5) breastfeeding. Participant characteristics are shown in 
Table 1. Twenty individuals [10 male, 10 female; age 48.7±13.9yrs] with chronic [4-
37yrs post-injury] SCI [C2-L4; ASIA Impairment Scale (AIS) A-D] were recruited for 
participation in the study. Twelve participants were randomly allocated to the treatment 
group, and were placed on the 12-week anti-inflammatory diet intervention, while 8 were 
allocated to the control group and received no intervention. Informed consent was 
obtained from all participants. The study was registered as a clinical trial 
(clinicaltrials.gov identifier: NCT02099890) and received ethical approval from the 
Brock University Research Ethics Board as well as the Natural Health Products 
Directorate of Canada. All data was collected on-site at Brock University and the Brock-
Niagara Center for Health and Well-being. 
Randomization  
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Randomization was computer generated by the primary investigator and stratified 
by participant sex and age using permuted blocks of 2 (male/female) and block of 3 (<40, 
40-60, >60yrs). Randomization was 3:2 to either the anti-inflammatory diet vs control.   
 
Table #1: Participant Characteristics  
 
Participant       Sex      Age   AIS Score 
Level of 
Injury 
Time Since 
Injury (yrs) 
Treatment 
1 F 44 D C5 10 
2 M 58 B T10 4 
3 F 62 D L3 4 
4 F 37 A T3 19 
5 M 22 A C7 5 
6 M 67 C C2 4 
7 M 66 D C5 6 
8 F 44 A C7 9 
9 F 65 D T6 4 
10 F 64 D C3 37 
11 M 45 A T6 28 
12 M 37 C C4 23 
AVE -- 51.5 -- -- 12.8 
SD -- 15.3 -- -- 11.3 
Control 
13 F 30 B C5 6 
14 F 63 D L4 2 
15 M 42 A C5 6 
16 F 58 D C5 33 
17 M 59 D T4 4 
18 F 33 A T1 17 
19 M 41 C C4 22 
20 M 36 A C5 19 
AVE -- 45.3 -- -- 13.6 
SD -- 12.9 -- -- 10.9 
p-value  0.38   0.87 
 
*AIS: ASIA (American Spinal Injury Association) Impairment Scale  
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Figure 8: CONSORT 2010 Flow Diagram  
 
 
 
 
Flow diagram of participant recruitment and allocation  
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Dietary Intervention Protocol  
 
The anti-inflammatory diet intervention focused on the elimination of common 
food intolerances and inflammation-inducing foods, as well as the introduction of foods 
and supplements with established ant-inflammatory properties. Examples of foods 
removed from the diet included those with high glycemic indices (such as refined wheat 
products and refined sugars), common intolerances such as cow’s milk, and foods which 
negatively influence cardiovascular health such as hydrogenated fats. Participants also 
consumed daily supplements with established anti-inflammatory benefits. Omega-3 fatty 
acids (Now Ultra omega-3) were taken in softgel form, containing 500mg EPA and 
250mg DHA, at a dosage of 3 pills per day. Chlorella (Now chlorella) was taken in pill 
form, containing 1000mg, at a dosage of 6 pills per day. Antioxidants (CanPrev 
antioxidant network) were taken in pill form, containing 100mg coenzyme Q10, 200mg 
n-acetyl-cysteine, 150mg mixed tocopherols, 100mg DL alpha lipoic acid, 60mg green 
tea extract, 5.5mg zinc, and 100ug selenium, at dosage of 2 pills per day. Curcumin 
(AOR Inflanox) was taken in pill form, containing 400mg, at a dosage of 3 pills per day. 
A vegetable based (yellow pea, brown rice, hemp seed) protein powder (Progressive 
Vegessential) containing 27g of protein was taken at a dosage of one scoop each 
morning.     
Both the treatment group and control group were asked to complete a detailed diet 
record for 7 days at baseline, as well as 3 days at 3-months. The treatment group also 
recorded a 3-day diet record at 1-month, 2-months. This allowed for the examination of 
baseline eating habits as well as the assessment of compliance throughout the 
intervention. Food intake was assessed using The Food Processor (ESHA Inc. 2014, 
version 10.14.2, Salem, OR). Compliance to the specific anti-inflammatory diet was also 
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assessed by a detailed analysis of all diet records. Each food item was categorized as 
either a ‘food to consume’ a ‘food to avoid’ or a ‘neutral food’ based on the parameters 
of the diet participants were instructed to follow. Food was also categorized into servings 
in accordance with Canada’s Food Guide. Therefore, compliance scores were based on 
standard servings of foods subjects were instructed to eat vs. foods they were instructed 
to avoid. To account for differences in total energy intake, compliance scores were 
expressed as a ratio of the servings of foods to consume over the total servings of food 
(avoid + consume) multiplied by 100. This yielded a measure of percent compliance.  
At the start of the study, the treatment group underwent an information seminar 
which explained the diet program followed by a one-on-one consultation with 
nutritionists during which their diet records were reviewed in detail and necessary 
changes were discussed. Participants received information regarding foods to eat and 
avoid, a supplement intake schedule and all necessary supplements, and list of approved 
recipes. Participants in the treatment group received support via weekly phone calls from 
members of our research team as well as a monitored online support group whereby 
participants could share recipes and experiences with one another. Participants in the 
control group were asked to maintain their current diets throughout the duration of the 
study.   
Outcome Measures  
 
All outcome measures were assessed at baseline, 1 month and 3 months. This 
allowed for the assessment of each of the outcome measures, under chronically elevated 
levels of proinflammatory mediators at baseline, as well as reduced levels of 
proinflammatory mediators at 1 and 3 months. Each testing session required a duration of 
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2 hours and included the assessment of: depression, cognitive function, neuropathic pain, 
and somatic nerve function. Blood draws were also performed for the quantification of 
associated inflammatory mediators and neuroactive compounds.   
Quantification of serum inflammatory markers and amino acids  
 
Blood draws (20ml) were taken from the antecubital vein of each participant at 
1pm at each of the 3 testing sessions (baseline, 1 month, and 3 months). Following 
extraction, the whole blood was allowed to clot for 30 minutes followed by centrifugation 
at 1000xg for 15 minutes. Serum was extracted and immediately stored at -80°C until 
later analysis. Inflammatory mediators of interest included: pro-inflammatory cytokines 
IL-2, IL-1β, IL-6, TNF-α, IFN-y, the acute phase protein CRP; anti-inflammatory 
cytokines IL-4, IL-10, and IL-1RA; eicosanoids PGE2, LTB4; and amino acids (AA) and 
AA metabolites tryptophan (TRP), tyrosine (TYR), phenylalanine (Phe), BCAA (leucine, 
isoleucine, valine) and kynurenine (KYN). Analysis of pro and anti-inflammatory 
cytokines was performed in triplicate via the Magpix Multiplex system (EMD Millipore, 
MA, U.S.A) and analyzed using Luminex software. CRP, PGE2, and LTB4 were 
analyzed in triplicate and quantified via enzyme-linked immunosorbent assay (R&D 
systems, Minneapolis, U.S.A.). TRP, Phe, TYR, BCAA, and KYN were analyzed in 
triplicate and quanitified via enzyme-linked immunosorbent assay (Immunodiagnostik, 
Bensheim, Germany; Labor Diagnostika, Nordhorn, Germany). 
Assessment of Depression  
 
 Participants completed the Center for Epidemiological Studies Depression 
Scale (CES-D) at each of the 3 testing sessions, as means of assessing symptoms of 
depression. The questionnaire consisted of 20 items related to depression and participants 
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were asked to rate how often they experienced each item over the previous 7-day period. 
Ratings were based on a 4-point scale including, ‘rarely or none of the time’ (less than 1 
day), ‘some or a little of the time’ (1-2 days), ‘occasionally or a moderate amount of the 
time’ (3-4 days), or ‘most or all of the time’ (5-7 days). Points for each item ranged from 
0-3 depending on frequency and each item was summed for a total score ranging from 0-
60 with higher scores indicating the presence of more symptomatology. A score of 0-15 
indicates no depressive symptoms, a score of 15-21 indicates mild to moderate depressive 
symptoms, and a score of >21 indicates the potential for major depression. The CES-D 
has been shown to be a valid and reliable measure of depression in SCI1.  
Inflammatory mediators of interest specific to depression included the 
proinflammatory cytokines: IL-1, IL-1β, IL-2, IL-6, and IFN-y. These proinflammatory 
cytokines were chosen (particularly IFN-y) due to their known ability to up-regulate the 
enzyme IDO. The quantity and activity of IDO was also examined due to its role in TRP 
degradation to a variety of metabolites including kynurenine and quinolinic acid2. Lastly, 
the large neutral amino acids, TRP, leucine, isoleucine, valine, and TYR were examined. 
TRP plays a critical role as a precursor in 5-HT synthesis and the other large neutral 
amino acids act as competitive antagonists for transportation across the blood brain 
barrier. Therefore, the TRP/LNAA ratio may be utilized as an indication of TRP 
availability for 5-HT synthesis.  
Assessment of Cognitive Function  
 
Participants were asked to perform the California verbal learning test (CVLT) as 
an indication of episodic learning and memory. This test consisted of 2 word lists each 
consisting of 4 categories of 4 words, for a total of 16 words per list. The test began with 
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the learning trial whereby the examiner read aloud the first list (List A) of words. These 
words were announced at one-second intervals, in a fixed order, over 5 learning trials. 
Following each trial, the participant was asked to recall as many words as possible in any 
order. An interference list (List B) was then presented in the same fashion as list A, but 
over only a single trial. This list (List B) consisted of 2 shared categories from List A as 
well as 2 unshared categories. Following the learning trial, both free and cued recall tests 
of List A were performed. Free recall involved subjects announcing as many words as 
possible in any order. Cued recall involved subjects announcing as many words as 
possible after the examiner specified each category in turn. Each of these tests were 
performed immediately following the learning trials (short-delay) and 20 minutes 
following the learning trials (long-delay). The CVLT concluded with a recognition task 
whereby a 44-word list was read aloud. This list consisted of the 16 target words (those 
from list A) as well as 28 distractor words. Distractor words were specially selected to 
share similar categories and/or sound similar to target words. The participant was told to 
indicate whether each word was a target word or a distractor word as they were 
announced.   
Inflammatory mediators of interest related to potential cognitive deficits included 
the proinflammatory cytokines IFN-y, IL-1, IL-2, and IL-6. Once again these cytokines 
were chosen due to their ability to up-regulate the enzyme IDO thereby increasing TRP 
degradation into metabolites such as kynurenine and quinolinic acid. The activity of IDO 
was assessed as well as levels of the neuroactive compounds TRP and KYN. As 
kynurenine is converted to kynurenic acid upon crossing the blood brain barrier and 
contributes to reductions in synaptic plasticity, elevated peripheral levels may be related 
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to cognitive impairment. Elevated levels of quinolinic acid also indicate a shift in the 
kynurenine pathway and has been shown to be apparent in individual’s suffering from 
Alzheimer’s disease3.      
Assessment of Neuropathic Pain  
 
Participants were asked to complete the Neuropathic Pain Questionnaire (NPQ) at 
each of the 3 testing sessions, as a means of assessing self-reported neuropathic pain. The 
questionnaire consisted of 32 items pertaining to 3 unique categories including sensory 
items, affective items, and sensitivity items. Sensory items were those related to the 
specific type and severity of pain felt (eg. degree of burning, stabbing, throbbing, etc.), 
affective items referred to those related to how the pain affected the participant in daily 
life (eg. how irritating is your usual pain?) and sensitivity items related to how various 
stimuli may act to increase pain (eg. increased pain due to heat). Participants were asked 
to rate their pain numerically on a scale from 0-100 whereby 0 indicated the complete 
absence of pain and 100 indicated the worst pain imaginable. Scores from each of the 3 
categories were averaged for use in statistical analysis.   
Inflammatory mediators of interest related to neuropathic pain will include the 
proinflammatory cytokines: IL-1β, IL-2, IL-6, TNF-α and IFN-y, as well as the anti-
inflammatory cytokines IL-4, IL-10, and IL-1RA. Both proinflammatory and anti-
inflammatory cytokines will be examined due to the finding that painful neuropathy is 
typically associated with an elevation in proinflammatory cytokine while non-painful 
neuropathy is typically associated with an elevation in anti-inflammatory cytokines4,5. 
The enzymes COX and LOX will be examined due to their role in the production of pain-
inducing pro-inflammatory eicosanoids and ability to be up-regulated by 
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proinflammatory cytokines. Lastly, the potent, proinflammatory eicosanoids PGE2 and 
LTB4 will be examined due to their role in neuropathic pain.      
Assessment of Somatic Nerve Function  
 
Action potential propagation velocity as well as M-wave amplitude were assessed 
by means of a nerve conduction velocity test. Both compound motor action potentials 
(CMAPs) and sensory nerve action potentials (SNAPs) were examined for the assessment 
of both motor and sensory nerves respectively. Prior to performing the test, the electrode 
locations were prepared by shaving the skin, removing any dead skin cells with an 
abrasive gel, and disinfecting the areas with rubbing alcohol. For the assessment of 
CMAPs, the recording electrode was placed over the muscle belly of the flexor pollicis 
brevis. The reference electrode was placed over the electrically neutral position of the 
tendon of 2nd metacarpophalangeal joint of the thumb. Lastly, a ground electrode was 
placed over the palm of the hand. The median nerve was then stimulated at known 
distance from the recording electrode at both a distal and proximal location. Stimulation 
intensity was determined by gradually increasing the amplitude until a maximal M-wave 
is achieved. A stimulation amplitude of 120% of this value was then used during testing. 
When electrically evoking an action potential, a standardized set of waveforms are 
displayed by means of an oscilloscope. A short duration spike known as the shock artifact 
represents the initial stimulation of the nerve and a longer duration wave known as the 
M-wave represents the motor response. By obtaining the time between the end of the 
shock artifact and initiation of the M-wave (latency), it was possible to calculate nerve 
conduction velocity by using the latency in conjunction with the measured distance 
between the stimulation and recording site. It was also possible to examine the strength of 
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the motor response of the flexor pollicis brevis by means of assessing the amplitude of 
the evoked M-wave. 
When assessing SNAPs, an anti-dromic electrode configuration was utilized. 
Stimulation was once again performed on the median nerve at the wrist at a known 
distance from the recording electrode. Ring electrodes were utilized for the recording of 
the signal. The active recording electrode was placed just proximal to the 2nd 
metacarpophalangeal joint and the reference was placed just proximal to the 3rd 
metacarpophalangeal joint of the 4th finger. The ground electrode was placed on the 
dorsal surface of the hand. The amplitude of the stimulation was gradually increased until 
a max SNAP amplitude was achieved. The stimulation used during the testing session 
corresponded to 120% of the max SNAP amplitude. A 10 stimulation train was then 
applied. Signals were averaged and used for the determination of nerve conduction 
velocity and SNAP amplitude using similar techniques as discussed for CMAP analysis.            
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Chapter 5  
 
Effectiveness of Intervention: Compliance and Effect on Biomarkers   
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Compliance to Anti-inflammatory Diet   
 
All participants from both the treatment and control group completed the entire 3-
month duration of the study and were included in the analysis. No adverse events were 
reported. The treatment groups’ overall compliance to the diet was assessed based on the 
average of the 3 diet records during the study (1 month, 2 months, and 3 months). One 
participant completed all three testing sessions but failed to produce the 2-month and the 
3-month diet record. This participant had a dietary compliance over the first month of 
92%. All other participants completed each of the required diet records and overall 
compliance ranged from 70-100%, with a mean compliance of 89%. 
Change in Inflammatory Mediators  
 
Changes in serum levels of inflammatory mediators are shown in Table 2. When 
considering a proinflammatory composite score (average of IL-2, IL-6, IL-1β, TNF-α, 
and IFNy), the Mann-Whitney test indicated that the change scores (3-month - baseline) 
were significantly different between the treatment group and the control group (U=13.0, 
p=0.01). The Friedman test showed that there was a statistically significant reduction in 
the proinflammatory composite scores in the treatment group (x2 = 6.50, p=0.04), but no 
significant change in the control group (x2=5.25, p=0.07). Post hoc analysis performed 
with the Wilcoxon signed-rank test showed significant reductions in the treatment group 
from both baseline to 1 month and baseline to 3 months (z=-2.197, p=0.03; z=-2.275, 
p=0.02 respectively). When analyzing each cytokine separately, the Mann-Whitney test 
indicated that the change scores (3-month - baseline) were significantly different between 
the treatment group and the control group for IFN-y (U=13.0, p=0.01.), IL-1β (U=14.0, 
p=0.01), and IL-2 (U=12.0, p=0.01) and showed a trend for CRP (U=27.0, p=0.10). The 
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Friedman test showed that in the treatment group there was a statistically significant 
reduction (pre to post intervention) in IFN-y (x2=8.67, p=0.01), IL-1β (x2=17.78, 
p<0.01), IL-6 (x2=6.17, p<0.05), and a trend for CRP (x2=4.5, p=0.10). The Friedman test 
showed no corresponding statistically significant reductions for any inflammatory 
mediator in the control group. Post-hoc analysis performed with the Wilcoxon signed-
rank test showed significant reductions in the treatment group for IFN-y from baseline to 
1 month and baseline to 3 months (z=-2.275, p=0.02; z=-2.510, p=0.01 respectively), as 
well as significant reductions in the treatment group for IL-1β from baseline to 1 month 
and baseline to 3 months (z=-3.059, p<0.01; z=-2.934, p<0.01 respectively), and a 
significant reduction in the treatment group for IL-6 from baseline to 1 month, and a 
trend from baseline to 3 months (z=-2.275, p=0.02; z=-1.726, p=0.08 respectively). Two-
way repeated measures ANOVA were performed for the normally distributed mediators’ 
TNF-α and PGE2 and showed trends towards group x time interactions (p=0.10; p=0.07 
respectively). No significant difference was found when examining changes in the anti-
inflammatory composite score (IL-4, IL-10, IL-1RA) or when examining changes in 
these anti-inflammatory cytokines individually.   
 
Change in Amino Acids   
 
Changes in serum amino acids are shown in Table 3. Two-way repeated measures 
ANOVA were performed for the normally distributed amino acids. There was a 
significant group x time interaction for the TRP/LNAA ratio (p=0.04, Cohen’s d=0.90). 
Post hoc analysis showed a trend towards an increase in TRP/LNAA in the treatment 
group from baseline to 3 months (p=0.06). Post hoc analysis showed no change in the 
control group at any time point. KYN showed a trend towards a group x time interaction 
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(p=0.06, Cohen’s d=0.81). A Mann-Whitney test was performed on the change scores for 
non-normally distributed amino acids. Change scores (3-month - baseline) were found to 
be significantly different between groups for the KYN/TRP ratio (U=20.0, p=0.03), 
BCAA (U=19.0, p=0.03), and LNAA (U=16.0, p=0.01). A Friedman’s test was 
performed to test for significant changes among repeated measures (baseline, 1 month, 3 
months) for the treatment group and control group. No significant changes were found for 
either the treatment group or control group.      
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Table #2: Change in Inflammatory Mediators  
 
 
All results are shown as mean ± SD. P-values correspond to group x time interactions, Mann-Whitney change scores, and Friedman scores 
for treatment group respectively.   
Proinflammatory composite consists of a composite score averaging IL-2, IL-6, IL-1β, TNF-α, and IFN-y 
Anti-inflammatory composite consists of a composite score averaging IL-4, IL-10, and IL1RA 
*Significantly different from baseline with P value <0.05; **Significantly different from baseline with P value <.01 
  
100 
 
 
Table #3: Change in Amino Acids 
 
 
 
All amino acids are displayed in µmol/L 
All results are shown as mean ± SD. P-values correspond to group x time interactions and Mann-Whitney test on change scores.   
TRP: tryptophan; TYR: tyrosine; PHE: phenylalanine; BCAA: branch chain amino acid; LNAA: large neutral amino acids; KYN: 
kynurenine. 
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ABSTRACT 
 
Background: The purpose of the present study was to examine the efficacy of targeting 
inflammation as a means of improving mood following spinal cord injury (SCI) and 
explore the potential mechanisms of action.  
 
Methods: The study was a randomized, parallel-group, controlled, clinical trial 
(NCT02099890) whereby 20 participants with varying levels and severities of SCI were 
randomized (3:2) to either the treatment group, consisting of a 12-week anti-
inflammatory diet, or control group. Outcome measures were assessed at baseline, 1 
month, and 3 months and consisted of CES-D scores of depression, markers of 
inflammation as assessed by various pro and anti-inflammatory cytokines, and several 
amino acids related to depression.  
 
Results: A significant group x time interaction was found for CES-D (center for 
epidemiological studies depression scale) score (p=0.01) and the TRP/LNAA 
(tryptophan/large neutral amino acid) ratio (p=0.04). A Mann-Whitney test indicated 
change scores (3 month-baseline) were significantly different between the treatment 
group and control group for a composite score of pro-inflammatory mediators (U=13.0, 
p=0.01), IFN-y (U=13.0, p=0.01.), IL-1β (U=14.0, p=0.01), and IL-2 (U=12.0, p=0.01) 
and showed a trend for CRP (U=27.0, p=0.10). A Friedman test showed significant 
reductions in the treatment group for pro-inflammatory composite scores (x2 = 6.50, 
p=0.04), IFN-y (x2=8.67, p=0.01), IL-1β (x2=17.78, p<0.01), IL-6 (x2=6.17, p<0.05), and 
a trend for CRP (x2=4.5, p=0.10), while the control had no significant changes for any 
inflammatory mediators. Pearson’s r correlation showed significance between the ∆IL-1β 
and both the ∆CES-D score (r=.740, p<.01) and the ∆KYN/TRP (kynurenine/tryptophan) 
ratio (r=.536, p=0.02). The ∆KYN/TRP ratio was also significantly correlated with the 
∆CES-D score (r=.586, p=0.01). Mediation analysis showed that the relationship between 
the ∆KYN/TRP ratio and the ∆CES-D score was mediated by the ∆IL-1β. Subgroup 
analysis showed participants with high CES-D scores had significantly higher 
concentrations of IL- 1β and all correlations were maintained or strengthened within this 
subgroup.  
 
Conclusions: Overall, the results demonstrated the effectiveness of targeting 
inflammation as a means of improving mood in SCI, with potential mechanisms relating 
to the reduction in IL-1β and improvements in levels of neuroactive compounds related to 
the kynurenine pathway. Due to the limited sample size, results should be interpreted 
with caution, however, they are worthy of further examination due to the potential impact 
of inflammation on depression.           
 
Trial Registration: ClinicalTrials.gov ID: NCT02099890 
 
Keywords: Depression; Mood; Spinal Cord Injury; Inflammation; IL-1β; Anti-
inflammatory Diet  
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Background 
 
Individuals with major depressive disorder (MDD) are commonly reported to 
demonstrate immune dysfunction in the form of chronic inflammation and likewise, 
individuals with chronic inflammatory disorders are more prone to MDD.1–3 Such a state 
has been proposed to be a contributing factor to symptoms of depression due to the 
complex bidirectional communicatory pathways between various systems of the body. In 
this respect, chronic inflammation may impact the endocrine and nervous systems 
causing respective imbalances in critical hormones and neuroactive compounds which 
may ultimately influence behavior and contribute to depressive symptoms.4  
Various proinflammatory mediators possess the ability to influence the function 
of transporters, enzymes, and receptors both in the periphery and within the brain. Certain 
proinflammatory cytokines are able to travel from the periphery to the brain via both 
active and passive mechanisms.5,6 Once in the brain, proinflammatory cytokines such as 
interleukin-1β (IL-1β) and tumour necrosis factor-α (TNF-α) can alter extra-cellular 
concentrations of serotonin (5-HT) by up-regulating corresponding transporters 
(SERT).7–9 In this way, such proinflammatory cytokines have the ability to directly 
reduce 5-HT levels within the brain which are associated with symptoms of depression.  
Peripherally, proinflammatory cytokines can influence the regulation of enzymes 
from critical metabolic pathways and induce imbalances in key mood altering 
neuroactive compounds. The kynurenine pathway is one such pathway which must be 
strictly regulated due to its role as the primary route for tryptophan (TRP) degradation. 
Approximately 95% of this critical 5-HT precursor is metabolized along this pathway 
meaning a cytokine-induced upregulation of TRP degradation may ultimately result in 
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the reduction in 5-HT levels within the brain.10,11 In the same respect, the increased 
degradation of TRP results in elevated levels of TRP metabolites. Certain TRP 
metabolites such as kynurenine (KYN) are BBB (blood brain barrier) transportable and 
have also been shown to contribute to symptoms of depression when at elevated 
concentrations within the brain (see Figure 1a and b). 
 
 
Figure #1: Tryptophan Metabolism along the Kynurenine Pathway  
 
Figure 1a depicts the kynurenine pathway within the periphery and brain under healthy 
conditions. Proper enzyme regulation results in a healthy balance of TRP and TRP 
metabolites. As a result, adequate levels of TRP are available for 5-HT synthesis and 
properly regulated SERT proteins ensure extracellular concentrations of 5-HT are not 
depleted. Healthy levels of TRP metabolites within the brain (eg. QUIN) ensure normal 
activation of NMDA receptors thereby maintaining healthy hippocampal function and 
proper regulation of the HPA axis.  
 
Figure 1b depicts the kynurenine pathway within the periphery and brain in a state of 
chronic inflammation. Elevated levels of proinflammatory cytokines cause up-regulation 
of enzymes such as IDO thereby resulting in an increased breakdown of TRP and 
production of TRP metabolites. As a result, reduced levels of TRP are available for the 
synthesis of 5-HT. Proinflammatory cytokines also up-regulate SERT proteins causing 
further depletion of extracellular 5-HT. Elevated levels of TRP metabolites within the 
brain such as QUIN (potent NMDA agonist) result in over-activation of NMDA 
receptors, neuronal damage, and potential atrophy. This may also lead to a loss of 
inhibition of the HPA axis and excessive production of stress hormones.      
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A low-grade chronic inflammatory state is very commonly reported following 
spinal cord injury (SCI) as characterized by elevated levels of circulating pro-
inflammatory mediators.12–16 This state of immune dysfunction can be attributed to a 
variety of factors ranging from the loss of autonomic innervation of lymphoid organs, 
endocrine dysfunction, metabolic disorders, and a heightened risk for secondary health 
complications.17 This population is also far more prone to depression with rates reaching 
up to 5 times (20-40%) that of healthy, able-bodied individuals.18,19 Suicide rates are also 
far more prevalent among this population with rates ranging from 3-5 greater than 
healthy able-bodied individuals.20,21 Provided that traditional pharmaceutical treatments 
for depression, such as selective serotonin reuptake inhibitors (SSRI’s), have commonly 
reported side effects,22 prove ineffective in approximately 30% of patients,23 and 
correspond to high rates of relapse,24 alternative treatments are needed.      
The link between inflammation and depression may provide the opportunity to 
treat the latter by targeting the immune system via anti-inflammatory strategies. As there 
is a need for drastic changes in dietary intake following paralysis, and these changes are 
typically not met, the eating habits of individuals with SCI commonly contribute to a 
state of chronic inflammation. This provides the opportunity to reduce inflammation via 
the implementation of a strict anti-inflammatory diet for the purposes of assessing the 
influence of reduced inflammatory mediators on mood following SCI. It was 
hypothesized that reducing inflammation would lead to corresponding changes in 
neuroactive compounds and improvements in mood and depressive symptoms.      
Methods  
 
*See Chapter 4 - Overview of Study Design for methodologies regarding participants, 
randomization, and anti-inflammatory diet    
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Measurement of serum inflammatory markers and amino acids: 
 Blood draws (20ml) were taken from the antecubital vein of each participant at 
1pm at each of the 3 testing sessions (baseline, 1 month, and 3 months). Following 
extraction, the whole blood was allowed to clot for 30 minutes followed by centrifugation 
at 1000xg for 15 minutes. Serum was extracted and immediately stored at -80°C until 
later analysis. Inflammatory mediators of interest included the pro-inflammatory 
cytokines IL-2, IL-1β, IL-6, TNF-α, IFN-y, the acute phase protein CRP, as well as the 
anti-inflammatory cytokines IL-4, IL-10, and IL-1RA. Amino acids of interest included 
tryptophan, phenylalanine, tyrosine, and branched-chain amino acids (valine, leucine, 
isoleucine) for the assessment of the TRP/LNAA ratio. Phenylalanine and tyrosine were 
also quantified for the assessment of the PHE/TYR ratio which provides an indication of 
phenylalanine (4)-hydroxylase activity. Chronic inflammation has been shown to impair 
the activity this enzyme thereby causing increases in PHE and an increase in the 
PHE/TYR, which provides some indication of the inflammatory state.25 Kynurenine 
levels were also analyzed for the assessment of the KYN/TRP ratio. Analysis of pro and 
anti-inflammatory cytokines was performed in triplicate via the Magpix Multiplex system 
(EMD Millipore, MA, U.S.A) and analyzed using Luminex software. CRP was analyzed 
in triplicate and quantified via enzyme-linked immunosorbent assay (R&D systems, 
Minneapolis, U.S.A.). TRP, Phe, TYR, BCAA, and KYN were analyzed in triplicate and 
quanitified via enzyme-linked immunosorbent assay (Immunodiagnostik, Bensheim, 
Germany; Labor Diagnostika, Nordhorn, Germany).             
107 
 
 
Assessment of mood: 
 Participants completed the Center for Epidemiological Studies Depression Scale 
(CES-D) at each of the 3 testing sessions, as means of assessing symptoms of depression. 
The questionnaire consisted of 20 items related to depression and participants were asked 
to rate how often they experienced each item over the previous 7-day period. Ratings 
were based on a 4-point scale including, ‘rarely or none of the time’ (less than 1 day), 
‘some or a little of the time’ (1-2 days), ‘occasionally or a moderate amount of the time’ 
(3-4 days), or ‘most or all of the time’ (5-7 days). Points for each item ranged from 0-3 
depending on frequency and each item was summed for a total score ranging from 0-60 
with higher scores indicating the presence of more symptomatology. A score of 16 points 
or greater is considered depressed.         
Statistical analysis:   
 Two-way (group x time) repeated measures ANOVA were performed to 
investigate possible changes in CES-D scores across 3 testing sessions. Two-way 
repeated measures ANOVA were also performed for the proinflammatory cytokine TNF-
α and the amino acids TRP, TYR, KYN, and the TRP/LNAA ratio. Post hoc analyses 
were used as needed to compare means when significant group x time interactions were 
found. These data are expressed as means ± standard deviations. As the remaining 
inflammatory mediators and amino acids were not normally distributed, non-parametric 
analyses were performed. A Friedman’s test of differences among repeated measures 
(baseline, 1 month, 3 month) for the treatment group and control was performed. If the 
Friedman’s test resulted in a significant value, a Wilcoxon signed-rank test was then 
performed to provide specific information regarding which time points were significantly 
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different from one another. Finally, A Mann-Whitney test was performed on change 
scores (3-month - baseline) between groups to establish if the change experienced in 
inflammatory mediators and amino acids significantly differed between groups. These 
data are expressed as means ± standard deviations. Correlations between changes in 
inflammatory mediators, amino acids, and CES-D scores were assessed by means of 
Pearson’s r correlation. A mediation analysis was performed to assess whether the 
relationship between the change in the KYN/TRP ratio and the change in CES-D score 
was mediated by the change in IL-1β. This analysis consisted of four steps of testing: (1) 
the association of the independent variable (∆KYN/TRP ratio) with the outcome variable 
(∆CES-D score), (2) the association of the independent variable with the mediator 
variable (∆IL-1β), (3) the association of the mediator variable with the outcome variable 
after controlling for independent variable, and (4) whether the effect of the independent 
variable on the dependent variable was reduced when the mediator was included in the 
model. Differences in IL-1β concentrations for subgroup analysis were assessed using the 
Student’s t-test. Statistical significance was set at p≤0.05 for all tests.          
Results 
 
All participants from both the treatment and control group completed the entire 3-
month duration of the study and were included in the analysis. No adverse events were 
reported. The participants’ overall compliance to the diet was assessed based on the 
average of the 3 diet records during the study (1 month, 2 months, and 3 months). One 
participant completed all three testing sessions but failed to produce the 2-month and the 
3-month diet record. This participant had a dietary compliance over the first month of 
92%. All other participants completed each of the required diet records and overall 
109 
 
 
compliance ranged from 70-100%, with a mean compliance of 89%. A detailed analysis 
regarding specific diet adherence data will be presented elsewhere.    
Change in CES-D scores: 
 Change in CES-D scores are shown in Table 1. There was a significant group x 
time interaction for CES-D scores (p=0.01, Cohen’s d=1.07). Post hoc analysis showed a 
significant reduction in CES-D scores in the treatment group from both baseline to 1 
month, as well as from baseline to 3 months (p=0.01 and p<0.01 respectively). Post hoc 
analysis showed a significant reduction in CES-D score in the control group from 
baseline to 1 month (p=0.03) but no significant change from baseline to 3 months 
(p=.74).      
 
Table 1: CES-D Scores:  
 
Change in Serum Amino Acids: 
Changes in serum amino acids are shown in Table 3 of Chapter 5. Two-way 
repeated measures ANOVA were performed for the normally distributed amino acids. 
There was a significant group x time interaction for the TRP/LNAA ratio (p=0.04, 
Cohen’s d=0.90). Post hoc analysis showed a trend towards a reduction in TRP/LNAA in 
the treatment group from baseline to 3 months (p=0.06) and no change in the control 
group at any time point. No significant group x time interaction was found for the 
PHE/TYR ratio (p=.435, Cohen’s d=0.43). KYN showed a trend towards a group x time 
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interaction (p=0.06, Cohen’s d=0.81). A Mann-Whitney test was performed on the 
change scores for non-normally distributed amino acids. Change scores (3-month - 
baseline) for the KYN/TRP ratio were shown to be significantly different between the 
treatment and control groups (U=20.0, p=0.03). A Friedman’s test was performed to test 
for significant changes among repeated measures (baseline, 1 month, 3 months) for the 
treatment group and control group. No significant change in the KYN/TRP ratio was 
found in the treatment (x2=2.09, p=0.35) or control (x2=4.75, p=0.09) group. 
Change in Inflammatory Mediators:  
 Changes in serum levels of inflammatory mediators are shown in Table 2 of 
Chapter 5. When considering a proinflammatory composite score (average of IL-2, IL-6, 
IL-1β, TNF-α, and IFNy), the Mann-Whitney test indicated that the change scores (3-
month - baseline) were significantly different between the treatment group and the 
control group (U=13.0, p=0.01). The Friedman test showed that there was a statistically 
significant reduction in the proinflammatory composite scores in the treatment group (x2 
= 6.50, p=0.04), but no significant change in the control group (x2=5.25, p=0.07). Post 
hoc analysis performed with the Wilcoxon signed-rank test showed significant reductions 
in the treatment group from both baseline to 1 month and baseline to 3 months (z=-2.197, 
p=0.03; z=-2.275, p=0.02 respectively). When analyzing each cytokine separately, the 
Mann-Whitney test indicated that the change scores (3-month - baseline) were 
significantly different between the treatment group and the control group for IFN-y 
(U=13.0, p=0.01.), IL-1β (U=14.0, p=0.01), and IL-2 (U=12.0, p=0.01) and showed a 
trend for CRP (U=27.0, p=0.10). The Friedman test showed that in the treatment group 
there was a statistically significant reduction in IFN-y (x2=8.67, p=0.01), IL-1β 
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(x2=17.78, p<0.01), IL-6 (x2=6.17, p<0.05), and a trend for CRP (x2=4.5, p=0.10). The 
Friedman test showed no statistically significant reductions for any inflammatory 
mediator in the control group. Post-hoc analysis performed with the Wilcoxon signed-
rank test showed significant reductions in the treatment group for IFN-y from baseline to 
1 month and baseline to 3 months (z=-2.275, p=0.02; z=-2.510, p=0.01 respectively), as 
well as significant reductions in the treatment group for IL-1β from baseline to 1 month 
and baseline to 3 months (z=-3.059, p<0.01; z=-2.934, p<0.01 respectively), and a 
significant reduction in the treatment group for IL-6 from baseline to 1 month, and a 
trend  from baseline to 3 months (z=-2.275, p=0.02; z=-1.726, p=0.08 respectively). Two-
way repeated measures ANOVA were performed for the normally distributed mediator, 
TNF-α which showed a trend towards a group x time interaction (p=0.10, Cohen’s 
d=0.12) 
Correlational Analysis:   
 Pearson’s r correlation coefficients for amino acid, cytokine, and CES-D data are 
shown in Table 2. The change in IL-1β was significantly correlated with both the change 
in CES-D score (r=.740, p<0.01) and the change in the KYN/TRP ratio (r=.536, p=0.02). 
The change in the KYN/TRP ratio was also significantly correlated with the change in 
CES-D score (r=.586, p=0.01). The relationship between the change in TRP/LNAA ratio 
and the change in CES-D score did not reach statistical significance (r=-0.378, p=0.10), 
whereas the relationship between the change in the TRP metabolite KYN and the change 
in CES-D score did reach statistical significance (r=.705, p<0.01).  
 
Table 2. IL-1β, Amino acid, and CES-D Correlations  
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        All Participants [n=20]   
 ∆CES-D ∆IL-1B ∆TRP/LNAA ∆KYN/TRP 
∆CES-D  --    
∆IL-1B   .740** --   
∆TRP/LNAA  -.378 .369 --  
∆KYN/TRP .586** .536* .345 -- 
∆KYN .705** .657** .114 .730** 
Subgroup (CES>16) [n=8] 
 ∆CES-D ∆IL-1B ∆TRP/LNAA ∆KYN/TRP 
∆CES-D  --    
∆IL-1B   .738* --   
∆TRP/LNAA  .569 .363 --  
∆KYN/TRP .937** .792* .436 -- 
∆KYN .800** .825** .192 .823** 
*p≤.05; **p≤ 0.01 
 
Mediation Analysis:  
 A mediation analysis was performed in order to test whether the change in IL-1β 
mediated the observed relationship between the change in KYN/TRP and the change in 
CES-D scores. In the first step of the mediation model, the association of the independent 
variable with the outcome variable was assessed. This regression of the change in the 
KYN/TRP ratio on the change in CES-D scores (ignoring the change in IL-1β) was 
significant, b=.586, t(18)=3.07, p=0.01. In step two the association of the independent 
variable with the mediator variable was assessed. It was shown that the regression of the 
change in the KYN/TRP ratio on the mediator (change in IL-1 β) was also significant, 
b=0.06, t(18)=2.70, p=0.02. In step 3 of the mediation process the association of the 
mediator variable with the outcome variable after controlling for the independent variable 
was assessed. The regression of the change in IL-1β on the change in CES-D score 
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(controlling for the change in the KYN/TRP ratio) was significant b=5.34, t(17)=3.30, 
p<0.01. In the last step we assessed whether the effect of the independent variable on the 
dependent variable was reduced when the mediator was included in the model. When 
controlling for the change in IL-1β, the change in the KYN/TRP ratio was not a 
significant predictor of the change in CES-D score, b=0.25, t(17)=1.45, p=0.16. A Sobel 
test was conducted and found full mediation in the model (z=2.04, p=0.04). Therefore, it 
was found that the change in IL-1β fully mediated the relationship between the change in 
the KYN/TRP ratio, and the change in CES-D scores.     
Subgroup Analysis:  
 A subgroup analysis was performed examining participants with CES-D scores 
greater than 16 (indicating depression) from both the treatment group (n=5) and control 
group (n=3). It was found that participants with CES-D scores indicating depression had 
concentrations of IL-1β which were 73% higher compared to those with lower (<16) 
CES-D scores (p=0.05). Pearson’s r correlation coefficients for amino acid, cytokine, and 
CES-D data are shown in Table 4. The significant relationship between change in IL-1β 
and the change in CES-D remained in this subgroup (r=.738, p=0.04) and the relationship 
between the change in IL-1β and the change in the KYN/TRP ratio became even stronger 
(r=.792, p=0.02). The change in the KYN/TRP ratio and the change in CES-D was also 
very strongly correlated in this subgroup (r=.937, p<0.01). Once again the change in the 
TRP/LNAA and the change in CES-D were not found to be significantly correlated 
(r=.569, p=0.11) while the change in KYN was strongly correlated with the change in 
CES-D score (r=.800, p=0.01).   
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Discussion 
 
The present study successfully obtained reductions in inflammatory mediators, 
modifications in neuroactive compounds, and improvements in mood in individuals with 
SCI by means of dietary alterations. As evidence suggests inflammation contributes to 
depression, and SCI is typically characterized by a state of chronic inflammation as well 
as a high prevalence of depression, it was hypothesized that reducing levels of 
inflammation in this population would result in both molecular changes and 
corresponding improvements in mood.      
Mood was significantly improved in the treatment group as demonstrated by the 
significant reduction in CES-D scores. When assessing potential mechanisms for such 
changes, a significant group x time interaction for the TRP/LNAA ratio was found and 
post hoc analysis revealed trends towards an increase in the treatment group at 1 month 
and 3 months following baseline. TRP is a critical precursor for 5-HT synthesis in the 
brain and competes for transportation across the BBB against other LNAA via common 
transport mechanisms. As such, an increase in the TRP/LNAA ratio signifies heightened 
TRP availability and would be expected to relate to improvements mood. However, the 
relationship between the change in the TRP/LNAA ratio and the change in CES-D scores 
did not reach statistical significance (p=0.10).        
A significant group x time interaction was found for both IFN-y and IL-1β and 
post hoc analysis showed trends towards reduction for IFN-y at 1 month and 3 months, 
and a significant reduction for IL-1β at 1 month and trend towards reduction at 3 months. 
Trends toward group x time interactions were also found for IL-6, TNF-α, and IL-1RA. 
Of these changes, only the reduction in IL-1β was shown to significantly correlate with 
115 
 
 
the reduction in CES-D score. As IL-1β is capable of gaining access to the brain via leaky 
sites at the circumventricular organs or by crossing the BBB or via specialized active 
transporters it may be possible for it to impose a direct influence.5,6 Once in the brain, IL-
1β has been shown to activate 5-HT transporters (SERT), thereby stimulating the re-
uptake of 5-HT from the synaptic cleft, leading to its functional depletion.7-9 Although it 
was not possible to directly assess SERT or 5-HT levels within the brain, it is possible for 
IL-1β to have contributed to changes in mood by means of such direct mechanisms.   
The change in IL-1β was also significantly correlated with the change in the 
KYN/TRP ratio. The KYN/TRP ratio can represent the activity of either indoleamine 2,3-
dioxygenase (IDO) or tryptophan 2,3 dioxygenase (TDO). Both are critical enzymes of 
the kynurenine pathway responsible for the degradation of TRP into KYN. TDO is 
however, mainly expressed in the liver and not regulated by the immune system.26 IDO is 
an immunoregulated enzyme and elevations in the KYN/TRP ratio have been previously 
shown to be significantly correlated with increases in IFNy activity27 as well as 
elevations in neopterin; a molecule synthesized by macrophages upon stimulation by 
IFNy, and indicator of a pro-inflammatory status.28 This strongly suggests that IDO is the 
main enzymatic contributor to changes in the KYN/TRP ratio in response to changes in 
inflammation.  Additional pro-inflammatory cytokines, including IL-1β, have been 
shown to up-regulate IDO activity, thereby increasing the rate of TRP metabolism and 
production of TRP metabolites.29 This selective TRP metabolism can lead to reductions in 
the TRP/LNAA ratio thereby limiting TRP availability for the synthesis of 5-HT. 
Additionally, the excessive breakdown of TRP results in the increased production of TRP 
metabolites which have also been shown to play an important role in factors related to 
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depression. As the change in the KYN/TRP ratio was also significantly correlated with 
the change in CES-D scores it may be possible that IL-1β influenced depression via such 
IDO-related mechanisms. Based on these findings, a mediation analysis was performed to 
further address the extent to which the link between change in the KYN/TRP ratio and 
change in the CES-D scores were mediated by change in the IL-1β. The analysis 
suggested that the relationship between change in the KYN/TRP and change in the CES-
D was fully mediated by change in the IL-1β.  
In addition to the potential reduction in TRP availability as shown by the 
TRP/LNAA ratio, a cytokine-induced up-regulation of IDO activity may result in 
elevations in TRP metabolites. Several TRP metabolites, including KYN, are BBB 
transportable and can be neurotoxic when at elevated concentrations within the brain. As 
in the periphery, once in the brain KYN can be further metabolized along the kynurenine 
pathway into other metabolites which have been shown to influence depression. One such 
metabolite, quinolinic acid (QUIN), acts as a potent agonist of the N-methyl-D-aspartate 
(NMDA) receptor which are densely populated on the hippocampus and play a critical 
role in synaptic plasticity. Elevated concentrations of QUIN may result in NMDA over-
activity resulting in an increased calcium influx leading to corresponding neuronal 
damage and potential atrophy.30 Smaller hippocampal volumes in individuals with MDD 
have been commonly reported.31-34 As the hippocampus plays an important role 
concerning the inhibition of HPA axis, hippocampal atrophy may result in an upregulated 
HPA axis and excessive glucocorticoid production from the adrenal gland. Hyperactivity 
of the HPA axis and elevated levels of stress hormones have also been commonly 
reported in individuals with MDD (see Figure 1).35,36   
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  Both the reduction in the TRP/LNAA ratio and increase in TRP metabolites have 
the potential to influence depression via the aforementioned mechanisms. However, the 
fact that the change in KYN was related to the change in CES-D scores, (while the 
change in TRP/LNAA was not) may suggest that the production of TRP metabolites had 
a larger impact on such mood changes. Similar findings have been demonstrated by 
Sublette et al. 2011, whereby levels of KYN have been shown to be elevated in suicide 
attempters with MDD and correlated with attempt status, while TRP was not related. 
Further, Sublette et al. found a correlation between the cytokine activation marker 
neopterin and the KYN/TRP ratio suggesting that KYN production may have been 
influenced by inflammation.37     
Additional subgroup analysis on those with baseline CES-D scores greater than 
16 (suggesting depression) further implicated a role for IL-1β in depression as levels 
were shown to be 73% higher than in those with CES-D scores indicating a lack of 
depression. Further, all relationships between IL-1β, the KYN/TRP ratio and CES-D 
scores were maintained or strengthened in this subgroup including a very strong 
relationship between the change in the KYN/TRP ratio and the change in CES-D scores. 
Despite the small sample size, it also worth noting that for the five participants in the 
treatment group who began with scores indicating depression, all five reached scores 
below 16 within the first month of the intervention.  
The above mechanisms may explain the link between the dietary-induced 
reductions in inflammation and the improvements in mood as assessed by CES-D scores. 
SCI is associated with substantial alterations in nutrient requirements and energy 
demands as well as an increased risk for numerous metabolic disorders and acute 
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infections. Appropriate dietary alterations are therefore a suitable method of reducing 
inflammation and have a number of established mechanisms of action ranging from 
altered gene transcription, changes in cell membrane composition, improved enzyme 
regulation, as well as improvements in metabolic heath and body composition.38     
Common pharmaceutical treatment modalities for depression, such as selective 
serotonin reuptake inhibitors (SSRI’s), are popular due to their ability to relieve 
symptoms in a relatively short period of time by acting on SERT proteins to help increase 
extracellular 5-HT levels. SSRI use is, however, associated with a number of side 
effects22, and only provide transient relief of symptoms as they do not target the 
etiological basis of the disorder. SSRI’s have also been shown to be ineffective in 
approximately 30% of patients23 of whom a particularly elevated inflammatory state is 
typically reported.39-40 Additionally, of those who do respond to treatment, an estimated 
20-80% will relapse within the first 1-5 years following initial treatment.24 As such, there 
is a clear need for a more sustainable, long-term treatment, free from the many side-
effects that coincide with prolonged use of traditional pharmaceutical treatments. 
Whether anti-inflammatory strategies could be used as a stand-alone treatment or 
would need to be used in conjunction with other interventions has yet to be determined. 
Future, long-term studies with larger sample sizes, and participants with various 
severities of depression will be needed. Several potential limitations of the current study 
should be noted. First, the study was only single blinded. While the examiner was blinded 
to group allocation during all blood analysis, participants were aware of their group 
assignment. Although placebo supplements could have been provided to the control 
group, it was not possible to adequately blind participants to all aspects of the diet. The 
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treatment group underwent a highly restrictive diet while the control group was free to 
consume unhealthy foods making distinction between groups quite obvious. Second, it is 
not possible to elucidate the specific mechanisms related to the reductions in 
inflammation, nor is it possible to discern which aspects of the dietary intervention may 
have had the strongest effects. It will be necessary for future studies to examine aspects 
such as transcription factor activity and membrane composition in order to truly elucidate 
the means by which such interventions act to reduce inflammation and improve 
symptoms of neuropathic pain. In terms of generalizability our sample was quite 
representative of the SCI population in Canada, in terms of age, level, and severity of 
injury41 however, the results may not necessarily be generalizable to all individuals with 
SCI with varying levels of inflammation and severities of depression (however, it is of 
interest that all participants with scores indicating depression improved to a score 
indicating a lack of depression in the current study). Finally, it is worth noting that 
utilizing an intervention which targets inflammation by such means as diet or exercise 
requires a commitment to a major lifestyle modification and may not provide the same 
immediacy of effects as traditional pharmaceuticals. Still, the current study showed 
strong compliance to the diet and achieved significant reductions in CES-D scores after 
only 1 month. Further, given the lack of side effects, and additional health benefits that 
coincide with healthy eating, such interventions may be a viable mode of treatment for 
this population and are worthy of further examination.  
Conclusion 
 
The present study demonstrated that it was possible to improve mood in 
individuals with SCI by means of reducing inflammation. Such improvements may relate 
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to positive changes in neuroactive compounds of the kynurenine pathway mediated by 
the significant reduction achieved in the proinflammatory cytokine IL-1β. These results 
suggest a potential role for anti-inflammatory interventions in the treatment of depression 
in spinal cord injured individuals. Due to the limited sample size of the present study, the 
results should be interpreted with caution. However, this influence is worthy of further 
examination in future larger scale studies, as it may help to reduce the reliance on 
traditional pharmaceuticals by complementing current treatments or by providing a safe 
and sustainable treatment alternative.     
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Abstract 
Study Design: This study was a randomized, parallel-group, controlled clinical trial 
(NCT02099890).     
 
Objectives: The purpose of this study was to examine the efficacy of targeting 
inflammation as a means of improving cognitive function in individuals with spinal cord 
injury.  
 
Setting: Participants were recruited from the Niagara region of Ontario Canada  
 
Methods: Indices of memory and verbal learning were assessed by means of the 
California Verbal Learning Test (CVLT). Inflammation and concentrations of 
neuroactive compounds related to the kynurenine pathway were assessed via a number of 
pro and anti-inflammatory cytokines, as well as tryptophan, kynurenine, and several large 
neutral amino acids. All assessments were performed at baseline as well as at 1-month 
and 3-months during a 3-month anti-inflammatory intervention.  
 
Results: Despite a reduction in inflammation, only intrusions were found to significantly 
improve in the treatment group (p=0.05). All other CVLT measures including list A, trial 
1 (p=0.48), learning slope (p=0.46), long delay free recall (p=0.83), and repetitions 
(p=0.07) showed no significant group x time interaction.  
 
Conclusion: It may be possible that the reduction in inflammation achieved in the current 
study was insufficient to induce substantial changes in most indices of verbal learning 
and memory. Alternatively, as these participants likely underwent years of previous 
chronic inflammation, underlying hippocampal damage may have negated potential 
improvements induced by acute reductions in inflammation. The isolated significant 
improvement in intrusions is difficult to explain, but may relate to the role of the frontal 
lobe in source memory and the ability to avoid incorrect responses.  
 
Trial Registration: ClinicalTrials.gov ID: NCT02099890 
 
Sponsorship: This study was funded by the Ontario Neurotrauma Foundation  
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128 
 
 
 
Introduction 
 
An estimated 10-60% of individuals with spinal cord injury (SCI) demonstrate 
some degree of cognitive impairment1–4. This dysfunction includes memory impairment4–
6, and deficits in verbal learning4–6, which would suggest a role for the hippocampus7. 
Cognitive deficits following SCI are often attributed to concomitant traumatic brain 
injury, and more recently, chronic hypotension8, however, there is evidence to suggest 
that the chronic inflammation typically demonstrated following SCI9,10 may also 
contribute to such deficits. Populations with severe cognitive impairment, such as those 
with Alzheimer’s disease, have been consistently shown to demonstrate high levels of 
inflammation11 and this elevated inflammatory state may indirectly influence 
hippocampal function.12    
Certain pro-inflammatory mediators such as IFN-y13,14, IL-1β14, and TNF-α13,14 
have been shown to possess the ability to up-regulate indoleamine 2,3 dioxygenase 
(IDO); a key enzyme of a critical metabolic pathway known as the kynurenine pathway. 
This enzyme plays a vital role in the metabolism of tryptophan (TRP) and the 
corresponding production of TRP metabolites such as kynurenine (KYN).12 Chronically 
elevated levels of proinflammatory mediators may therefore result in the chronic 
upregulation of IDO, resulting in excessive TRP breakdown and the overproduction of 
TRP metabolites such as KYN. As KYN is a blood brain barrier (BBB) transportable 
metabolite, it can move from the periphery and influence concentrations within the brain. 
Once in the brain, KYN can be further metabolized into non-BBB transportable 
metabolites such quinolinic acid (QUIN) and kynurenic acid (KYNA). These metabolites 
are produced via two distinct branches of the kynurenine pathway. The kynurenine-
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nicotinamide adenine dinucleotide (KYN-NAD) branch involves the enzyme kynurenine 
monooxygenase (KMO) and is responsible for converting KYN to 3-hydroxykynurenine 
(3-HK) and QUIN. A second branch, known as the kynurenine-kynurenic acid (KYN-
KYNA) branch, involves the enzyme kynurenine aminotransferase (KAT) and is 
responsible for the conversion of KYN to KYNA15 (see Figure 1). The enzyme KMO has 
been shown to be far less active within the brain than in the periphery, and as such, 
becomes rapidly saturated by elevated levels of KYN. It is therefore likely, that in the 
presence of high KYN levels within the brain, a shift towards the KYN-KYNA branch 
would occur resulting in the increased production of KYNA16. KYNA is a neuroactive 
compound which acts as an antagonist of two receptors which have been found to be 
densely populated on the hippocampus including the alpha-7-nicotinic acetylcholine 
(α7nACh) receptor and (to a lesser extent) the N-methyl-D-aspartate (NMDA) receptor. 
Each of these receptors play a critical role in synaptic plasticity associated with learning 
and memory17. The inhibition of α7nACh receptors by KYNA has been shown to result 
in the reduced release of neurotransmitters such as glutamate, acetylcholine, and 
dopamine; each which plays a critical role in cognitive processes.18–20 Therefore, by 
influencing neuroactive compounds of the kynurenine pathway, it may be possible for 
chronically elevated levels of inflammation to indirectly influence cognitive processes.   
Evidence of this relationship has been demonstrated in animal models whereby 
elevations in KYNA within the brain have been shown to induce cognitive deficits 
whether induced indirectly via intraperitoneal administration of KYN21 or via direct 
intracerebroventricular KYNA infusion22. Further, KAT II knockout mice, who lack the 
enzyme responsible for producing KYNA have been shown to have 66% lower 
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extracellular concentrations of KYNA as well as superior cognitive performance17. In 
humans, the administration of the non-competitive NMDA glutamate receptor antagonist, 
ketamine, has been shown to result in a reduction in verbal declarative memory23. 
Individuals with Alzheimer’s disease have also been shown to exhibit reduced 
concentrations of TRP and heightened concentrations of QUIN in the periphery24. 
Further, elevated concentrations of the potent IDO activator TNF-α, has been 
demonstrated in this population, and the administration of the TNF- α antagonist, 
etanercept, has been shown to result in improved cognitive scores11,25. 
Despite the evidence pertaining to the mechanisms behind such inflammatory-
induced cognitive deficits and changes in outcome in both animal models and humans, no 
study has attempted to define the inflammatory etiology of cognitive deficits in 
individuals with SCI. The purpose of the present study was therefore to assess whether 
reducing levels of inflammation in individuals with SCI would be sufficient to induce 
improvements in memory and verbal learning. It was hypothesized that due to the role 
chronic inflammation plays in the regulation of the kynurenine pathway, reductions in 
inflammation would result in improved scores memory and verbal learning.      
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Figure 1: The kynurenine pathway and the influence of proinflammatory mediators  
Tryptophan which is not transported across the blood brain barrier (BBB) for the synthesis of 
serotonin (5-HT) can be degraded in the periphery by indoleamine 2,3-dioxygenase (IDO) into 
kynurenine (KYN). KYN may then be metabolized within the periphery or after entering the 
brain along one of two distinct branches to produce either kynurenic acid (KYNA) or 3-
hydroxykynurenine (3-HK) and quinolinic acid (QUIN). Pro-inflammatory mediators are capable 
of up-regulating the activity of enzymes such indoleamine 2,3-dioxygenase (IDO), kynurenine 3-
monooxygenase (KMO), and kynurenine aminotransferase (KAT) thereby increasing the 
production such TRP metabolites. This may result in elevated levels of TRP metabolites with 
neuroactive properties within the brain.   
 
 
Materials and Methods  
 
*See Chapter 4 - Overview of Study Design for methodologies regarding participants, 
randomization, and anti-inflammatory diet   
 
Measurement of serum inflammatory markers and amino acids: 
 Blood draws (20ml) were taken from the antecubital vein of each participant at 
1pm at each of the 3 testing sessions (baseline, 1 month, and 3 months). Following 
extraction, the whole blood was allowed to clot for 30 minutes followed by centrifugation 
at 1000xg for 15 minutes. Serum was extracted and immediately stored at -80°C until 
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later analysis. Inflammatory mediators of interest included the pro-inflammatory 
cytokines IL-2, IL-1β, IL-6, TNF-α, IFN-y, the acute phase protein CRP, as well as the 
anti-inflammatory cytokines IL-4, IL-10, and IL-1RA. Amino acids of interest included 
tryptophan, kynurenine, phenylalanine, tyrosine, and branched-chain amino acids (valine, 
leucine, isoleucine). This allowed for the assessment of TRP concentrations as well as the 
TRP/LNAA ratio (an indicator of TRP availability). Kynurenine levels were also 
analyzed for the assessment of the KYN/TRP ratio (an indicator of IDO regulation). 
Analysis of pro and anti-inflammatory cytokines was performed in triplicate via the 
Magpix Multiplex system (EMD Millipore, MA, U.S.A) and analyzed using Luminex 
software. CRP was analyzed in triplicate and quantified via enzyme-linked 
immunosorbent assay (R&D systems, Minneapolis, U.S.A.). TRP, Phe, TYR, BCAA, and 
KYN were analyzed in triplicate and quanitified via enzyme-linked immunosorbent assay 
(Immunodiagnostik, Bensheim, Germany; Labor Diagnostika, Nordhorn, Germany).    
Assessment of cognitive function:  
Participants were asked to perform the California Verbal Learning Test (CVLT) 
as an indication of verbal learning and memory. This test consisted of 2 word lists each 
consisting of 4 categories of 4 words, for a total of 16 words per list. The test began with 
the learning trial whereby the examiner read aloud the first list (List A) of words. These 
words were announced at one-second intervals, in a fixed order, over 5 learning trials. 
Following each trial, the participant was asked to recall as many words as possible in any 
order, including those recalled on previous trials. Following these 5 learning trials, a 
single trial of an interference list (List B) was presented and participants were asked to 
immediately recall as many words as possible from this new list. This list (List B) 
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consisted of 2 shared categories from List A as well as 2 unshared categories. Following 
the presentation and recall of List B, short delay recall of list A was performed whereby 
participants were asked once again to recall as many words as possible from List A, both 
freely (with no help from the examiner), and with semantic cues, whereby participants 
were told the category (eg. types of vegetables). Following a 20-minute delay, long-delay 
recall of list A was assessed, once again first freely, and then with semantic cues. Finally, 
a recognition task was performed whereby participants were verbally presented with 44 
words consisting of 16 target words (those from List A) as well as 28 distractor words 
(those from List B and off-list words). Following the presentation of each word, 
participants were asked to identify whether or not the word was from List A.     
 Cognitive performance was examined based on the following: (1) scores from 
trial 1 of List A, as an indication of short-term memory, (2) the learning slope (slope of 
scores across the initial 5 trials of List A), as an indication of the rate of learning (3) 
scores of long-delay free recall, as an indication of longer-term memory, and (4) errors, 
including the total number of intrusions (incorrect off-list words) and repetitions (both 
incorrect and correct) across all trials.   
Statistical analysis:   
Two-way (group x time) repeated measures ANOVA were performed to 
investigate possible changes in scores of the CVLT across the 3 testing sessions 
(baseline, 1 month, 3 month). All CVLT subtests were calculated as a T-score (M=50; 
SD=10). Two-way repeated measures ANOVA were also performed for the 
proinflammatory cytokine TNF-α and the amino acids TRP, TYR, KYN and the 
TRP/LNAA ratio. As the remaining inflammatory mediators and amino acids were not 
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normally distributed, non-parametric analyses were performed. A Friedman’s test of 
differences among repeated measures (baseline, 1 month, 3 month) for the treatment 
group and control was performed. If the Friedman’s test resulted in a significant value, a 
Wilcoxon signed-rank test was then performed to provide specific information regarding 
which time points were significantly different from one another. Finally, A Mann-
Whitney test was performed on change scores (3-month - baseline) between groups to 
establish if the change experienced in inflammatory mediators and amino acids 
significantly differed between groups. These data are expressed as means ± standard 
deviations. Statistical significance was set at p≤0.05 for all tests. 
Results 
 
All participants from both the treatment and control group completed the entire 3-
month duration of the study and were included in the analysis. No adverse events were 
reported. The participants’ overall compliance to the diet was assessed based on the 
average of the 3 diet records during the study (1 month, 2 months, and 3 months). One 
participant completed all three testing sessions but failed to produce the 2-month and the 
3-month diet record. This participant had a dietary compliance over the first month of 
92%. All other participants completed each of the required diet records and overall 
compliance ranged from 70-100%, with a mean compliance of 89%. A detailed analysis 
regarding specific diet compliance data will be presented elsewhere. 
Change in CVLT Scores:  
 Changes in CVLT scores are shown in Table 2. No significant group x time 
interactions were observed for List A, Trial 1 free recall (p=0.48, Cohen’s d=0.04), 
learning slope coefficient (p=0.46, Cohen’s d=0.04), or long delay free recall (p=0.83, 
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Cohen’s d=0.01). When comparing errors, a significant time x interaction was observed 
for total intrusions (p=0.03, Cohen’s d=0.17), and a trend was observed for total 
repetitions (p=0.07, Cohen’s d=0.14). Post hoc analysis for total intrusions revealed a 
significant improvement for the treatment group from baseline to 3 month (p=0.05), 
while there was no significant change in the control group at any time point.   
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Table 2: Change in CVLT Scores 
 
 
All results are shown as mean ± SD. 
P-values correspond to group x time interactions 
*Significantly different from baseline with a P value ≤ 0.05 
 
. 
 
 
Treatment (n=12) Control (n=8) P-value 
 
Baseline 1 Month 3 Month Baseline 1 Month 3 Month  
Trial 1, List A 
Free Recall  
6.1±1.2 7.2±1.5 8.3±1.7 6.0±1.7 7.0±2.2 7.3±2.1 
0.48 
Learning Slope 
Coefficient   
1.1±0.5 1.2±0.4 0.9±0.7 1.5±0.8 1.2±0.4 1.0±0.5 
0.46 
Long Delay Free 
Recall 
9.8±3.1 11.2±3.3 11.8±2.9 10.6±3.3 11.6±2.9 12.1±4.1 
0.83 
Total Intrusions  5.3±4.7 3.1±4.1 2.9±3.4* 5.0±4.2 6.5±8.0 12.0±14.6 0.03 
Total Repetitions  4.9±4.3 3.4±3.7 4.8±3.7 5.1±4.5 8.8±6.3 4.5±3.5 0.07 
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Change in Inflammatory Mediators:  
Changes in serum levels of inflammatory mediators are shown in Table 2 of 
Chapter 5. When considering a proinflammatory composite score (average of IL-2, IL-6, 
IL-1β, TNF-α, and IFNy), the Mann-Whitney test indicated that the change scores (3-
month - baseline) were significantly different between the treatment group and the 
control group (U=13.0, p=0.01). The Friedman test showed that there was a statistically 
significant reduction in the proinflammatory composite scores in the treatment group (x2 
= 6.50, p=0.04), but no significant change in the control group (x2=5.25, p=0.07). Post 
hoc analysis performed with the Wilcoxon signed-rank test showed significant reductions 
in the treatment group from both baseline to 1 month and baseline to 3 months (z=-2.197, 
p=0.03; z=-2.275, p=0.02 respectively). When analyzing each cytokine separately, the 
Mann-Whitney test indicated that the change scores (3-month - baseline) were 
significantly different between the treatment group and the control group for IFN-y 
(U=13.0, p=0.01.), IL-1β (U=14.0, p=0.01), and IL-2 (U=12.0, p=0.01) and showed a 
trend for CRP (U=27.0, p=0.10). The Friedman test showed that in the treatment group 
there was a statistically significant reduction in IFN-y (x2=8.67, p=0.01), IL-1β 
(x2=17.78, p<0.01), IL-6 (x2=6.17, p<0.05), and a trend for CRP (x2=4.5, p=0.10). The 
Friedman test showed no statistically significant reductions for any inflammatory 
mediator in the control group. Post-hoc analysis performed with the Wilcoxon signed-
rank test showed significant reductions in the treatment group for IFN-y from baseline to 
1 month and baseline to 3 months (z=-2.275, p=0.02; z=-2.510, p=0.01 respectively), as 
well as significant reductions in the treatment group for IL-1β from baseline to 1 month 
and baseline to 3 months (z=-3.059, p<0.01; z=-2.934, p<0.01 respectively), and a 
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significant reduction in the treatment group for IL-6 from baseline to 1 month, and a 
trend from baseline to 3 months (z=-2.275, p=0.02; z=-1.726, p=0.08 respectively). Two-
way repeated measures ANOVA were performed for the normally distributed mediator, 
TNF-α which showed a trend towards a group x time interaction (p=0.10, Cohen’s 
d=0.12) 
Change in Serum Amino Acids: 
Changes in serum amino acids are shown in Table 3 of Chapter 5. Two-way 
repeated measures ANOVA were performed for the normally distributed amino acids. 
There was a significant group x time interaction for the TRP/LNAA ratio (p=0.04, 
Cohen’s d=0.90). Post hoc analysis showed a trend towards a reduction in TRP/LNAA in 
the treatment group from baseline to 3 months (p=0.06). Post hoc analysis showed no 
change in the control group at any time point. KYN showed a trend towards a group x 
time interaction (p=0.06, Cohen’s d=0.81). A Mann-Whitney test was performed on the 
change scores for non-normally distributed amino acids. Change scores (3-month - 
baseline) for the KYN/TRP ratio were shown to be significantly different between the 
treatment and control groups (U=20.0, p=0.03). A Friedman’s test was performed to test 
for significant changes among repeated measures (baseline, 1 month, 3 months) for the 
treatment group and control group. No significant change in the KYN/TRP ratio was 
found in the treatment (x2=2.09, p=0.35) or control (x2=4.75, p=0.09) group. 
Discussion 
 
The present study was the first to examine the influence of reducing chronically 
elevated levels of inflammation on cognitive function in-vivo, in humans with spinal cord 
injury. The intervention successfully reduced levels of pro-inflammatory mediators but 
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only achieved significant improvement in total intrusions. It was hypothesized that a 
significant reduction in pro-inflammatory mediators would be sufficient to induce 
alterations in neuroactive compounds of the kynurenine pathway resulting in 
corresponding improvements in memory. Significant group differences were found for 
the change in the TRP/LNAA ratio (significant group x time interaction) as well as the 
KYN/TRP ratio (significant Mann-Whitney test of change scores). The magnitude of 
change in these ratios, however, did not reach statistical significance in either the 
treatment or control group. It may be possible that the significant reductions obtained in 
pro-inflammatory mediators were not considerable enough to induce substantial 
alterations in IDO regulation and therefore did not allow for meaningful changes in 
corresponding amino acids. This may explain, in part, the lack of change in scores of 
memory and verbal learning related to scores of Trial 1, List A, Learning Slope 
Coefficient, and Long Delay Free Recall.  
The lack of such changes may also be attributable to previously developed and 
potentially irreversible hippocampal atrophy. The TRP metabolite 3-HK is able to cross 
the BBB from the periphery and induce oxidative damage via the production of reactive 
oxygen species following an interaction with the enzyme xanthine oxidase.27 
Additionally, 3-HK may be further metabolized once in the brain into the non-BBB 
transportable metabolite QUIN. QUIN is a potent agonist of NMDA receptors which are 
densely populated on the hippocampus. Chronically elevated concentrations of QUIN 
within the brain are therefore capable of inducing excitotoxicity by causing an over-
activation of NMDA receptors resulting in an increased influx of calcium ions and 
corresponding neuronal damage.28 This may also further contribute to the production of 
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free radicals and oxidative stress brought on by 3-HK. Together, these mechanisms may 
contribute to hippocampal atrophy stemming from a chronic elevation in inflammatory 
mediators. Hippocampal volume loss in the form of reduced grey matter density has been 
demonstrated in individuals with major depressive disorder (also a chronic inflammatory 
condition) and has been shown to correlate with reduced scores in verbal recognition 
memory.29 As the sample of the current study consisted of individuals with chronic SCI, 
it may be possible that years of chronic inflammation resulted in hippocampal atrophy 
which contributed to deficits in memory and verbal learning which could not be 
attenuated by an acute reduction in inflammation.   
The significant improvement in intrusions may be due to the fact that the ability to 
recognize the source of information (e.g. List A versus List B) and avoid incorrect 
responses is reflective of frontal lobe function rather than hippocampal function. 
Accordingly, the frontal lobe has been suggested to play an important role in source 
memory and the ability to avoid distractor or lure items in cognitive tests.30 This has been 
demonstrated in individuals with frontal lobe damage whereby unusually high numbers 
of false recognitions have been reported on recall tests.31,32 
In the current study, it may be possible that the frontal lobe was more responsive 
to the anti-inflammatory intervention compared to the hippocampus. Specifically, the 
hippocampus has been shown to be susceptible to inflammation-induced excitotoxicity 
and eventual atrophy, which may make it less responsive to changes in inflammation. 
The frontal lobe may however be influenced by alternative mechanisms. For example, 
frontal lobe dysfunction has been demonstrated in individuals with cardiovascular disease 
(a condition associated with a state chronic inflammation) and has been shown to be 
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correlated with reduced cerebral blood flow (CBF) and elevated levels of CRP.33 A 
reduction in cerebral blood flow may be induced by inflammatory mediators such as CRP 
by means of their ability to cause a reduction in vasodilators such nitric oxide as well 
their contribution to plaque formation. Although CBF was not assessed in the current 
study, previous studies have suggested a relationship whereby diminished CBF and 
cerebral hypoperfusion may contribute to cognitive deficits in individuals with paraplegia 
and tetraplegiea.8 Such speculation may explain the link between the reduction in 
inflammation and intrusion scores, however, further studies are required to elucidate such 
a potential effect.     
Several potential study limitations should be noted. Although a significant 
reduction in pro-inflammatory mediators was achieved, it is unclear how large of 
reduction may be necessary to induce potential changes in cognition. It may be possible 
that larger reductions could have had a greater influence. Additionally, as hippocampal 
volume and CBF were not assessed in the current study, it is not possible to claim that 
such influences were responsible for the lack of effect. In terms of generalizability, our 
sample was quite representative of the SCI population in Canada, regarding age, level of 
injury34 and the levels of inflammation demonstrated were comparable to those 
previously reported for this population.9,35,36 It may be necessary however, for future 
studies to evaluate and control for hippocampal volume when assessing populations that 
have undergone long periods of chronic inflammation.        
Conclusion 
 
 The present study demonstrated an improvement in intrusions while other indices 
of verbal learning and memory remained unchanged despite a significant reduction of 
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proinflammatory mediators in a population with SCI. These results suggest that 
reductions in inflammation to this magnitude may not be sufficient to induce meaningful 
alterations in related neuroactive compounds or corresponding changes in cognition. It 
may be possible that the ability to avoid incorrect responses is the most sensitive to 
change, thereby explaining the significant improvement in intrusions. As it is possible 
that underlying hippocampal atrophy may have contributed to the lack of improvements 
in most aspects of the test, it will be necessary for future studies to evaluate hippocampal 
volume when assessing the efficacy of anti-inflammatory interventions for the treatment 
of cognitive impairment.    
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Abstract 
 
Study Design: This study was a randomized, parallel-group, controlled clinical trial 
(NCT02099890).   
Objectives: The purpose of the present study was to examine the effectiveness of an anti-
inflammatory intervention as a treatment for neuropathic pain following spinal cord 
injury (SCI). 
Setting: Participants were recruited from the Niagara region of Ontario Canada  
 
Methods: Twenty participants with varying levels and severities of SCI, were 
randomized (3:2) to either a 12-week anti-inflammatory diet, or control group. Outcome 
measures consisted of self-determined indices of pain as assessed using the neuropathic 
pain questionnaire (NPQ), and markers of inflammation as assessed by various pro and 
anti-inflammatory cytokines, as well as the eicosanoids PGE2 and LTB4.  
Results: A significant group x time interaction was found for sensory pain scores 
(p<0.01). A Mann-Whitney test revealed that the change scores (3 month-baseline) were 
significantly different between groups for IFNy (U=13.0, p=0.01.), IL-1β (U=14.0, 
p=0.01), and IL-2 (U=12.0, p=0.01). A Friedman test revealed the treatment group had a 
significant reduction in IFNy (x2=8.67, p=0.01), IL-1β (x2=17.78, p<0.01), IL-6 (x2=6.17, 
p<0.05), while the control group showed no significant change in any inflammatory 
mediator. A step-wise backward elimination multiple regression analysis showed that the 
change in sensory neuropathic pain was a function of the change in the proinflammatory 
cytokines IL-2, and IFN-y, as well as the eicosanoids PGE2 (R=.689, R2=.474).  
Conclusion: Overall the results of the study demonstrate the efficacy of targeting 
inflammation as a means of treating neuropathic pain in SCI, with a potential mechanism 
relating to the reduction in proinflammatory cytokines and PGE2.     
Trial Registration: ClinicalTrials.gov ID: NCT02099890 
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Introduction 
 
Damage to the nervous system may result in persistent or permanent changes to 
nociceptive thresholds resulting in a unique pain state characterized by allodynia and/or 
hyperalgesia1. This form of pain, known as neuropathic pain, effects an estimated 29-
75% of the spinal cord injured (SCI) population2. Such a condition can be severely 
debilitating following SCI and may contribute to inactivity and related metabolic 
conditions, as well as behavioral disorders such depression, anxiety, and insomnia3. 
Neuropathic pain is notoriously difficult to treat and no current treatment has been 
consistently proven as universally effective, predictable and safe for long-term use4. 
Based on the widespread potential to impact quality of life, it is imperative to gain a 
better understanding of the underlying mechanisms of neuropathic pain and explore novel 
treatments.   
Traditionally, neuropathic pain has been viewed as a purely neuronal issue, 
stemming from structural damage to the neuron itself. However, it is now well-
established that supporting glial cells and the environment with which the nociceptor 
interacts are important factors5. A number of inflammatory mediators are known to 
reduce the nociceptive threshold, resulting in symptoms of hyperalgesia5. 
Proinflammatory cytokines such as IL-1β, IFN-y, IL-6, and TNF-α have been proposed to 
induce algesic effects by both direct6 and indirect7 (prostaglandin-dependent) influences. 
The inflammatory etiology of neuropathic pain is further supported based on evidence 
that analgesic effects have been produced following the reduction of pro-inflammatory 
cytokine concentrations. This has been demonstrated in animal models following the 
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administration of antibodies against TNF-α8 as well as in transgenic animal models with 
impaired IL-1β production9,10.   
Pharmacological treatment strategies are currently the most heavily relied upon 
form of neuropathic pain management. Studies have, however, shown mixed results 
concerning the efficacy, universality, and associated side effects of treatments such as 
tricyclic antidepressants, SSRI’s, cannabinoids, anticonvulsants, and opioids4. This 
inconsistency across studies may be due, in part, to variability in protocols (e.g. duration, 
dosage) but may also relate to the varied etiological basis across different participants. A 
better understanding of the various mechanisms at play and a more advanced mechanism-
based classification system will be critical to enhance the specificity and efficacy of 
current pharmacological treatments. This may contribute to the development of 
pharmacological treatments which target the underlying mechanisms responsible for 
neuropathic pain as opposed to focusing solely on symptom relief. 
An alternative to traditional pharmaceutical treatments may be the 
implementation of anti-inflammatory interventions. Such strategies would target the 
common inflammatory mechanisms which underlie various etiologies thereby having the 
potential to provide a more universally applicable treatment option. Further, if such 
strategies prove effective, it may be possible to produce such anti-inflammatory effects 
via simple lifestyle alterations without the use of pharmaceuticals. This may help to 
reduce the reliance on traditional pharmaceuticals thereby helping to avoid associated 
side effects. Appropriate dietary alterations including foods and supplements with 
established anti-inflammatory benefits have been shown to effectively reduce 
inflammation via a number of mechanisms ranging from altered gene transcription, 
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changes in cell membrane composition, improved enzyme regulation, as well as 
improvements in metabolic heath and body composition11.  
Dietary needs, including nutrient requirements and caloric intake, change 
drastically following SCI, and are often not adequately met. Diet is therefore, likely a 
substantial contributing factor to the chronic inflammation typically observed following 
SCI12,13. A dietary intervention consisting of foods and supplements with established anti-
inflammatory benefits was therefore utilized in the current study with the intention of 
reducing inflammation for the purpose of studying the effect on neuropathic pain. It was 
hypothesized that by reducing chronically elevated levels of inflammatory mediators, 
corresponding reductions in neuropathic pain would be achieved. 
Materials and Methods  
 
*See Chapter 4 - Overview of Study Design for methodologies regarding participants, 
randomization, and anti-inflammatory diet   
 
Measurement of serum inflammatory markers: 
 Blood draws (20ml) were taken from the antecubital vein of each participant at 
1pm at each of the 3 testing sessions (baseline, 1 month, and 3 month). Following 
extraction, the whole blood was allowed to clot for 30 minutes followed by centrifugation 
at 1000xg for 15 minutes. Serum was extracted and immediately stored at -80°C until 
later analysis. Inflammatory mediators of interest included the pro-inflammatory 
cytokines IL-2, IL-1B, IL-6, TNF-alpha, IFN-y, acute phase protein CRP, eicosanoids 
PGE2 and LTB4, as well as the anti-inflammatory cytokines IL-4, IL-10, and IL-1RA. 
Both pro and anti-inflammatory cytokines were assessed due to findings that painful 
neuropathy has been shown to be associated with elevated levels of proinflammatory 
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mediators and reduced levels of anti-inflammatory mediators while non-painful 
neuropathy has shown the opposite.12,15 Improvements in neuropathic pain may therefore 
relate to reductions in proinflammatory mediators and/or elevations in anti-inflammatory 
mediators. Analysis of pro and anti-inflammatory cytokines was performed in triplicate 
via the Magpix Multiplex system and analyzed using Luminex software. CRP, PGE2, and 
LTB4 were analyzed in triplicate and quantified via enzyme-linked immunosorbent assay 
(R&D systems, Minneapolis, U.S.A.).     
Assessment of neuropathic pain:  
 Participants were asked to complete the Neuropathic Pain Questionnaire (NPQ) at 
each of the 3 testing sessions, as a means of assessing self-reported neuropathic pain. The 
questionnaire consisted of 32 items pertaining to 3 unique categories including sensory 
items, affective items, and sensitivity items. Sensory items were those related to the 
specific type and severity of pain felt (e.g. degree of burning, stabbing, throbbing, etc.), 
affective items referred to those related to how the pain affected the participant in daily 
life (e.g. how irritating is your usual pain?) and sensitivity items related to how various 
stimuli may act to increase pain (e.g. increased pain due to heat). Participants were asked 
to rate their pain numerically on a scale from 0-100 whereby 0 indicated the complete 
absence of pain and 100 indicated the worst pain imaginable. Scores from each of the 3 
categories were averaged for use in statistical analysis.   
Statistical analysis:   
Two-way (group x time) repeated measures ANOVA were performed to 
investigate possible changes in pain scores related to sensory and affective pain across 3 
testing sessions (baseline, 1 month, 3 month). Two-way repeated measures ANOVA were 
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also performed for the proinflammatory cytokine TNF-α and the eicosanoid PGE2. As 
the remaining inflammatory mediators as well as sensitivity pain scores were not 
normally distributed, non-parametric analyses were performed. A Friedman’s test of 
differences among repeated measures (baseline, 1 month, and 3 month) for the treatment 
group and control was performed. If the Friedman’s test resulted in a significant value, a 
Wilcoxon signed-rank test was then performed to provide specific information regarding 
which time points were significantly different from one another. Finally, A Mann-
Whitney test was performed on change scores (3-month - baseline) between groups to 
establish if the change experienced significantly differed between groups. These data are 
expressed as means ± standard deviations. Correlations between changes in inflammatory 
mediators, and neuropathic pain scores were assessed by means of Pearson’s r 
correlation. Statistical significance was set at p≤0.05 for all tests. The proportional 
contribution of the change in each inflammatory mediator to the change in pain score was 
evaluated using a step-wise backwards elimination multiple regression. Levels of F to 
enter and F to remove were set to correspond to p-levels of .05 and .10 respectively.     
Results 
 
All participants from both the treatment and control group completed the entire 3-
month duration of the study and were included in the analysis. No adverse events were 
reported. The participants’ overall compliance to the diet was assessed based on the 
average of the 3 diet records during the study (1 month, 2 months, and 3 months). One 
participant completed all three testing sessions but failed to produce the 2-month and the 
3-month diet record. This participant had a dietary compliance over the first month of 
92%. All other participants completed each of the required diet records and overall 
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compliance ranged from 70-100%, with a mean compliance of 89%. A detailed analysis 
regarding specific diet adherence data will be presented elsewhere.    
Change in pain scores: 
 Changes in sensory, affective, and sensitivity pain scores are shown in table 2. 
There was a significant group x time interaction for the sensory component of the self-
reported neuropathic pain scores (p<0.01; cohen’s d=1.29). Post hoc analysis showed a 
significant reduction in sensory scores in the treatment group from both baseline to 1 
month, as well as baseline to 3 months (p=<0.01 and p=.01 respectively). Post hoc 
analysis showed a significant increase in sensory scores in the control group from 
baseline to 1 month (p=.04) but no significant change from baseline to 3 months (p=.210) 
No significant group x interaction was found for the affective component of the self-
reported neuropathic pain scores (p=0.17; cohen’s d=0.63). In regard to the non-
parametric analysis of sensitivity scores, the Mann-Whitney test indicated that change 
scores of sensitivity pain were not significantly different between the treatment group and 
control group (U=36.0, p=0.35). The Friedman test showed that there was no significant 
change in sensitivity pain scores for either the treatment group (x2=3.38, p=0.19) or 
control group (x2=0.09, p=0.96) across testing sessions.    
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Table 2: Change in NPQ Scores  
 
All results are shown as mean ± SD. P-values correspond to group x time interactions, Mann-Whitney change scores, and Friedman scores 
for treatment group respectively (Friedman scores for control group not shown).   
*Significantly different from baseline with P value <0.05 
**Significantly different from baseline with P value <.01 
 Treatment (n=12) Control (n=8) 
2-Way 
ANOVA 
(p-value) 
Mann-
Whitney 
(p-value) 
Friedman 
[Treat.] 
(p-value) 
 Baseline 1 Month 3 Month Baseline 1 Month 3 Month    
Sensory 
Score 
32.8±23.4 23.4±20.2** 19.8±15.8** 18.1±17.2 25.2±22.2* 21.3±20.1 <0.01 -- -- 
Affective 
Score 
34.7±28.6 24.3±21.9 21.2±19.0 27.5±24.4 20.1±23.0 23.7±25.3 0.18 -- -- 
Sensitivity 
Score 
26.8±26.1 22.6±21.2 22.6±20.7 29.7±32.9 33.7±26.9 32.6±26.3 -- 0.35 0.19 
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Change in Inflammatory Mediators:  
 Changes in serum levels of inflammatory mediators are shown in Table 2 of 
Chapter 5. When considering a proinflammatory composite score (average of IL-2, IL-6, 
IL-1β, TNF-α, and IFNy), the Mann-Whitney test indicated that the change scores (3-
month - baseline) were significantly different between the treatment group and the 
control group (U=13.0, p=0.01). The Friedman test showed that there was a statistically 
significant reduction in the proinflammatory composite scores in the treatment group (x2 
= 6.50, p=0.04), but no significant change in the control group (x2=5.25, p=0.07). Post 
hoc analysis performed with the Wilcoxon signed-rank test showed significant reductions 
in the treatment group from both baseline to 1 month and baseline to 3 months (z=-2.197, 
p=0.03; z=-2.275, p=0.02 respectively). When analyzing each cytokine separately, the 
Mann-Whitney test indicated that the change scores (3-month - baseline) were 
significantly different between the treatment group and the control group for IFN-y 
(U=13.0, p=0.01.), IL-1β (U=14.0, p=0.01), and IL-2 (U=12.0, p=0.01) and showed a 
trend for CRP (U=27.0, p=0.10). The Friedman test showed that in the treatment group 
there was a statistically significant reduction in IFN-y (x2=8.67, p=0.01), IL-1β 
(x2=17.78, p<0.01), IL-6 (x2=6.17, p<0.05), and a trend for CRP (x2=4.5, p=0.10). The 
Friedman test showed no statistically significant reductions for any inflammatory 
mediator in the control group. Post-hoc analysis performed with the Wilcoxon signed-
rank test showed significant reductions in the treatment group for IFN-y from baseline to 
1 month and baseline to 3 months (z=-2.275, p=0.02; z=-2.510, p=0.01 respectively), as 
well as significant reductions in the treatment group for IL-1β from baseline to 1 month 
and baseline to 3 months (z=-3.059, p<0.01; z=-2.934, p<0.01 respectively), and a 
157 
 
 
significant reduction in the treatment group for IL-6 from baseline to 1 month, and a 
trend from baseline to 3 months (z=-2.275, p=0.02; z=-1.726, p=0.08 respectively). Two-
way repeated measures ANOVA were performed for the normally distributed mediators 
TNF-α and PGE2 and showed trends towards group x time interactions (p=0.10; p=0.07 
respectively).     
Relationship between inflammatory mediators and indices of pain: 
 Results from the multiple regression are shown in table 4. To help elucidate a 
potential mechanism between the reduction in neuropathic pain scores and inflammatory 
mediators a step-wise backwards multiple regression analysis was performed. When 
assessing the change in sensory pain score as the outcome variable, results from the 
regression analysis provided partial confirmation of the research hypothesis that change 
in sensory neuropathic pain is a function of the change in proinflammatory cytokines and 
eicosanoids. The 3 variable model included the proinflammatory cytokines IL-2 and IFN-
y, as well as the eicosanoid PGE2 (R=.689, R2=.474). The overall F statistic for the 
model was 4.811, df=3,16, p=.014. Standardized beta weights were -.730 for IL-2, .544 
for IFN-y, and .526 for PGE2. When assessing the change in affective pain score as the 
outcome variable only PGE2 remained in the model (R=.558, R2=.312). The overall F 
statistic for the 1 variable model was 8.145, df=1.18, p=.011, and the standardized beta 
weight was .558. Lastly, when assessing the change in sensitivity score as the outcome 
variable, a 3 variable model including the proinflammatory cytokines IL-1B and IL-2 as 
well as the eicosanoid PGE2 remained (R=.715, R2=.511). The overall F statistic for the 
3 variable model was 5.580, df=3,16, p=.008. Standardized beta weights were .491 for 
IL-1B, -.666 for IL-2 and .378 for PGE2.     
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Table 4: Multiple Regression  
 
Outcome Variable 
Predictor 
Variables 
b SE-b Beta t p value Tolerance VIF 
Sensory  IL-2 -1.386 .483 -0.73 -2.87 0.01 0.51 1.97 
(R=.69, R2=.47) IFN-y .179 .081 0.54 2.21 0.04 0.52 1.91 
 PGE2 .022 .008 0.53 2.79 0.01 0.92 1.08 
Affective  PGE2 .02 .01 0.56 2.85 0.01   
(R=.56, R2=.31)         
Sensitivity  IL-1B 9.67 4.93 0.49 1.96 0.07 0.49 2.05 
(R=.72, R2=.51) IL-2 -1.49 .49 -0.67 -3.07 0.01 0.65 1.54 
 PGE2 .02 .01 0.38 1.8 0.09 0.69 1.45 
Backward stepwise multiple regression analysis of the relationship between the change in 
neuropathic pain scores and the change in inflammatory mediators 
 
Discussion 
 
The present study successfully obtained reductions in inflammatory mediators and 
scores of sensory neuropathic pain in individuals with chronic SCI by means of dietary 
alterations. The relationship between changes in inflammatory mediators and changes in 
sensory neuropathic pain scores was assessed via a step-wise, backwards elimination 
multiple regression analysis. It was demonstrated that approximately 47% of the change 
in sensory neuropathic pain scores could be explained by the change in three 
inflammatory mediators including IL-2, IFN-y, and PGE2. Both IFN-y and PGE2 
demonstrated positive relationships whereby a one-unit decrease in these mediators, was 
related to a respective .544 and .526-unit decrease in sensory neuropathic pain scores. IL-
2 demonstrated a negative relationship whereby a one-unit increase was related to a .730-
unit decrease in sensory neuropathic pain scores. Such findings may be explained by the 
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various peripheral and central mechanisms through which these mediators have been 
shown influence pain.   
Under non-pathological conditions, free nerve endings in the periphery detect 
painful mechanical, thermal, or chemical stimuli and generate nerve impulses which then 
travel along afferent A-delta, or C fibers to the dorsal horn of the spinal cord. At this 
point A-delta fibers synapse with second order neurons (while C fibers first synapse with 
interneurons) before ascending along the spinothalamic tract to the thalamus and 
somatosensory cortex whereby the magnitude and location of pain is processed. Under 
pathological conditions, chronic inflammation may influence pain signaling at different 
points along this pathway.  
PGE2 has been shown to be a key factor in inflammatory-evoked pain by means 
of inducing sensitization of peripheral nociceptors as well as by inducing central changes 
concerning the processing of spinal nociceptive input16. Peripherally, PGE2 acts on 
corresponding receptors (EP) on the nociceptor which causes a protein kinase A (PKA)-
mediated phosphorylation of sodium channels thereby causing peripheral sensitization16. 
PGE2 has also been shown to induce similar effects centrally by inducing membrane 
depolarization of dorsal horn neurons leading to action potential generation17. There is 
also evidence that PGE2 may target the inhibitory glycine receptor thereby reducing 
inhibitory glycinergic synaptic transmission. This provides a second mechanism by 
which PGE2 may facilitate transmission of nociceptive input through the dorsal horn of 
the spinal cord18.         
IFN-y has also been shown to induce central effects which contribute to the 
enhancement of neuropathic pain. Spinal microglia express receptors for IFN-y. Once 
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activated by IFN-y they have been shown to induce the production of bioactive factors 
such as cytokines and neurotrophic factors19,20 thereby influencing the excitability of the 
dorsal horn pathway21 and injury-induced pain behaviours22. Through this process IFN-y 
is able to indirectly enhance pain processing in the dorsal horn and influence neuropathic 
pain.        
 The negative relationship found between IL-2 and sensory pain scores can be 
explained by previous reports which have demonstrated anti-nociceptive properties of IL-
2. Pain transmission can be depressed by means of inducing hyperpolarization, thereby 
reducing neuronal excitability, and depressing the release of nociceptive 
neurotransmitters23. Free intracellular calcium (Ca2+) plays a key role in the release of 
nociceptive neurotransmitters such as substance P from the presynaptic neuron24,25. It is 
through this mechanism that opioids have been demonstrated to produce their analgesic 
effects. The activation of opioid receptors has been shown to suppress high threshold 
Ca2+ currents in rat dorsal root ganglion thereby inducing presynaptic inhibition26,27. IL-
2 administration has been demonstrated to induce a similar influence on high threshold 
Ca2+ currents and inhibit the depolarization-evoked increase in intracellular Ca2+ 
concentration28. The fact that administration of the u-opioid antagonist naloxone 
produces dramatic reductions in this effect suggests that IL-2 may also be producing 
these effects by acting on opioid receptors29. 
Although speculative, the mechanisms discussed above may explain the link 
between the dietary-induced reduction in inflammation and the reductions in neuropathic 
pain scores observed in the current study. The fact that dietary alterations may target the 
underlying mechanisms of neuropathic pain may explain its effectiveness as a treatment 
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modality. This could provide some advantage over traditional pharmacological treatments 
which focus on symptom relief aimed at downstream targets such as those involving the 
direct reduction of neuronal hyperexcitability. Such strategies have demonstrated mixed 
results in terms of efficacy, universality, and associated side effects. Examples include 
the use of tricyclic antidepressants which have shown efficacy for central pain30, but also 
a lack of effect for HIV neuropathy31,32, or chemotherapy-induced neuropathic 
symptoms33,34. SSRI’s have also been shown to produce only weak analgesic effects35–37. 
The use of cannabinoids has been shown to relieve peripheral neuropathic pain in some 
studies38–40, but has shown no effect in painful poly-neuropathy41. Anticonvulsants such 
as Gabapentin have been shown to be effective for the relief of painful polyneuropathy42, 
but have also demonstrated a lack of effect in several studies30,43–45. Finally, opioids have 
been demonstrated, fairly consistently to benefit symptoms of neuropathic pain46–50, 
however, the risk of addiction and gastrointestinal side effects may make long-term use 
inappropriate51. The fact that the etiological basis of neuropathic pain may be highly 
variable from one individual to another makes it difficult to establish a universally 
effective treatment and may explain the marginal effectiveness of many drug trials. While 
a particular drug treatment may demonstrate a large effect on a small subgroup of 
participants it also commonly shows a complete lack of effect in others, resulting in 
minimal overall efficacy. As dietary alterations are capable of targeting the underlying 
inflammatory mechanisms of neuropathic pain they may provide a more universal 
treatment option.  
In addition to the potential for a greater universality and reduction in undesirable 
side-effects, anti-inflammatory strategies such as that utilized in the current study, may 
162 
 
 
provide benefits comparable in magnitude to traditional pharmacological methods. 
Gabapentin is currently among the most promising pharmaceutical treatments for 
neuropathic pain. Studies which examined an 8-week administration of gabapentin have 
demonstrated reductions in neuropathic pain scores of 40.6% in individuals with painful 
diabetic neuropathy52, 33.3% in individuals with postherpetic neuralgia53, and 21.1% in 
individuals with mixed neuropathic pain syndromes54 (based on an 11-point Likert scale). 
The 39.6% reduction in sensory neuropathic pain scores achieved in the current study is 
therefore of comparable or better magnitude to that achieved following gabapentin 
administration. Further, according to Farrar et al. 2001, a 30% reduction in a pain 
intensity numerical rating scale (PI-NRS) represents a clinically important difference in 
pain55.     
 Several potential study limitations should be noted. First, the study was only 
single blinded. While the examiner was blinded to group allocation during all blood 
analysis, participants were aware of their group assignment. Although placebo 
supplements could have been provided to the control group, it was not possible to 
adequately blind participants to all aspects of the diet. The treatment group underwent a 
highly restrictive diet devoid of any refined, processed, or fried foods while the control 
group was free to consume such foods, making distinction between groups quite obvious.  
Second, it is not possible to elucidate the specific mechanisms related to the reductions in 
inflammation, nor is it possible to discern which aspects of the dietary intervention may 
have had the strongest effects. It will be necessary for future studies to examine aspects 
such as transcription factor activity and membrane composition in order to truly elucidate 
the means by which such interventions act to reduce inflammation and improve 
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symptoms of neuropathic pain. Third, although our sample was quite representative of the 
SCI population in Canada, in terms of age, level and severity of injury56, the results are 
not necessarily generalizable to other chronic inflammatory populations or all forms of 
neuropathic pain. It also worth noting that the use of interventions which target 
inflammation by such means as diet or exercise requires commitment to major lifestyle 
alterations and it may be possible that improvements are less drastic and occur at a slower 
rate than that of certain pharmaceuticals. However, given the potential for such anti-
inflammatory interventions to provide a more universal aid for neuropathic pain 
symptoms, (in addition to contributing to a multitude of other health benefits), while 
lacking the side effects associated with traditional pain medications, there is seemingly 
little reason not to promote such lifestyle alterations as a treatment option.    
Conclusion 
 
The present study demonstrated that it was possible to improve symptoms of 
neuropathic pain in spinal cord injury by means by reducing levels inflammation. 
Secondarily, appropriate dietary alterations may be one such intervention strategy which 
could be used to reduce inflammation and induce such benefits. This influence is worthy 
of further examination as it may help to reduce the reliance on traditional pain 
medications and provide a safe, sustainable, and more universally applicable treatment 
modality. 
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Abstract 
 
Study Design: This study was a randomized, parallel-group, controlled clinical trial 
(NCT02099890).     
 
Objectives: The purpose of the present study was to examine the efficacy of targeting 
inflammation as a means of improving somatic nerve conduction following spinal cord 
injury (SCI).  
 
Setting: Participants were recruited from the Niagara region of Ontario Canada  
 
Methods: The study was a randomized, parallel-group, controlled, clinical trial 
(NCT02099890) whereby 20 participants with varying levels and severities of SCI were 
randomized (3:2) to either the treatment group, consisting of a 12-week anti-
inflammatory diet, or control group. Outcome measures were assessed at baseline, 1-
month, and 3-months and consisted of measures of both motor and sensory nerve 
conduction velocity (NCV) and amplitudes, as well as markers of inflammation as 
assessed by various pro and anti-inflammatory cytokines.  
 
Results: Despite a significant reduction in inflammation in the treatment group, two-way 
repeated measures ANOVA showed no significant group x time interaction for motor 
NCV (p=0.77) or M-wave amplitude (p=0.61). There was also no significant group x 
time interaction for sensory NCV (p=0.32) or sensory nerve action potential (SNAP) 
amplitude (p=0.91). Further, there were no significant correlations between the change in 
either motor NCV or M-wave amplitude and the change in any inflammatory mediator of 
interest.   
 
Conclusion: These results suggest that at physiologically relevant concentrations, 
inflammatory mediators may not have a substantial influence on peripheral nerve 
function following SCI. Anti-inflammatory strategies may therefore not provide a 
suitable treatment option, however, future larger scale are still needed to examine the 
potential for central effects. 
  
Trial Registration: ClinicalTrials.gov ID: NCT02099890 
 
 
Keywords 
 
Motor; Sensory; Nerve conduction velocity; Chronic inflammation; Spinal cord injury; 
Anti-inflammatory 
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Introduction 
 
A state of chronic inflammation is commonly reported following spinal cord 
injury (SCI)1–5. This persistent inflammatory state, characterized by chronically elevated 
levels of proinflammatory cytokines, can be attributed to a number of factors which 
commonly arise following SCI. This population is at a heightened risk for a number acute 
secondary health complications such as pressure ulcers, as well as urinary tract, and 
respiratory infections. In addition, the loss of motor function often leads to a more 
sedentary lifestyle contributing to the risk for the development of a variety of 
inflammation-inducing metabolic disorders such as obesity, cardiovascular disease and 
type 2 diabetes. Damage to the spinal cord may also directly result in immune and 
endocrine dysfunction due to the respective loss of sympathetic innervation of lymphoid 
organs and dysregulation of the hypothalamic-pituitary-adrenal axis6.   
 In addition to concerns related to immune dysregulation and the heighted risk of 
infection, a primary issue of SCI is the loss of varying degrees of motor and sensory 
function. Such losses arise from structural damage to neural tracts within the spinal cord 
whereby an injury affecting all tracts, would result in a motor and sensory complete 
injury. Interestingly, previous research has demonstrated that it is possible for an injury to 
present clinically as motor or sensory complete despite the preservation of structurally 
healthy neural tracts (as shown by MRI). Such injuries are classified as discomplete, and 
may indicate that some form of non-structurally based influence is inducing deficits in 
these otherwise healthy tracts 7,8. Evidence exists to suggest that inflammatory mediators 
may possess the ability to influence ion channel kinetics and induce channelopathy, 
resulting in conduction deficits.    
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A study by Davies et al. (2006) demonstrated in ex-vivo conditions that highly 
elevated concentrations of different cytokines (e.g. TNF-α) were capable of inducing 
conduction deficits in a reversible, dose-dependent manner9. This relationship has also 
been demonstrated in-vivo, in humans, under conditions of acute, exercise-induced 
elevations of inflammatory mediators10. Further, a case study performed by Mcdonald et 
al. (2002) provided some indirect, yet intriguing, results concerning the neural influence 
of chronically elevated levels of inflammation in humans11. In this study, an individual 
with complete tetraplegia began an intensive diet and exercise program following a 5-
year post SCI period in which no observable improvements were achieved. The 
intervention resulted in a dramatic reduction in clinical events which were matched by 
significant improvements in scores of both motor and sensory function. Unfortunately, 
inflammatory mediators were not quantified in this study, however, as a large reduction 
in events would be expected to coincide with a reduction in inflammation, it is possible to 
speculate that similar channelopathic mechanisms to that discussed previously9 may have 
been responsible.  
Despite previous research, suggesting the potential for an inflammatory-induced 
channelopathy, no study has demonstrated a causal relationship in humans, under 
physiologically relevant levels of chronic inflammation. If such a relationship exists, it 
may be possible to induce improvements in motor and/or sensory function in those with 
SCI via the implementation of anti-inflammatory strategies. The purpose of this study 
was therefore, to examine the efficacy of targeting inflammation as a means of improving 
somatic nerve conduction following SCI. Based on the relationship observed between 
acute elevations in inflammatory mediators and nerve conduction in previous studies, it 
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was hypothesized that reducing levels of chronic inflammation would result in 
corresponding improvements in both motor and sensory nerve function.   
 
Materials and Methods  
*See Chapter 4 - Overview of Study Design for methodologies regarding participants, 
randomization, and anti-inflammatory diet   
 
Measurement of serum inflammatory markers: 
 Blood draws (20ml) were taken from the antecubital vein of each participant at 
1pm at each of the 3 testing sessions (baseline, 1 month, and 3 months). Following 
extraction, the whole blood was allowed to clot for 30 minutes followed by centrifugation 
at 1000xg for 15 minutes. Serum was extracted and immediately stored at -80°C until 
later analysis. Inflammatory mediators of interest included the pro-inflammatory 
cytokines IL-2, IL-1β, IL-6, TNF-α, IFN-y, the acute phase protein CRP, the anti-
inflammatory cytokines IL-4, IL-10, and IL-1RA, and the pro-inflammatory eicosanoid 
PGE2. Analysis of pro and anti-inflammatory cytokines was performed in triplicate via 
the Magpix Multiplex system (EMD Millipore, MA, U.S.A) and analyzed using Luminex 
software. CRP and PGE2 was analyzed in triplicate and quantified via enzyme-linked 
immunosorbent assay (R&D systems, Minneapolis, U.S.A.).  
Assessment of Nerve Conduction: 
Motor nerve conduction velocity and M-wave amplitude was assessed using 
compound motor action potential (CMAP’s) recordings by means of stimulation of the 
median nerve and recording the corresponding motor response of the thenar muscles. 
Subjects lay in a supine position with the elbow in full extension. Prior to performing the 
test, the electrode locations were prepared by shaving the skin, removing any dead skin 
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cells with an abrasive gel, and disinfecting the areas with rubbing alcohol. Surface 
electrodes were placed in a monopolar configuration with the recording electrode directly 
over the motor point of the thenar muscles, the reference electrode over the tendon of the 
interphalangeal joint, and the ground on the palm of the hand. Stimulation of the median 
nerve was performed distally at the wrist between the flexor tendons of the hand, as well 
as proximally on the medial side of the biceps brachii. Stimulation intensity was 
determined by gradually increasing the amplitude until a maximal M-wave was achieved. 
A stimulation amplitude of 120% of this value was then used during testing. The evoked 
responses were amplified using a bandwidth of 10Hz-1kHz. A total of 10 trials were 
taken and averaged for each stimulation site and M-wave onset was used to determine 
latency. The amplitude of the M-wave was also assessed as an indication of the strength 
of the motor response. Sweep speed was 2ms per division, sensitivity was 2uV per 
division, and stimulus duration was 0.2ms at a stimulus rate of 3Hz. Recordings were 
performed on the Dantec Keypoint EMG (Dantec Medical A/S, Skovlunde, Denmark). 
Skin temperature was assessed with a surface probe placed over the thenar muscles to 
ensure consistent temperatures between testing session (MLT422/D Skin temperature 
probe, AD Instruments, Colorado Springs, USA).    
 The assessment of sensory NCV and sensory nerve action potential (SNAP) 
amplitude was performed using an orthodromic electrode configuration. Stimulation was 
applied using ring electrodes placed just proximal to the second and third 
metacarpophalangeal joints of the fourth finger. The ground electrode was place on the 
dorsal surface of the hand. In order to determine an appropriate stimulation amplitude, 
stimulation was gradually increased until a maximum SNAP amplitude was achieved. 
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The stimulation utilized during testing was 120% of this maximum SNAP amplitude. A 
train of 10 impulses was then applied and averaged for the determination of sensory NCV 
and SNAP amplitude. Sweep was set at 1ms per division, sensitivity was set at 20uV for 
division, and stimulus duration was set at 0.2ms at a rate of 2Hz. Recordings were once 
again performed using the Dantec Keypoint EMG. 
Statistical analysis:   
Two-way (group x time) repeated measures ANOVA were performed to 
investigate possible changes in scores of motor and sensory NCV and amplitude across 3 
testing sessions (baseline, 1 month, 3 month). Two-way repeated measures ANOVA were 
also performed for the proinflammatory cytokine TNF-α and the eicosanoid PGE2. As 
the remaining inflammatory mediators were not normally distributed, non-parametric 
analyses were performed. A Friedman’s test of differences among repeated measures 
(baseline, 1 month, 3 month) for the treatment group and control was performed. If the 
Friedman’s test resulted in a significant value, a Wilcoxon signed-rank test was then 
performed to provide specific information regarding which time points were significantly 
different from one another. Finally, A Mann-Whitney test was performed on change 
scores (3-month - baseline) between groups to establish if the change experienced in 
inflammatory mediators significantly differed between groups. These data are expressed 
as means ± standard deviations. Correlations between changes in inflammatory 
mediators, and measures of nerve conduction were assessed by means of Pearson’s r 
correlation. Statistical significance was set at p≤0.05 for all tests. 
Results 
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All participants from both the treatment and control group completed the entire 3-
month duration of the study and were included in the analysis. No adverse events were 
reported. The participants’ overall compliance to the diet was assessed based on the 
average of the 3 diet records during the study (1 month, 2 months, and 3 months). One 
participant completed all three testing sessions but failed to produce the 2-month and the 
3-month diet record. This participant had a dietary compliance over the first month of 
92%. All other participants completed each of the required diet records and overall 
compliance ranged from 70-100%, with a mean compliance of 89%. A detailed analysis 
regarding specific diet adherence data will be presented elsewhere. 
Change in Motor and Sensory Nerve Conduction:  
 Changes in motor NCV and M-wave amplitude are shown in Table 2. No 
significant group x time interactions were observed for motor NCV (p=0.77, Cohen’s 
d=0.26) or M-wave amplitude (p=0.61, Cohen’s d=0.35). Change in sensory NCV and 
SNAP amplitude are shown in Table 2. No significant group x time interactions were 
observed for sensory NCV (p=0.32, Cohen’s d=0.54) or sensory amplitude (p=0.91, 
Cohen’s d=0.16). 
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Table 2: Change in Motor and Sensory NCV and Amplitude  
 
Treatment  Control 
 Baseline 1 Month 3 Month Baseline 1 Month 3 Month 
Motor 
NCV 
(m/s)  49.8±6.9 49.1±4.0 51.2±5.4 52.0±5.6 52.3±3.5 52.8±6.1 
M-Wave 
Amp. 
(mV)  4.0±1.5 4.0±2.2 3.3±1.8 5.9±1.6 5.8±2.2 5.9±2.3 
Sensory 
NCV 
(m/s) 43.5±9.1 42.7±7.7 40.5±6.5 44.1±7.9 45.8±7.4 44.9±8.6 
Sensory 
Amp (µV) 8.5±3.0 6.9±2.0 5.3±1.4 10.9±3.7 9.7±5.1 7.7±3.5 
 
All results are shown as mean ± SD. 
 
Change in Inflammatory Mediators:  
Changes in serum levels of inflammatory mediators are shown in Table 2 of 
Chapter 5. When considering a proinflammatory composite score (average of IL-2, IL-6, 
IL-1β, TNF-α, and IFNy), the Mann-Whitney test indicated that the change scores (3 
month - baseline) were significantly different between the treatment group and the 
control group (U=13.0, p=0.01). The Friedman test showed that there was a statistically 
significant reduction in the proinflammatory composite scores in the treatment group (x2 
= 6.50, p=0.04), but no significant change in the control group (x2=5.25, p=0.07). Post 
hoc analysis performed with the Wilcoxon signed-rank test showed significant reductions 
in the treatment group from both baseline to 1 month and baseline to 3 months (z=-2.197, 
p=0.03; z=-2.275, p=0.02 respectively). When analyzing each cytokine separately, the 
Mann-Whitney test indicated that the change scores (3-month - baseline) were 
significantly different between the treatment group and the control group for IFN-y 
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(U=13.0, p=0.01.), IL-1β (U=14.0, p=0.01), and IL-2 (U=12.0, p=0.01) and showed a 
trend for CRP (U=27.0, p=0.10). The Friedman test showed that in the treatment group 
there was a statistically significant reduction in IFN-y (x2=8.67, p=0.01), IL-1β 
(x2=17.78, p<0.01), IL-6 (x2=6.17, p<0.05), and a trend for CRP (x2=4.5, p=0.10). The 
Friedman test showed no statistically significant reductions for any inflammatory 
mediator in the control group. Post-hoc analysis performed with the Wilcoxon signed-
rank test showed significant reductions in the treatment group for IFN-y from baseline to 
1 month and baseline to 3 months (z=-2.275, p=0.02; z=-2.510, p=0.01 respectively), as 
well as significant reductions in the treatment group for IL-1β from baseline to 1 month 
and baseline to 3 months (z=-3.059, p<0.01; z=-2.934, p<0.01 respectively), and a 
significant reduction in the treatment group for IL-6 from baseline to 1 month, and a 
trend from baseline to 3 months (z=-2.275, p=0.02; z=-1.726, p=0.08 respectively). Two-
way repeated measures ANOVA were performed for the normally distributed mediator’s 
TNF-α and PGE2 and showed trends towards group x time interactions (p=0.10; p=0.07 
respectively).   
Correlational Analysis: 
Pearson’s r correlation coefficients for the change in inflammatory mediators and 
the change in nerve conduction data are shown in Table 4. Scores related to the change in 
both motor NCV and motor amplitude were not significantly correlated with the change 
in any inflammatory mediators. The change in sensory NCV was significantly correlated 
with only the change in TNF-α (r=.583, p=0.01). The change in sensory amplitude was 
correlated with the change in IL-1B (r=.576, p=0.01), the change in IL-2 (r=.700, p<.01), 
the change in CRP (r=.506, p=.03), and the change in PGE2 (r=.568, p=0.01).   
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Table 4: Correlation Matrix  
All Participants 
 
∆CMAP-NCV ∆CMAP-AMP ∆SNAP-NCV ∆SNAP-AMP 
∆Proinflammatory 
Composite -.386 -.205 .404 .364 
∆CRP -.116 -.366 .269 .506* 
∆IL-2 -.225 -.416 .147 .700** 
∆IL-6 -.342 -.381 .444 .297 
∆IL-1B -.133 -.043 .126 .576* 
∆TNF-α -.191 -.034 .583* -.005 
∆IFN-y -.415 -.401 .384 .334 
∆Anti-inflammatory 
Composite 
-.443 -.200 .144 .212 
∆IL-4 -.267 -.093 -.269 .323 
∆IL-10 -.028 -.070 .070 .039 
∆IL-1RA -.408 -.152 .378 .039 
∆PGE2 .194 .305 -.019 .568* 
*p≤.05; **p≤ 0.01 
CMAP-NCV: Compound motor action potential nerve conduction velocity; CMAP-AMP: 
Compound motor action potential amplitude; SNAP: Sensory nerve action potential nerve 
conduction velocity; SNAP-AMP: Sensory nerve action potential amplitude  
Proinflammatory composite consists of a composite score averaging IL-2, IL-6, IL-1B, TNF-α, 
and IFN-y 
Anti-inflammatory composite consists of a composite score averaging IL-4, IL-10, and IL1RA 
 
Discussion: 
 
The present study was the first to examine the influence of reducing chronically 
elevated levels of inflammation on somatic nerve function in-vivo, in humans. The 
intervention was successful at obtaining reductions in inflammatory mediators, yet failed 
to induce any changes in peripheral motor or sensory nerve conduction. As previous 
research has provided evidence that certain inflammatory mediators may induce 
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channelopathy under acutely elevated concentrations9,10, it was hypothesized that similar 
or even more severe effects would be observed under chronically elevated conditions. 
Further, if such channelopathic effects were to occur in humans, in-vivo, individuals with 
SCI may be expected to be particularly at risk due to the high prevalence of both chronic 
inflammation and somatic nerve deficits.    
Inflammatory mediators have been proposed to contribute to such somatic nerve 
deficits by interfering with neuronal membrane channels and blocking the exchange of 
ions across the membrane. If sodium (Na+) and potassium (K+) exchange is sufficiently 
blocked, normal membrane depolarization and/or repolarization may be disrupted thereby 
causing a reduction in nerve excitability related to motor nerve channelopathy9,13. Such 
an influence would be fitting of the dose-dependent, reversible conduction deficits 
observed in previous ex-vivo studies9, but did not seem apparent in the current study.  
Inflammatory mediators also have a well-established enhancing effect on 
nociceptive sensory fibers. While a potential influence on A-β fibers remains unclear, 
inflammatory mediators are known to sensitize fibers responsible for nociception, such as 
A-δ, and C fibers, at various points along the nociceptive pathway. Peripherally, 
inflammatory mediators such as PGE2 may act on corresponding receptors on the 
nociceptor and induce a protein-kinase A-mediated phosphorylation of sodium channels, 
thereby causing peripheral sensitization14. IL-1β and TNF-α have also been shown to 
increase excitability in nociceptive neurons and enhance sodium currents 15–17. As 
stimulations performed at low frequencies (such as those of the present study) have been 
shown to result in the recruitment A-β, a-δ, and C fibers 18,19, the SNAP amplitudes and 
NCV’s recorded in the present study would be expected to represent each of these fibers. 
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The enhancing effect of inflammatory mediators on A-delta, and C fibers may therefore 
explain the positive correlation between indices of sensory nerve conduction and several 
inflammatory mediators found in the present study.    
Despite these few positive correlations, no significant change in either motor or 
sensory nerve conduction was achieved, suggesting that under physiologically relevant 
concentrations, reducing chronically elevated inflammatory mediators may not be 
sufficient to induce meaningful changes in somatic nerve conduction. No significant 
group x time interaction was observed for either motor or sensory NCV or amplitude. 
Further no significant correlations were observed between the changes in either index of 
motor conduction and the change in any inflammatory mediator. The positive correlations 
observed between of the change in sensory nerve conduction and the change in several 
inflammatory mediators are in agreement with previous reports which have demonstrated 
the relationship between inflammation and nociceptor hyper-excitability20. This does not 
however imply any channelopathic effect of inflammatory mediators on non-nociceptive 
sensory fibers. These results are clinically relevant as it may suggest that interventions 
which target inflammation may not be an effective strategy in terms of improving motor 
and/or sensory function in individuals with SCI.   
Study Limitations  
 Several potential study limitations should be noted. Although no changes in motor 
or sensory nerve conduction were observed in the present study, some degree of influence 
may still be possible under particularly severe levels of inflammation. It may also be 
possible that other inflammatory mediators, not assessed in the current study may have 
demonstrated a stronger relationship with measures of somatic nerve conduction. 
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However, in terms of generalizability, our sample was quite representative of the SCI 
population in Canada, regarding age, level, and severity of injury21 and the levels of 
inflammation demonstrated were comparable to those previously reported for this 
population1,3,22. In addition, the current study examined a wide array of both pro and anti-
inflammatory cytokines. As such, we feel confident that these results are representative of 
the average SCI population. It should also be noted that as only peripheral nerve 
conduction was examined it is not possible to form any conclusions regarding potential 
central effects. Future research will be necessary to confirm or deny a lack of effect on 
central somatic nerve function. Finally, as the SNAP’s recorded in the current study are 
representative of A-β, A-δ, and C fibers, it is not possible to make any conclusions 
regarding specific sensory fiber types. Future studies which utilize stimulations of 
varying frequencies will be necessary to differentiate between such fibers.    
Conclusion 
 
The present study demonstrated a lack of change in peripheral somatic nerve 
function despite the reduction of proinflammatory mediators in a population with SCI. 
Such results may suggest that, when at physiologically relevant concentrations, 
inflammatory mediators do not have a substantial enough influence to induce meaningful 
alterations in peripheral somatic nerve conduction. This result is of clinical significance, 
as it may suggest that despite previously reported ex-vivo findings, inflammatory 
mediators may not provide a suitable target for the enhancement of peripheral somatic 
nerve conduction in human populations with chronic inflammation.  
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Chapter 10  
 
General Discussion  
 
 
 
  
188 
 
 
Traditionally, the study of the human body involves its categorization into various 
individual components such as the immune, endocrine, or nervous system and it is 
common practice for researchers and health care professionals to specialize in one 
particular system. This inherent way by which we study the body influences the way we 
characterize disease states and ultimately molds the way in which we treat different 
diseases. When an individual is found to demonstrate characteristics which deviate from 
what is considered ‘normal’ they are diagnosed with a disorder or disease which is 
typically characterized as belonging to one particular system. This characterization, then 
dictates the way in which treatment interventions are implemented. For example, as 
depression is characterized as a behavioural disorder, known to relate to abnormalities of 
neurotransmitters within the brain, the vast majority of treatment strategies involve 
pharmaceuticals which target such neurotransmitters. The major flaw concerning this 
traditional mode of characterizing and treating disease, is that, in reality, the body does 
not act as a collection of isolated systems, but rather as a single entity whereby individual 
‘systems’ as we define them, work together as one and are able to communicate, interact, 
and influence one another. Based on this understanding it would seem inappropriate to 
characterize most disorders or diseases as belonging to one isolated system. Although a 
disorder may display more prominently in one system, it will almost certainly influence 
and in-turn be influenced by, a multitude of systems.   
 As such, a narrow focused or one-tiered approach to disease prevention and 
treatment may not provide maximum efficacy. Regardless of the traditional 
characterization of a disease or disorder, it is critical to gain an understanding of the 
potential influence and contribution of other systems. The use of an interdisciplinary 
189 
 
 
approach to the prevention or treatment of disease may lead to a better understanding of 
the complex nature of different pathologies, allow for the identification of the various 
systems involved, and further the establishment of novel and more efficacious treatment 
strategies.    
 The current prevalence of immune dysfunction in North America makes an 
understanding of the potential influence of the immune system on various aspects of 
health particularly important. Numerous metabolic conditions such as obesity, 
cardiovascular disease, and type 2 diabetes are now characterized as chronic 
inflammatory conditions, and as these conditions grow ever more prevalent, so too does 
the prevalence of chronic inflammation. The ability of the immune system to interact 
with other systems of the body by means of various mechanisms, makes it possible, and 
highly likely, that dysfunction within the immune system may spread and contribute to 
dysfunction in other systems. For example, the ability of various pro-inflammatory 
mediators to influence enzyme function provides a link between the immune system and 
the nervous system via the regulation of critical neuroactive compounds. Such 
compounds may act within the periphery, inducing effects such as nociceptor 
sensitization, or within the brain to induce behavioural deficits such as depression and 
cognitive impairment. Inflammatory mediators may also act in a more direct fashion and 
contribute to neural dysfunction, independent of their influence on neuroactive 
compounds.  
 Spinal cord injury is a condition which may be at a particularly high risk for 
inflammatory-induced neural and behavioural deficits. This is due in part to a 
susceptibility to immune dysfunction in the form of chronic inflammation stemming from 
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the high risk for the development of numerous metabolic conditions as well as the 
contraction of several common secondary health complications such UTI, or pressure 
ulcers. This population also demonstrates a much higher prevalence for numerous neural 
and behavioural disorders including depression, cognitive impairment, neuropathic pain, 
and somatic nerve deficits related to both motor and sensory impairment. As each of the 
disorders are notoriously difficult to treat, it was of value to examine novel intervention 
strategies which go beyond traditional treatment interventions and consider the potential 
contribution of the immune system. Such an approach has the potential to aid in the 
development of new treatment alternatives which may provide a more efficacious, and 
safe long-term strategy, devoid of the many side effects associated with traditional 
pharmaceutical treatment modalities.  
Summary of Findings   
 
Results from chapter 6 demonstrated that it was possible to improve mood and 
treat symptoms of depression in individuals with SCI by targeting the immune system 
and reducing levels of chronic inflammation. This was the first study to investigate the 
relationship between inflammation, its influence on neuroactive compounds of the 
kynurenine pathway, and symptoms of depression in individuals with SCI. These results 
suggest that the immune system may provide a viable target for intervention in 
individuals demonstrating chronic inflammation and symptoms of depression. The 55.1% 
improvement in CES-D scores obtained in the current study is comparable to that 
achieved in studies utilizing traditional pharmacological treatment strategies. In a study 
by Stahl 2000, 323 individuals with moderate to severe depression were treated with the 
SSRI’s Citalopram or Sertraline over a 24-week period. The Citalopram group 
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experienced a 54.7% improvement and the Sertraline group experienced a 48.8% 
improvement based on scores from the Hamilton Depression Rating Scale (HAMD). Of 
these groups, adverse events resulted in a 14% and 19% dropout rate in the Citalopram 
and Sertraline groups respectively1. The improvement achieved in the current study was 
therefore comparable in magnitude to these SSRI’s and acted in a shorter time frame 
while lacking negative side effects.  Results from chapter 7 demonstrated a lack in 
response in most measures of cognitive function associated with verbal learning and 
memory despite a significant reduction in proinflammatory mediators. A significant 
improvement in intrusions (recall of incorrect off-list words) was the only aspect of the 
test to reach statistical significance. This may relate to the role of the frontal lobe in 
source memory and the ability to avoid incorrect responses2. While the hippocampus may 
have had preexisting hippocampal atrophy brought on by prolonged periods of chronic 
inflammation, the frontal lobe may not have been influenced as severely. Other 
mechanisms, more responsive to the intervention may have been responsible frontal lobe 
dysfunction. For example, individuals with cardiovascular disease (a chronic 
inflammatory condition) have been shown to demonstrate frontal lobe dysfunction which 
was correlated with cerebral blood flow and levels of CRP3. It is possible to speculate 
that the reduction in inflammation achieved in the current study was sufficient to improve 
cerebral blood flow, thereby improving frontal lobe function but not hippocampal 
function.   
 Results from chapter 8 demonstrated that it was possible to improve symptoms of 
neuropathic pain in individuals with SCI by targeting the immune system and reducing 
levels of chronic inflammation. This was the first study to examine the detailed 
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relationship between inflammatory mediators, corresponding concentrations of 
eicosanoids, and indices of neuropathic pain. The results suggest that the immune system 
may provide a suitable target for intervention in individuals with chronic inflammation 
and neuropathic pain following SCI. The significant 39.6% reduction in sensory 
neuropathic pain scores as assessed by the NPQ in the current study was comparable to 
that achieved by studies utilizing pharmacological treatment interventions. Gabapentin is 
a commonly used pharmaceutical for the treatment of neuropathic pain4. Studies have 
shown 8 weeks of Gabapentin administration to be sufficient to cause a 40.6% reduction 
in neuropathic pain scores in individuals with painful diabetic neuropathy5, a 33.3% 
reduction in individuals with postherpetic neuralgia6, and a 21.1% reduction in 
individuals with mixed neuropathic pain syndromes7 based on an 11-point Likert scale. 
Significant changes occurred in these studies between 1-2 weeks following the initiation 
of treatment. According to Farrar et al. 2001, a 30% reduction in a pain intensity 
numerical rating scale (PI-NRS) represents a clinically important difference in pain8. 
Based on these results, the improvement in neuropathic pain scores achieved in the 
current study would be considered a clinically important difference and one that is 
comparable to that achieved following administration of gabapentin in painful diabetic 
neuropathy, and more effective than gabapentin administered to patients with 
postherpetic neuralgia or mixed neuropathic pain syndromes.   
 Results from chapter 9 demonstrated a lack of response in somatic nerve 
conduction, including both motor and sensory nerve conduction velocity and amplitude, 
despite a significant reduction in pro-inflammatory mediators. This was the first study to 
examine the influence of chronically elevated inflammatory mediators in humans, in-
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vivo. These results may suggest that, despite previous findings in ex-vivo animal models, 
in humans, under physiologically relevant concentrations, inflammatory mediators do not 
seem to have a substantial influence on somatic nerve function.          
Limitations and Future Directions 
 
The results of the studies presented in this dissertation suggest that chronic 
inflammation may contribute to symptoms of depression and neuropathic pain and may 
therefore provide an appropriate target for intervention. Although these results are 
encouraging, several potential limitations should be noted. First, although the current 
sample size is considered relatively large in the area of SCI research, future, larger scale 
studies will be necessary in order to confirm such results and to further elucidate potential 
mechanisms. Physiological studies are frequently underpowered due to smaller sample 
sizes which may result in effects of practical importance going undetected. This may 
have been the case in the current study concerning changes in neuroactive compounds as 
many that were not significantly altered showed large effect sizes.  
Second, due to the nature of the intervention in the current study it was not 
possible to blind participants to their condition. Although placebo supplements could 
have been provided to the control group, it was not possible to adequately blind 
participants to all aspects of the diet. This is a common issue/feature in clinical 
nutrition/diet intervention studies. The treatment group underwent a highly restrictive diet 
while the control group was free to consume their usual diet (which often consisted of 
unhealthy foods and foods from the ‘foods to avoid’ list supplied to the treatment group), 
making the differences in dietary intake between groups quite apparent. It may be 
possible for future studies to also alter the diet of the control group, in a way that will not 
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reduce inflammation, however, due to the easy access of nutritional information online, it 
will likely prove difficult to keep participants unaware of their group allocation. 
Alternatively, it may be possible for future studies to attempt to reduce inflammation by 
utilizing supplementation only, thereby allowing for the control group to unknowingly 
receive a placebo.  
Third, it is not possible to elucidate which specific aspects of the dietary 
intervention induced the strongest anti-inflammatory effects. Although this was not the 
purpose of the present study, it will be necessary for future studies to examine various 
groups, utilizing various aspects of the diet along with a detailed mechanistic analysis of 
aspects such as transcription factor activity and membrane compositions in order to truly 
elucidate which features of the diet had the most substantial influence and by what 
means. Further, participants were allowed to continue exercising throughout the duration 
of the study and improvements in metabolic health induced by both the diet and exercise 
may have contributed to changes in inflammation. For example, although not assessed in 
the current study, reductions in adipose tissue may have contributed to the reductions in 
inflammation. Adipose tissue acts as an endocrine organ and possesses the ability to 
secrete proinflammatory mediators termed adipokines such as TNF-α, IL-1, and IL-69. 
Therefore, a reduction in adipose tissue may have contributed to the reduction in such 
mediators. In addition, such adipokines have been suggested to play a role in insulin 
resistance via the downregulation of GLUT 4 gene transcription and translocation as well 
as the inhibition of insulin receptors by mechanisms related to the upregulation of the 
suppressors of cytokine signaling proteins10,11. Reductions in adipose tissue and 
adipokines may therefore also result in reduced blood glucose concentrations thereby 
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reducing strain on the kidneys and potential tissue damage which could contribute to 
further inflammation. Finally, improved cardiovascular health in the form of reduced 
platlet aggregation and plaque formation may contribute to reduced endothelial damage 
and related reductions in inflammation12.   
It may also prove extremely valuable for future studies to examine the efficacy of 
anti-inflammatory intervention strategies early in life. As prolonged periods of chronic 
inflammation may lead to potentially irreversible hippocampal atrophy, it may explain, in 
part, the difficulty in treating behavioural disorders such as depression and cognitive 
impairment later in life. Strategies aimed at reducing chronic inflammation in childhood 
may therefore help avoid the development of such intractable neuroanatomical 
complications and produce even more favorable results when treating behavioural 
disorders. 
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1. Raw Data  
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B) CES-D Scores of Depression  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUBJECT 
TREATMENT GROUP Baseline Mid Post 
S1 39 11 16
S6 4 2 5
S7 26 18 16
S8 22 6 6
S9 11 2 1
S11 7 1 1
S12 2 0 2
S13 20 7 12
S15 11 14 5
S16 8 5 4
S17 8 4 3
S18 16 11 12
AVERAGE 14.50 6.75 6.92
Standard Deviation 10.67 5.64 5.58
CONTROL GROUP Baseline Mid Post 
S2 18 15 22
S3 3 0 4
S4 11 7 10
S5 37 29 41
S10 22 19 20
S14 4 4 2
S19 15 16 18
S20 1 0 0
AVERAGE 13.88 11.25 14.63
Standard Deviation 12.01 10.25 13.62
CSE-D Score
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C) CVLT Scores 
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D) NPQ Scores  
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E) Somatic Nerve Conduction Scores  
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2. Inflammatory Mediators – Normative Values  
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3.  Center for Epidemiological Studies Depression Scale  
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4. Neuropathic Pain Questionnaire   
 
Neuropathic Pain Questionnaire 
 
In order to assess and treat your pain problem, we need to thoroughly understand just exactly what type of 
pain you have, and how it may or may not change over time. You may have only one site of pain, or you 
may have more than 
one. 
 
Please name the site of pain which is most severe or disturbing for you (eg, arm, foot, etc): 
________________ 
 
 
For all of the following questions, please rate your pain at the site you just listed. 
Please use the space below to describe your pain in your own words as well: 
 
 
Please use the items below to rate your pain as it usually feels. Indicate a number which represents your 
pain on each scale. For example, if you have no tingling pain, you would rate the first item “0”. If you have 
the worst tingling pain imaginable, you would rate it “100.” If neither of those fits your pain because it is in 
between, choose a number which fits your pain. 
 
Sensory Items  
 
1. Burning Pain  
 0 <================================>100  Please rate  
 No burning   Worst burning    your usual pain: 
_________ 
 pain    pain imaginable  
 
2. Sharp Pain  
 0 <================================>100  Please rate  
 No sharp   Worst sharp    your usual pain: 
_________ 
 pain    pain imaginable  
 
3. Dull, Aching Pain  
 0 <================================>100  Please rate  
 No aching   Worst aching    your usual pain: 
_________ 
 pain    pain imaginable  
 
4. Overly Sensitive to Touch  
 0 <================================>100  Please rate  
 No increase   Greatest increase your usual pain: 
_________ 
 at all    imaginable  
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5. Shooting Pain  
 0 <================================>100  Please rate  
 No shooting   Worst shooting   your usual pain: 
_________ 
 pain    pain imaginable  
 
6. Throbbing Pain  
 0 <================================>100  Please rate  
 No throbbing   Worst throbbing your usual pain: 
_________ 
 pain    pain imaginable  
 
7. Stabbing Pain  
 0 <================================>100  Please rate  
 No stabbing   Worst stabbing   your usual pain: 
_________ 
 pain    pain imaginable  
 
8. Numbness  
 0 <================================>100  Please rate  
 No numbness   Worst numbness your usual pain: 
_________ 
     imaginable  
 
9. Electric Pain  
 0 <================================>100  Please rate  
 No electric    Worst electric     your usual pain: 
_________ 
 pain    pain imaginable  
 
10. Grinding Pain 
 0 <================================>100  Please rate  
 No grinding   Worst grinding    your usual pain: 
_________ 
 pain    pain imaginable  
  
11. Tearing Pain  
 0 <================================>100  Please rate  
 No tearing   Worst tearing    your usual pain: 
_________ 
 pain    pain imaginable  
  
12. Cramping Pain 
 0 <================================>100  Please rate  
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 No cramping   Worst cramping your usual pain: 
_________ 
 pain    pain imaginable  
 
13. Soreness  
 0 <================================>100  Please rate  
 No soreness   Worst soreness   your usual pain: 
_________ 
     imaginable  
   
14. Tingling Pain  
 0 <================================>100  Please rate  
 No tingling   Worst tingling    your usual pain: 
_________ 
 pain    pain imaginable  
 
15. Squeezing Pain  
 0 <================================>100  Please rate  
 No squeezing   Worst squeezing your usual pain: 
_________ 
 pain    pain imaginable  
 
 
16. Itching Pain  
 0 <================================>100  Please rate  
 No itching   Worst itching    your usual pain: 
_________ 
 pain    pain imaginable  
 
17. Freezing Pain  
 0 <================================>100  Please rate  
 No freezing   Worst freezing   your usual pain: 
_________ 
 pain    pain imaginable  
 
18. Pinching Pain 
 0 <================================>100  Please rate  
 No pinching   Worst pinching   your usual pain: 
_________ 
 pain    pain imaginable  
  
 
 
We are also interested in learning how your pain effects you. Please write the number that indicates 
the amount you experience each of the following: 
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Affective Items  
 
19. How unpleasant is your usual pain? 
 0 <================================>100  Please rate  
 Not unpleasant   Most unpleasant  your usual pain: 
_________ 
  at all    pain imaginable 
 
20. How annoying is your usual pain?  
 0 <================================>100  Please rate  
 Not annoying   Most annoying   your usual pain: 
_________ 
 at all    pain imaginable 
 
21. How frightening is your usual pain? 
 0 <================================>100  Please rate  
 Not frightening   Most frightening your usual pain: 
_________ 
 at all    pain imaginable 
 
22. How confusing is your usual pain? 
 0 <================================>100  Please rate  
 Not confusing   Most confusing  your usual pain: 
_________ 
  at all    pain imaginable 
 
23. How distressing is your usual pain? 
 0 <================================>100  Please rate  
 Not distressing   Most distressing your usual pain: 
_________ 
 at all    pain imaginable 
 
24. How irritating is your usual pain?  
 0 <================================>100  Please rate  
 Not irritating   Most irritating    your usual pain: 
_________ 
 at all    pain imaginable 
 
25. How overwhelming is your usual pain? 
 0 <================================>100  Please rate  
 Not overwhelming  Most overwhelming your usual pain: 
_________ 
 at all    pain imaginable 
 
26. How exasperating is your usual pain?  
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 0 <================================>100  Please rate  
 Not exasperating  Most exasperating your usual pain: 
_________ 
  at all    pain imaginable 
 
 
We are also interested in learning what circumstances cause changes in your pain. Please write the 
number that indicates the amount you experience each of the following: 
 
 
Sensitivity Items 
 
27. Increased pain due to heat  
 0 <================================>100  Please rate  
 No increase   Greatest increase your usual pain: 
_________ 
 at all    imaginable  
 
28. Increased pain due to cold  
 0 <================================>100  Please rate  
 No increase   Greatest increase your usual pain: 
_________ 
  at all    imaginable 
 
29. Increased pain due to touch  
 0 <================================>100  Please rate  
 No increase   Greatest increase your usual pain: 
_________ 
  at all    imaginable 
 
30. Increased pain to fatigue  
 0 <================================>100  Please rate  
 No increase   Greatest increase your usual pain: 
_________ 
  at all    imaginable 
 
31. Increased pain due to emotional upset  
 0 <================================>100  Please rate  
 No increase   Greatest increase your usual pain: 
_________ 
  at all    imaginable 
 
32. Increased pain due to weather changes  
 0 <================================>100  Please rate  
 No increase   Greatest increase your usual pain: 
_________ 
  at all    imaginable 
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5. Ethical Approval  
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Research Ethics Office  
  
 Tel: 905-688-5550 ext. 3035  
 Email:  reb@brocku.ca  
Bioscience Research Ethics Board 
 
 
 Certificate of Ethics Clearance for Human Participant Research  
  
 
                       
  
DATE:  9/23/2014  
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FILE:  13-192 - DITOR  
    
TYPE:  Ph. D.  STUDENT:  David Allison  
 SUPERVISOR:  David Ditor  
TITLE: Neural Consequences of Chronic Inflammation in Spinal Cord Injury  
  
 
  
ETHICS CLEARANCE GRANTED  
  
Type of Clearance:  NEW  Expiry Date:  9/30/2015  
 
  
The Brock University Bioscience Research Ethics Board has reviewed the above named research 
proposal and considers the procedures, as described by the applicant, to conform to the 
University’s ethical standards and the Tri-Council Policy Statement.  Clearance granted from 
9/23/2014 to 9/30/2015.    
  
The Tri-Council Policy Statement requires that ongoing research be monitored by, at a minimum, 
an annual report.  Should your project extend beyond the expiry date, you are required to submit a 
Renewal form before 9/30/2015.  Continued clearance is contingent on timely submission of 
reports.  
  
To comply with the Tri-Council Policy Statement, you must also submit a final report upon 
completion of your project.  All report forms can be found on the Research Ethics web page at 
http://www.brocku.ca/research/policies-and-forms/research-forms.    
  
In addition, throughout your research, you must report promptly to the REB:  
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a) Changes increasing the risk to the participant(s) and/or affecting significantly the conduct 
of the study;  
b) All adverse and/or unanticipated experiences or events that may have real or potential 
unfavourable implications for participants;  
c) New information that may adversely affect the safety of the participants or the conduct of 
the study;  
d) Any changes in your source of funding or new funding to a previously unfunded project.  
  
We wish you success with your research.  
  
  
  
Approved:         
   
 ____________________________    
 Brian Roy, Chair  
    Bioscience Research Ethics Board   
  
Note:  Brock University is accountable for the research carried out in its own jurisdiction or 
under its auspices and may refuse certain research even though the REB has found it 
ethically acceptable.  
  
If research participants are in the care of a health facility, at a school, or other institution 
or community organization, it is the responsibility of the Principal Investigator to ensure 
that the ethical guidelines and clearance of those facilities or institutions are obtained and 
filed with the REB prior to the initiation of research at that site.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
217 
 
 
6. Review Papers  
 
Allison DJ & Ditor DS. The common inflammatory etiology of depression and cognitive 
impairment: A therapeutic target. Journal of Neuroinflammation, September 2014, 
11(1):151. 
 
 
 
 
 
218 
 
 
Allison DJ & Ditor DS. Immune dysfunction and chronic inflammation following spinal 
cord injury. Spinal Cord, September 2014, 53:14-18. 
 
 
 
